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CHAPTER 1
General introduction
Chapter 1
WATER HOMEOSTASIS IN BODY VOLUME REGULATION
Maintaining body fluid volume homeostasis is of vital importance for proper 
functioning of most physiological processes in the human body. Humans can 
survive for several weeks without food, but for only a few days without water. 
Hypervolemia, or fluid overload, can result in edema, ascites and dyspnea. 
Hypovolemia, or volume depletion, can result in multiple organ damage 
including kidney damage, brain damage, coma and death. Fluid enters the 
human body via the diet, and leaves in many ways including voiding, 
defecation, breathing and sweating. Water constitutes approximately 60% of 
the total body weight and is divided over two compartments: the intracellular 
fluid (ICF) and the extracellular fluid (ECF) compartment. The ICF is 
separated from the ECF by the cell membrane and contains approximately 
two thirds of the total body water content. As the cell membranes are highly 
permeable to water but not to ions, water, but not ions, moves freely between 
the various body fluid compartments. The ECF consists of interstitial fluid 
(ISF) and plasma, which are separated by the capillary wall. The capillary 
wall is freely permeable to small ions, and therefore the ionic composition of 
the two compartments of the ECF (ISF and plasma) is similar. Sodium and 
chloride are the major solutes of the ECF and therefore the major 
determinants of the osmolality of ECF. The kidneys are responsible for the 
maintenance of volume homeostasis by controlling the excretion of sodium 
and water in the urine in response to various hormones. Under most 
conditions the major route for elimination of water from the body is the urine. 
Water loss by other ways is only limitedly regulated.
Under normal conditions, the kidneys keep the volume of ECF constant by 
adjusting the sodium excretion level to the amount of intake. When sodium 
intake exceeds excretion, ECF volume increases above normal; the opposite 
occurs if excretion exceeds intake. Volume regulation is also relevant to the 
regulation of blood pressure. A reduction of ECF volume coincides with a 
(temporary) fall in arterial blood pressure. Although a temporary fluid shift 
occurs from the interstitial fluid compartment to the plasma compartment due 
to increased colloid osmotic pressure, a signal is released to increase renal 
uptake of sodium and water to start compensating the loss of blood pressure.
The changes of ECF volume as well as the blood pressure are sensed by a 
complex system of sensors and effector signals that act primarily on the 
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kidneys to regulate the excretion of sodium. By this regulation of excretion of 
sodium, a constant ECF volume is maintained. These sensors include low- 
pressure baroreceptors, high-pressure baroreceptors, hepatic sensors, and 
central nervous system sodium sensors[1].
Low-pressure baroreceptors are located within the walls of the cardiac atria 
and pulmonary vessels, and respond to the distension of these structures. In a 
state of hypovolemia, these baroreceptors activate the sympathetic nervous 
system and stimulate the anti-diuretic hormone arginine vasopressin (AVP) 
secretion, which eventually results in increased distal nephron water 
reabsorption. Moreover, the activation of the sympathetic nervous system 
results in activation of the renin-angiotensin-aldosterone system (RAAS) by 
inducing the renal release of renin.
High-pressure baroreceptors are located in the walls of the aortic arch, the 
carotid sinus, and the afferent arteriole of the kidneys. These baroreceptors 
primarily respond to blood pressure. With hypotension, the sympathetic nerve 
and AVP secretion is activated. Furthermore, the juxtaglomerular apparatus 
(JGA) of the kidney, particularly the afferent arterioles that are located in the 
JGA, respond directly to the decreased blood pressure to stimulate renin 
release from the granules of the juxtaglomerular cells.
The Renin-angiotensin-aldosterone system (RAAS) plays an important role in 
the renal volume regulation. Renin is synthesized in the juxtaglomerular cells 
in the kidney glomerulus. Mature renin is stored in granules of the 
juxtaglomerular cells and is released by an exocytic process into the renal and 
then the systemic circulation. Renin release is stimulated primarily by (1) 
decreased renal perfusion pressure sensed by the renal baroreceptor in the 
granular cells of the afferent arteriole in the JGA, (2) decreased delivery of 
NaCl (sensed as changes in Cl- concentration) to the macula densa cells in 
JGA, (3) increased sympathetic nerve stimulation via beta-1 adrenergic 
receptors, and (4) negative feedback by a direct action of angiotensin II (Ang 
II) on the granular cells in JGA[2]. The sole function of released renin is to 
cleave angiotensinogen, a circulating protein produced by the liver. The 
cleavage product is a 10 amino acid peptide, angiotensin (Ang) I. A  further 
cleavage of Ang I by angiotensin converting enzyme (ACE) yields an 8 - 
amino acid peptide, Ang II. Ang II further stimulates the aldosterone secretion 
by the adrenal cortex. Ang II and aldosterone are the primary active products
11
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of RAAS and act as potent vasoconstrictors. Moreover, Ang II enhances 
sodium reabsorption by the kidney proximal tubule. At least 4 Ang II 
receptors have been described. Of these, the type 1 (AT1) receptor mediates 
most of the established physiological effects of Ang II, including renal 
sodium reabsorption in the early proximal tubule, inhibition of renin release, 
stimulation of aldosterone synthesis in the adrenal cortex and stimulation of 
thirst and AVP release from the pituitary gland. The half life of Ang II in the 
systemic circulation is 30 seconds and in the tissues 15-30 minutes[1;3;4]. 
Aldosterone is a steroid hormone produced by the glomerulosa cells of the 
adrenal cortex. Aldosterone stimulates sodium reabsorption in the distal 
tubule and collecting duct. Activation of RAAS, as occurs with volume 
depletion, results in increased sodium reabsorption by the kidneys.
Conversely, this system is suppressed with volume expansion, with which 
renal sodium excretion is enhanced. In addition, with volume expansion, 
release of atrial natriuretic peptide (ANP) is induced. The cardiac atria are the 
site for synthesis, storage and release of ANP, which, when released, 
increases sodium excretion by inhibiting sodium uptake in aldosterone­
sensitive tubular segments.
In the liver, some hepatic sensors respond to blood pressure within the 
hepatic vasculature, and others respond to the concentration of sodium in the 
portal vein blood. Increased pressure within the hepatic vasculature, or an 
increase in portal vein sodium concentration, results in a decrease in renal 
sympathetic nerve activity, which subsequently leads to an increase in renal 
sodium excretion. Similarly, sensing of increased sodium concentration in the 
carotid artery blood or the cerebrospinal fluid by the central nervous system 
sodium sensors also results in a decrease in renal sympathetic nerve activity, 
which subsequently leads to an increase in renal sodium excretion[1].
The regulating systems, including the renin-angiotensin-aldosterone system 
(RAAS), the sympathetic nervous system, and the hormones such as AVP and 
ANP, are the main coordinators to maintain sodium and water balance. 
However, other effectors such as hormones endothelin, dopamine, and 
prostaglandins also contribute to this maintenance [1].
12
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WATER HOMEOSTASIS IN BODY OSMOREGULATION
Changes in whole-body water content lead to changes in osmolality. Despite 
the large fluctuation in water intake, the plasma osmolality doesn’t vary by 
more than 1-2%. The maintenance of a proper osmolality depends on 
osmoreceptors that locate in the brain. These osmoreceptors trigger 
physiological responses such as thirst, thus regulating water intake, and 
release of AVP, thus regulating water excretion by the kidney (Fig. 1). AVP 
plays a central role in osmoregulation. When the osmolality of the body fluids 
increases, osmoreceptors in the subfornical organ (SFO) and organum 
vasculosum lamina terminalis (OVLT) activate neurons projecting to the 
paraventricular nucleus (PVN) and the supraoptic nucleus (SON) in the 
hypothalamus to stimulate thirst and AVP secretion[5-7]. The antidiuretic 
hormone AVP is a small peptide of 9 amino acids in length. After synthesis in 
the AVP secretory cells of SON and PVN in the hypothalamus, AVP is stored 
in the posterior pituitary and released into the blood after stimulation by 
increased osmolality in for example hypernatremia[6 ;8 ]. Once released, 
circulating AVP acts on the kidney to decrease renal water excretion. 
Conversely, when the effective osmolality of the body fluid is reduced, AVP 
secretion is inhibited. Because AVP is rapidly broken down in the plasma, 
circulating levels can be reduced to zero within minutes after secretion is 
inhibited. As described above, reductions in ECF alter AVP secretion, but this 
volume-derived activation of AVP release is weaker than that of an increased 
osmolality, because a 10% reduction in ECF gives a similar increase in AVP 
release as 1% increase in osmolality[1].
Some studies suggested that there may be other osmoreceptors to contribute to 
the effects in osmoregulation as well, such as hepatic portal osmoreceptors in 
the abdominal viscera[9;10]. Evidences include that in rats gastric sodium 
loading stimulated thirst and AVP secretion before any increase in systemic 
plasma osmolality[1 0 ].
RENAL ASPECTS OF VOLUME REGULATION
A human kidney consists of approximately 1,000,000 nephrons. The nephron 
is the functional unit of the kidney and each nephron consists of a glomerulus
13
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Figure 1. Process of body osmoregulation. In body osmoregulation, 
osmoreceptors located in the brain trigger physiological responses such as thirst, 
thus regulating water intake, and release of AVP from the pituitary, thus 
regulating water excretion by the kidney.
and a tubule. The unique structure of the glomerulus forms a filter that 
restricts the filtration of molecules from the blood plasma on the basis of size 
and electrical charge. The tubule components include proximal tubule, thin 
descending and ascending limbs of Henle’s loop, thick ascending limb of 
Henle’s loop, distal convoluted tubule and connecting tubule, which connects 
the nephron to the collecting duct (Fig. 2).
Different segments of the nephron have different histological characteristics 
and therefore exert different functions. Figure 3 shows cell models of the 
proximal tubule, the thick ascending limb of Henle’s loop, the distal 
convoluted tubule, connecting tubule, and the collecting duct and the most 
important transporters and channels involved in sodium and water 
reabsorption.
14
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Glomerulus 
Proximal tubule
Loop of Henle: 
Thick ascending limb
Thin descending limb 
Thin ascending limb
Figure 2. Nephron segments. Renal tubular segments (yellow), glomerular 
capillaries (red) and peritubular capillaries (red and blue).
Volume regulation and osmoregulation rely on the kidneys to control the salt 
and water reabsorption. The glomerular filtration rate (GFR) of 2 kidneys 
amounts 180 liters/day in healthy humans. Of this huge volume, also called 
the pro-urine, approximately 90% of the water is reabsorbed in the proximal 
tubule and descending limb of Henle’s loop, which is a constitutive process. 
According to the body’s demand, the remaining fluid can be reabsorbed in the 
collecting duct. Tubular reabsorption allows the kidney to retain the 
substances that are essential and to regulate their levels in the plasma by 
altering the degree to which they are reabsorbed. While the proximal tubule 
and the loop of Henle are responsible for the bulk reabsorption of sodium and 
water, the distal segments, including the distal tubules and collecting duct, 
have a more limited reabsorption capability. However, the final adjustments 
in the composition and volume of the urine and most of the regulation by 
hormones and other factors occur in the distal segments as the final fine- 
tuning. In these processes, various hormones, sympathetic nerves, and other 
factors regulate sodium and water reabsorption by the kidneys.
Besides the tubular system, the juxtaglomerular apparatus (JGA) is an
15
Figure 3. Cell models of 
renal tubular transport.
Major transporters and 
channels involved in 
sodium and water 
reabsorption are 
demonstrated in the 
proximal tubule (PT), the 
thick ascending limb of 
Henle’s loop (TAL), the 
distal convoluted tubule 
(DCT), the connecting 
tubule (CNT), and the 
collecting duct (CD). 
Aquaporin (AQP), Na+- 
H+-exchanger 3 (NHE3). 
Na+-K+-2Cr co­
transporter 2 (NKCC2), 
chloride channel Kb 
(CLCNKB), renal outer 
medullary potassium 
channel (ROMK), Na+-Cl_ 
co-transporter (NCC), 
epithelial sodium channel 
(ENaC) are abbreviated in 
the figure.
PT
h 2o H20
VTP
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important kidney component and part of the complex feedback mechanism 
RAAS that regulates sodium balance, renal blood flow and GFR[11]. JGA 
locates between the vascular pole of the renal corpuscle and the returning 
distal convoluted tubule of the same nephron. The structures of JGA include 
the macula densa cells of the thick ascending limb, the extraglomerular 
mesangial cells and the granular cells in the afferent arteriole. The macula 
densa cells form a morphologically distinct region of the thick ascending limb 
and contact the extraglomerular mesangial cells and the granular cells in the 
afferent arteriole. The granular cells are modified smooth muscle cells that 
manufacture, store and release renin. The renin release from the granular cells 
of the JGA is a principal factor controlling ANG II levels, and thus RAAS 
activity as mentioned above[1].
The functions of different kidney tubular segments are explained below.
The proximal tubule reabsorbs approximately 67% of the filtered water, Na+, 
Cl-, K+ and other solutes. In addition, the proximal tubule reabsorbs virtually 
all the glucose and amino acids filtered by the glomerulus. The mechanisms 
of Na+ reabsorption differ in the early and later segments of the proximal 
tubule. In the early proximal tubule, Na+ reabsorption primarily occurs in 
exchange with H+, of which H+ is formed from H2O and CO2 to generate 
HCO3-, which is the key base of our body to regulate our acid-base balance. 
The key transporter on the apical membrane in this process is the Na+-H+ 
exchanger 3 (NHE3). Besides, Na+ is reabsorbed together with a number of 
organic molecules such as glucose and amino acids. Na+ that enters the cell 
across apical membrane leaves the cell and enters the blood via the Na+/K+- 
ATPase. In the late proximal tubule, Na+ is primarily reabsorbed with Cl- 
across both the transcellular and paracellular pathways. The transport of Na+ 
and Cl- through the paracellular pathway accounts for reabsorption of about 
one third of the filtered NaCl load in the proximal tubule. The reabsorption of 
Na+ and other solutes provides a driving force for water to be reabsorbed 
across the proximal tubular cells. The key protein for the transcellular water 
transport is the aquaporin-1 (AQP1) water channel, which locates on the 
apical and basolateral membranes of these cells[12-14]. With hypovolemia, 
the released Angiotensin II, a member of the RAAS hormones (see above), 
potently stimulates the NaCl and water reabsorption in this segment.
17
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The loop of Henle reabsorbs approximately 23% of the filtered water and 
25% of filtered sodium. Water reabsorption occurs exclusively in the thin 
descending limb and is mediated by AQP1 and this segment does not reabsorb 
significant amount of solute. In contrast, the ascending limb of Henle’s loop is 
impermeable for water, but is responsible for the reabsorption of the 25% of 
filtered sodium. The thick ascending limb (TAL) plays an important role in 
active sodium reabsorption and expresses the furosemide-sensitive Na+-K+- 
2Cl- co-transporter 2 (NKCC2)[15] and the renal outer medullary potassium 
channel (ROMK)[16]. Efficient operation of NKCC2 requires K+ to recycle 
across the apical membrane through ROMK to sustain the transepithelial 
current and electroneutral entry of NaCl. Cl- exits basolaterally through the 
chloride channel, CLCNKB. Na+/K+-ATPase in the basolateral membrane of 
the TAL epithelial cells maintains a low intracellular [Na+] and together with 
ROMK provide a positive transcellular charge, which is needed as a driving 
force for the reabsorption of sodium. The positive charge is also an important 
driving force for the sodium reabsorption through the paracellular pathway. In 
TAL, AVP induces sodium reabsorption by increasing the expression and 
activity of NKCC2 through binding to V2 receptors and thereby stimulating 
adenylyl cyclase activity[17]. In addition to AVP, a number of other peptide 
hormones stimulate sodium reabsorption through the activation of adenylyl 
cyclase activity in TAL, including glucagon, calcitonin and PTH[18;19]. 
Some studies reported that Ang II receptors and mineralocorticoid receptors 
are present in the TAL[20-22]. In a decreased ECF volume or blood pressure, 
Ang II and aldosterone were shown to stimulate sodium reabsorption in the 
TAL, possibly through modulating the expression of NKCC2 and the activity 
of Na+/K+ ATPase respectively[23-28]. Mutation of genes encoding NKCC2, 
ROMK, or CLCNKB causes Bartter syndrome, a group of autosomal 
recessive disorders associated with severe reduction or loss of sodium 
reabsorption by TAL (see review[29]).
The distal convoluted tubule is also impermeable to water. NaCl enters the 
cell on the apical side through the thiazide-sensitive Na+-Cl- co-transporter 
(NCC), which mediates sodium and chloride reabsorption and is regulated by 
the mineralocorticoid aldosterone[30]. Na+ exits the cell to the interstitium via 
Na+/K+-ATPase in the basolateral membrane. Decreased blood pressure or 
ECF volume stimulates secretion of Ang II, which thereby promotes 
aldosterone secretion. Binding of aldosterone to the mineralocorticoid 
receptors results in a translocation of the mineralocorticoid receptors to the
18
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nucleus, which upregulates the expression of NCC. Thiazide diuretics, on the 
contrary, inhibit NCC and therefore reduce Na+ reabsorption. Inactivating 
mutation of NCC results in Gitelman syndrome, an autosomal recessive 
disorder associated with reduction of sodium reabsorption by the distal 
convoluted tubule [31;32].
The connecting tubule connects to the distal convoluted tubule with the 
collecting duct[33]. The connecting tubule and collecting duct reabsorb 
sodium and variable amount of water, depending on the expression and 
localization of their key transporters, the amiloride-sensitive epithelial sodium 
channel (ENaC) and the AQP2 water channel, respectively. ENaC and AQP2 
are expressed in the principal cells of these segments. With hypovolemia, the 
increased release of aldosterone activates the mineralocorticoid receptors, 
which in turn increases the expression of ENaC and the Na+/K+-ATPase and 
induces the translocation of ENaC to the plasma membrane. Therewith, it 
stimulates active sodium reabsorption which is in the collecting duct coupled 
to potassium and hydrogen secretion. Furthermore, the AngII (RAAS)- 
induced increase of sodium concentration, together with the baroreceptor 
stimulation, induces AVP release from the pituitary to facilitate renal water 
reabsorption that is needed for correction of the volume. Amiloride diuretics, 
on the contrary, inhibit Na+ reabsorption by directly inhibiting ENaC, which 
further indirectly inhibit Cl- reabsorption and K+ secretion due to the reduced 
negative charge in the lumen[34]. Specific point mutations of ENaC, resulting 
in increased presence of ENaC in the plasma membrane leads to Liddle’s 
syndrome, an autosomal dominant disorder associated with excess 
reabsorption of sodium and loss of potassium due to the over-activity of 
ENaC[35;36].
RENAL OSMOREGULATION
The antidiuretic hormone AVP acts on the kidneys to regulate the osmo- 
balance. Following volume depletion and the consequent increase in renal 
sodium reabsorption, the osmolality of the body fluids increases and is the 
main trigger for the release of AVP from the pituitary. The same pathway is 
activated with normovolemia and hypernatremia, e.g. when eating salty fries. 
Released AVP binds to the V2R in the basolateral membrane of collecting 
duct principal cells. The occupation of V2R by AVP causes activation of
19
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adenylyl cyclase (AC) and a subsequent rise in intracellular cAMP levels. The 
increased cAMP concentration activates protein kinase A (PKA), which has at 
least two targets involved in the regulation of AQP2. First, PKA 
phosphorylates AQP2 itself. Phosphorylation of at least three out of four 
monomers of an AQP2 tetramer is sufficient to redistribute AQP2 
homotetramers from storage vesicles to the apical membrane of the principal 
cells, consequently rendering the cells permeable to water[37;38]. Second, 
PKA phosphorylates the cAMP responsive element binding protein (CREB), 
a transcription factor of AQP2. Activated by the phosphorylation, CREB then 
binds and activates the AQP2 gene promoter and therefore increases AQP2 
transcription[39-42]. Due to the increased total and plasma membrane 
expression of AQP2, water is able to pass the apical membrane passively 
through AQP2 along the osmotic sodium and urea gradient and exits across 
the basolateral membrane through AQP3 and AQP4, which are constitutively 
expressed in this membrane[43;44]. This process in turn results in 
concentrated urine. When sufficient water is reabsorbed to restore isotonicity, 
plasma AVP levels will decrease[45], and AQP2 will be internalized from the 
apical membrane.
In the AVP-induced intracellular regulation of AQP2, phosphorylation of 
AQP2 at Ser256 by PKA is a prerequisite for AVP-induced apical 
translocation of AQP2[41;46]. The role of other putative phosphorylation 
sites in AQP2, three putative casein kinase II sites (Ser148, Ser229 and 
Thr244), and one PKC site (Ser231) was also investigated but could not be 
associated with AQP2 trafficking[46]. Recently, three novel phosphorylation 
sites (Ser261, Ser264 and Ser269) were identified in the C-terminus of 
AQP2[47], which are of potential importance in AVP-induced AQP2 
trafficking. Studies of native rat IMCD cells demonstrated that 
phosphorylation of AQP2 Ser256, Ser264 and Ser269 are increased with AVP 
stimulation, while Ser261 is decreased[47;48]. Furthermore, the AQP2 
proteins phosphorylated at either of the four sites show distinct subcellular 
localization[48-50]. This suggests the presence of distinct subcellular pools of 
AQP2 and that phosphorylation at these sites may be involved in regulating 
the subcellular localization of AQP2.
Besides AQP2 phosphorylation, depolymerisation of actin, which forms the 
cytoskeleton, also plays an important role in the trafficking of AQP2. Recent 
studies showed that actin depolymerisation is a prerequisite for cAMP-
2 0
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dependent translocation of AQP2[51;52]. Before fusion with the apical 
membrane, the AQP2-bearing vesicles have to travel to the apical regions 
after rearrangement of the cytoskeleton. In renal principal cells, small GTPase 
RhoA was found to play an important role in actin depolymerisation[51-54]. 
Inhibition of RhoA activity through Rho phosphorylation by PKA and 
interaction with Rho GDP dissociation inhibitor induces partial 
depolymerisation of the actin cytoskeleton, thereby facilitating the 
translocation of AQP2-bearing vesicles to the apical membrane[53]. Besides 
actin, only 3 other proteins are known to directly interact with AQP2, signal- 
induced proliferation-associated protein 1 (SPA-1), heat shock protein 70 
(Hsc70), and myelin and lymphocyte-associated protein (MAL)[55]. The 
PDZ-domain containing protein SPA-1 is a specific GTPase-activating 
protein for Rap1 and inactivates Rap1[56]. Noda et al. demonstrated that 
AQP2 trafficking is impaired in SPA-1 deficient mice and in MDCK-AQP2 
cells expressing constitutively activated Rap1. Heat shock protein 70 (Hsc70) 
interacts directly with AQP2, which is a part of the endocytotic machinery 
that regulates clathrin-mediated endocytosis[57]. In addition to Hsc70, AQP2 
also co-immunoprecipitated in a complex with proteins in the clathrin- 
mediated endocytosis pathway, including clathrin, dynamin, and the clathrin 
adaptor protein AP2, suggesting an involvement of this pathway in AQP2 
endocytosis[58-60]. Finally, MAL, also known as vesicle integral protein of 
17 kDa (VIP17), is abundant in the kidney collecting duct and expressed 
restrictively in the apical membrane[61;62]. Kamsteeg et al. recently 
demonstrated that MAL interacted with AQP2 in the collecting duct and 
enhanced AQP2 apical surface expression[63]. MAL increases the steady- 
state phosphorylation of AQP2 (Ser256), and enhances its apical surface 
expression by decreasing its internalization. Presumably MAL accomplishes 
the decrease in net AQP2 internalization through some combination of a 
decrease in the endocytosis of surface AQP2 and an increase in the exocytosis 
of AQP2 from recycling endosomes, although the precise mechanism remains 
to be studied.
AQP2 recycles constitutively and rapidly between intracellular stores and the 
cell surface. Upon AVP removal or PKC activation, AQP2 is internalized 
from the plasma membrane and accumulates in intracellular 
vesicles[46;64;65]. This endocytotic process is possibly through the clathrin- 
mediated endocytosis pathway[58;66]. Inhibition of clathrin-mediated 
endocytosis resulted in AQP2 accumulation at the plasma membrane[60].
21
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While phosphorylation of Ser256 is essential for AVP-induced AQP2 
translocation to the plasma membrane, dephosphorylation of AQP2 does not 
seem to be required for its internalization[46]. The molecular mechanisms 
underlying AQP2 endocytosis is not yet clear. Kamsteeg et al. demonstrated 
that AVP removal or PKC activation by TPA induced short-chain 
ubiquitination of AQP2 at position Lys270, followed by endocytosis and 
degradation[67]. Consistently, AQP2-K270R was delayed in its 
internalization, demonstrating the importance of ubiquitination in AQP2 
endocytosis. However, although delayed, AQP2-K270R was still internalized, 
which indicated that there are other mechanisms involved in AQP2 
endocytosis. Furthermore, internalized ubiquitinated AQP2 is targeted for 
lysosomal degradation.
In addition to its direct regulation of water transport through AQP2, AVP also 
increases sodium transport in the collecting duct via ENaC by upregulating 
ENaC expression and translocation to the plasma membrane[68;69]. The 
effect of AVP on ENaC, however, is minor compared to that of aldosterone. 
AVP also increases urea transport via the UT-A1 transporter by increasing the 
cAMP-dependent phosphorylation of UT-A1[70]. Both these actions are 
meant to generate a hypertonic interstitium, needed as a driving force for the 
uptake of water.
DISTURBANCES IN OSMOREGULATION
As osmoregulation is influenced by the volume regulation, a disturbed 
osmobalance, which is characterized by hypo or hypernatremia, can be an 
indirect result of a disturbance in the volume balance or a direct result of a 
disturbance in the osmobalance. As there are some excellent reviews on 
disturbances in volume balance[71;72], I will focus here on direct 
disturbances of the osmobalance.
The syndrome of inappropriate antidiuretic hormone secretion (SIADH)
is a common clinical problem and is attributed to excessive ADH (AVP) 
release resulting in increased renal water reabsorption. Due to the excess of 
water reabsorption, SIADH leads to hyponatremia, characterized as a decrease 
in plasma sodium concentration lower than 136 mmol/L and a corresponding 
plasma osmolality of less than 280 mOsmo/kg H2O. In SIADH, AVP
2 2
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secretion is unrelated to the sensing of osmolality or ECF volume. SIADH 
occurs most frequently in association with vascular, infectious or neoplastic 
abnormalities in the central nervous system or the lung[73]. The 
neurophysiologic inputs for AVP release arise both from the central nervous 
system and from the chest via baroreceptors and neural input. Therefore, the 
abnormalities in these areas, as well as some carcinomas that can 
independently synthesize and release AVP, are the common causes of SIADH 
(review see[74]). In an experimental SIADH rat model, it was demonstrated 
that AQP2 mRNA and protein expressions were significantly increased in the 
collecting duct, indicating that increased expression of AQP2 in the collecting 
duct accounts for the water retention and pathological state of SIADH[75].
Diabetes insipidus (DI) is characterized by an inability of the kidney to 
concentrate urine, resulting in excessive renal water excretion (polyuria) and 
consequently, polydipsia. As water is not always accessible, DI is often 
associated with hypernatremia, a status characterized as a sodium 
concentration higher than 145 mmol/L, which is indicative of a greater water 
than sodium loss. In central DI, normal vasopressin production is impaired 
and therefore the urine concentrating ability to reabsorb water from pro-urine 
is lost. The causes of central DI are brain carcinoma, local inflammatory, 
autoimmune or vascular diseases, head trauma or diseases in the 
hypothalamus or pituitary gland, and AVP gene mutations[76-79]. Central DI 
can be reversed by the administration of the synthetic AVP homologue 1- 
desamino-8 -D-arginine vasopressin (dDAVP)[80]. In nephrogenic DI (NDI), 
although normal vasopressin production is available, the kidney is unable to 
respond to vasopressin stimulation. NDI is further characterized as congenital 
and acquired NDI. X-linked NDI, the most frequently occurring form of 
congenital NDI, is caused by the loss-of-function mutations in the AVPR2 
gene which encodes V2R, resulting in an insensibility of the collecting ducts 
to AVP[81;82]. Less frequently occurring congenital NDI forms are the 
autosomal recessive and dominant NDI, both due to mutations in the AQP2 
gene[83;84].
In contrast to congenital DI, acquired forms of NDI are much more common 
and are often secondary to drugs such as lithium, or metabolic disturbances 
such as hypokalemia and hypercalcemia. Acquired NDI is a common 
consequence of lithium therapy, which is given to patients with bipolar 
disorders. As lithium is prescribed to 0.1% of the population and
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approximately 20% of patients develop NDI, it is the most common form of 
NDI. Lithium-induced NDI is associated with significant decreased AQP2 
protein and mRNA levels in the collecting duct in rats and a decreased urinary 
AQP2 excretion in humans[85;86]. Lithium-induced NDI also coincides with 
cellular remodeling of collecting duct[87]. Nevertheless, the underlying 
mechanism how lithium causes NDI is unknown. Moreover, both diuretics 
amiloride and thiazide are proposed as therapeutics in lithium-induced 
NDI[88;89], but their effect and mechanism of action are unclear.
Hypokalemia and hypercalcemia are relatively common electrolyte disorders 
and well-known causes of acquired NDI[73]. Studies using potassium- 
depleted rats and vitamin-D induced hypercalcemia rats have shown a reduced 
expression and plasma membrane targeting of AQP2[90;91]. Furthermore, 
both conditions were also shown to be associated with reduced expression of 
Na-K-2Cl-cotransporter (NKCC2) in the TAL in different rat studies[92;93], 
indicating that the urine concentrating defect might also be due to the reduced 
sodium and chloride reabsorption in the TAL and the consequently decreased 
medullary osmolality.
Several susceptible proteins expressed in brain and kidney might also be 
involved in direct disturbance of osmoregulation. Although the process of 
central osmoregulation has been studied for many years, the proteins involved 
in this process, of which mutations/polymorphisms lead to hyponatremia and 
hypernatremia, are just beginning to be identified. These candidate proteins 
include the transient receptor potential vanilloid ion channels 1 and 4 (TRPV1, 
TRPV4) and newly identified V2R mutations. Both TRPV1 and TRPV4 
calcium channels localize in osmo-sensitive neurons and translate the osmo- 
sensing signal to vasopressin release. Mice lacking these proteins showed 
disturbed osmoregulation, indicating the importance of these proteins to 
osmoregulation[94-96]. Mice lacking TRPV1 have a reduced number of 
action potentials in osmo-sensitive neurons and are hypernatremic, while 
TRPV4 knockout mice become hypernatremic upon dehydration due to a 
blunted increase in vasopressin release. Humans with reduced activity of 
TRPV4, however, are hyponatremic. In addition to the expression and 
function in the brain, both TRPV1/TRPV4 also seem to be present in the 
kidney, but their role is unknown. V2R gain-of-function mutations R137C 
and R137L, different from the loss-of-function mutations in congenital NDI, 
were proposed to cause the nephrogenic syndrome of inappropriate
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antidiuresis (NSIAD), a pseudoform of SIADH[97]. NSIAD, compared to 
SIADH, showed a similar clinical phenotype (namely hyponatremia) except 
the detectable plasma AVP level that is often seen in SIADH. These findings 
illustrate a diversity of the involvement of genes/factors other than 
vasopressin in the disturbance of osmoregulation. Identification of these 
candidate genes and those to-be-identified in osmo-(dis)-regulation will 
increase our understanding of systemic osmoregulation.
AIM AND OUTLINE OF THIS THESIS
Regulation of AQP2 in its expression and trafficking is critical to 
osmoregulation and maintenance of body water homeostasis. However, the 
exact molecular mechanisms which regulate and recruit AQP2 in various 
(patho-) physiological conditions are still unknown.
In osmoregulation, AVP triggers a cAMP-mediated signaling pathway that 
activates PKA. PKA has been regarded as the main, if not the only, effector of 
cAMP in the various cellular processes in the kidney. However, the newly 
identified cAMP targets, the exchange protein directly activated by cAMP 
(Epac) 1 and 2 that mediate alternative pathways other than PKA, are found 
highly expressed in the kidney[98;99] and possibly involved in the 
translocation of AQP2 in response to cAMP activation[100]. In Chapter 2, 
Epac 1 and 2 antibodies were characterized and used to investigate the renal 
localization of these two proteins[1 0 1 ].
In osmoregulation, AVP triggers a cAMP-mediated signaling pathway that 
activates through PKA the transcription of AQP2 and translocation of AQP2 
to the apical membrane of collecting duct cells. For this latter process, 
phosphorylation of AQP2 at S256 by cAMP-dependent PKA is considered to 
be essential. A novel mutation of AQP2, p.R254Q, was identified in a 5 year 
old girl of a family with an autosomal dominant form of inheritance of NDI. 
This mutation is located within the carboxyl terminal tail o f  AQP2 and 
thereby destroys the PKA consensus site. To identify whether the mutation 
p.R254Q can be causal to NDI and to determine the underlying mechanism of 
this mutation in dominant NDI, we expressed AQP2-p.R254Q in oocytes and 
polarized epithelial MDCK cells and analyzed in detail as described in 
Chapter 3[102].
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Lithium-induced NDI, the most common form of NDI, is associated with a 
decreased AQP2 expression and which is generally ascribed to reduced 
adenylyl cyclase activity and thereby a reduced cAMP cascade[85;103]. 
Chronic lithium treatment also leads to severe loss of the renal principal 
cells[87]. At present, however, it is unclear how lithium causes NDI and 
whether lithium-induced NDI can be attenuated. Resolving the underlying 
molecular cause of lithium-induced NDI will provide insights of this disorder 
and the regulation of AQP2, and it is also essential for the development of 
putative therapeutic treatments. As an appropriate cell model that expresses 
AQP2 endogenously and is sensitive to the therapeutic lithium doses has been 
lacking, we characterized the mpkCCD cells as a suitable cell model to study 
lithium-induced NDI in vitro and assessed the involvement of adenylyl 
cyclase in lithium-induced NDI, as described in Chapter 4[104]. Furthermore, 
as amiloride is proposed as therapeutics in lithium-induced NDI, and 
amiloride directly inhibits ENaC activity in the collecting duct principal cells 
in which resides AQP2, the association of ENaC, amiloride, and lithium- 
induced NDI was investigated in Chapter 5[105]. Gene profiling of the 
kidney inner medullar collecting duct cells from rats of short-term lithium 
treatment provides a unique possibility for finding novel genes that are 
potentially involved in the pathogenesis of lithium-induced NDI, as well as 
signaling pathways involved in the regulation of AQP2. Chapter 6  describes 
the essential establishment of the earliest moment at which lithium induces 
polyuria and downregulation of AQP2 mRNA and protein levels in vivo. 
Following cDNA microarray analysis upon the first observed changes in the 
cells, the distinct genes were further analyzed using the Ingenuity pathways 
analysis program.
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ABSTRACT
In the kidney, many physiological processes of ion transport and cellular 
proliferation are mediated via cAMP, which classically activates protein 
kinase A (PKA). Recently, however, two new cAMP targets, the exchange 
protein directly activated by cAMP (Epac) 1 and 2 were identified, which 
mediate alternative pathways to PKA. To investigate their renal expression, 
antibodies specifically recognizing Epac1 and Epac2 were generated and used 
in rat immunohistochemistry with antibodies recognizing Aquaporin-1, 
Tamm-Horsfall protein, Calbindin-D28K and aquaporin-2 to mark proximal 
tubules (PT)/thin descending limbs of Henle’s loop (tDLH), thick ascending 
limbs of Henle’s loop (TAL), distal convoluted tubule/connecting tubule 
(DCT/CNT), and the collecting duct (CD) principal cells, respectively. Epac1 
and Epac2 were expressed at the brush border of PT cells, but were absent 
from tDLH cells. In the TAL, Epac1 and Epac2 were expressed throughout 
the cells with some confinement towards the apical membrane. In the 
DCT/CNT, Epac1 was confined to the apical region of the cells, whereas 
Epac2 was mainly expressed in the apical and basolateral regions. In the CD, 
a dispersed Epac1 expression was found in intercalated cells only (CCD), 
principal and intercalated cells (OMCD), and mainly AQP2-negative cells in 
the IMCD. In contrast, Epac2 expression was at the apical and basolateral 
membrane of cortical principal cells, dispersed and apical in the OMCD, and 
in all cells of the IMCD. A similar distribution for Epac1/2 was found in the 
human kidney. The observed expression in different tubular segments 
suggests a major role for Epac 1/2 in tubular transport physiology and cellular 
proliferation.
INTRODUCTION
Cyclic adenosine monophosphate (cAMP) is a common second messenger 
controlling many cellular processes. Protein kinase A (PKA) is a general 
acceptor for cAMP, resulting in the phosphorylation of a large variety of 
cellular targets. A newly described cAMP-target, exchange protein directly 
activated by cAMP (Epac) 1, and its close relative Epac2 contain cAMP- 
binding domains very similar to the cAMP-binding domains in the regulatory 
subunit of PKA and activate specifically the monomeric G proteins of Ras
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family, Rapl and Ras[1;2]. Many actions of cAMP, which were thought to be 
mediated exclusively by PKA, are now found to be likely mediated through 
Epac, including integrin-mediated cell adhesion[3], vascular endothelial cell 
barrier formation[4;5], cardiac gap junction formation[6 ], mitogen-activated 
protein kinase (MAPK) signaling[7], hormone gene expression[8 ], and 
phospholipase C-epsilon (PLC-s) activation[9;10]. Intriguingly, newly 
published findings demonstrate that Epac-mediated actions of cAMP 
influence Na+, K+, Ca2+ and Cl" channel function[11-13], Na+/H+ and Na+/K+ 
transporter activity, and exocytosis in multiple cell types[14-16].
Interestingly, the kidney is one of the organs that show the highest levels of 
expression of mRNAs encoding Epac1[2], especially in the collecting ducts, 
suggesting an important role of Epac in cAMP signalling mechanisms in the 
kidney. Therefore, to identify which renal segments might involve Epacl or 2 
in their cellular processes, we investigated the localization of Epacl and 2 in 
the rat kidney.
MATERIALS AND METHODS 
Cell culture
Human embryonic kidney 293 (HEK293) cells were grown in Dulbecco's 
modified Eagle's medium (DMEM) supplemented with 10% (v/v) fetal calf 
serum at 37°C in 5% CO2 and transiently transfected with the empty 
expression vector pcDNA3, or those containing Flag-tag-full length human 
Epacl (GI: 3978530) cDNA or Flag-tag-full length mouse Epac2 (GI: 
9790086) cDNA using polyethylenimine (Polysciences Inc., Germany). 
HEK293 cells were seeded on polylysine-coated glass slides in 12-well-plate 
(Corning Costar, Cambridge, MA) at a density o f 1 x 105 cells/ well. The 
medium was refreshed and the cells were transfected 3 hrs later. The 
transfection mix for each well consisted of 1 ^g cDNA and 6  ^l 
polyethylenimine (1 ^g/^l) in a total volume of 30 ^l Opti-MEM (Invitrogen). 
It was incubated for 20 min at room temperature and added to the cells. After 
an overnight incubation at 37°C, the medium was refreshed and the cells were 
grown for 2~3 days.
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Tissue preparation
Male Wistar rats were obtained from the University Animal Facility, Radboud 
University Nijmegen Medical Centre. Following anaesthesia with 
isofluorothane, the rats were sacrificed after which the kidneys were rapidly 
removed, fixed in 1% (wt/vol) periodate-lysine- paraformaldehyde (PFA) for 
2 h and 15% (wt/vol) sucrose in PBS for 16 hours, fast frozen in liquid 
nitrogen and stored at -80°C.
Human donor kidneys were provided by Eurotransplant. These kidneys had 
not been transplanted for technical reasons (branching o f the renal artery), but 
showed no histological abnormalities.The warm ischemia time of these 
kidneys was 8 8  minutes, and the cold ischemia time was 32 hours. These 
kidneys did not show significant signs of ischemia reperfusion injury [17;18]. 
All samples were obtained after informed consent of the donors. Their use 
was approved by the medical ethical committee o f Eurotransplant. Kidney 
cortex and medulla samples were fixed in 4% buffered formalin and 
embedded in paraffin.
Antibodies
For Epac detection, a cDNA fragment encoding human Epac1 (GI: 3978530) 
except for amino acids 1-148 (ADEP-Epac1) and a cDNA fragment encoding 
mouse Epac2 (GI: 9790086) except for amino acids 1-279 (ADEP-Epac2) 
were cloned into the pGEX expression vector to produce recombinant 
proteins. Rabbits were immunized with the GST-coupled ADEP-Epac1 or 
ADEP-Epac2 recombinant proteins and, after development o f proper antibody 
titres, the rabbits were bled. Polyclonal rabbit anti-serum 2293 was used to 
detect Epac1; rabbit polyclonal anti-serum 2295 was used to detect Epac2. 
Pre-immune sera were used as negative controls. Mouse monoclonal anti-Flag 
antibody (M2; Sigma-Aldrich, St. Louis, MO) was used to detect the Flag- 
Epac proteins in transfected HEK293 cells.
As primary antibodies against renal segment marker proteins, we used mouse 
monoclonal AQP1 antibodies (kindly provided by Dr. Jennings, University of 
Texas, Galveston, USA) to detect proximal tubules (PT) and thin descending 
limbs of Henle’s loop (tDLH), polyclonal goat Tamm Horsfall protein (THP) 
antibodies (ICN Biomedicals, Inc, Aurora, Ohio, USA) to reveal the thick 
ascending limbs of Henle’s loop (TAL), mouse monoclonal Calbindin-D28K 
antibodies (Swant, Bellinzona, Switzerland) to detect the distal convoluted
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tubule (DCT) and connecting tubule (CNT), and affinity-purified guinea pig 9 
AQP2 antibodies, raised against the last 15 amino acids o f the AQP2 C- 
terminus[19] to reveal the principal cells of the collecting duct. Mouse 
monoclonal anti-P-actin antibodies were from Sigma-Aldrich (St. Louis, MO).
As secondary antibodies, Alexa 594-conjugated goat anti-mouse, donkey 
anti-goat or goat anti-guinea pig antibodies were used to detect AQP1, THP, 
Calbindin-D28K and AQP2. Alexa 488-conjugated goat anti-rabbit were used 
to detect Epac1 and 2 on the kidney sections. All secondary antibodies were 
purchased from Molecular Probes (Leiden, the Netherlands).
Immunoblotting
Transfected HEK293 cells from 12-well-plate were lysed in 200 ^l Laemmli 
buffer/well and 15 ^l samples were analyzed. PAGE, blotting and blocking of 
the PVDF membranes were done as described [20]. Membranes were 
incubated for 16 h with 1:1000-diluted polyclonal rabbit anti-Epac1 or Epac2 
antibodies, or 1:1,000-diluted monoclonal mouse anti-Flag antibody, in Tris- 
Buffered Saline Tween-20 (TBS-T) supplemented with 5% non-fat dried 
milk. Blots were incubated for 1 h with 1:5,000-diluted goat anti-rabbit IgG’s 
or 1:2,000 goat anti-mouse IgG’s (Sigma-Aldrich, St. Louis, MO) as 
secondary antibodies coupled to horseradish peroxidase. Proteins were 
visualized using enhanced chemiluminescence (ECL, Pierce, Rockford, IL). 
Equal loading o f the samples was confirmed by parallel immunoblotting 
against 1:25,000 diluted mouse P-actin antibody.
Immunocytochemistry and Immunohistochemistry
For immunocytochemistry, transfected HEK293 cells were washed twice with 
PBS-CM (PBS with 0.1 mM CaCl2, 1 mM MgCl2) and fixed in 3% 
paraformaldehyde for 30 min. Following quenching of aldehyde groups with 
50 mM NH4O  in PBS for 15 min, cells were permeabilized with 0.3% Triton 
X-100 in PBS for 15 min, incubated with goat serum dilution buffer (GSDB; 
16% goat serum, 0.3% Triton X-100, 0.3 M NaCl in PBS) for 30 min to block 
non-specific antibody binding, and incubated O/N with polyclonal rabbit anti- 
Epac1 or 2 antibody at 1:100 dilution in GSDB. After washing twice with 
permeabilization buffer (0.3% Triton X-100, 0.1% BSA in PBS), cells were 
incubated with 1:100 diluted goat anti-rabbit antibodies coupled to Alexa 488 
in GSDB for 45 min. Next, cells were rinsed twice with permeabilization 
buffer and mounted on glass slides with Mowiol.
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For immunohistochemistry on 7-^m cryosection of the rat kidney, the 
following protocol was used: 1) for antigen retrieval, the sections were 
immersed in boiled citrate target retrieval buffer (0.01 M sodium citrate and 
0.01 M citric acid [pH 6.0]) and left to cool for 30 min. 2) to block non­
specific antibody binding, sections were incubated in TN-B buffer (TN: 0.1 M 
Tris / HCl [pH 7.6], 0.15 M NaCl; B: 0.5% Blocking Reagent, Perkin Elmer 
Life Sciences, Boston, USA) for 30 min. 3) sections were incubated O/N at 
4°C with 1:100 diluted Epac1 or Epac2 antibodies or their pre-immune sera. 
4) following 3 times of 10 min washing with TN-T buffer (TN buffer with 
0.05% Tween-20), the sections were incubated for 1 h at room temperature 
with Alexa 488-conjugated goat anti-rabbit antibodies. 5) after being washed, 
the sections were incubated with mouse AQP1 antibodies (1:100), goat Tamm 
Horsfall antibodies (1:200), mouse Calbindin-D28K antibodies (1:100) or 
guinea pig AQP2 antibodies (1:50) for 1 h at room temperature, followed by 
Alexa 594-conjugated goat anti-mouse, donkey anti-goat or goat anti-guinea 
pig antibodies for 1 h at room temperature. 6 ) sections were dehydrated, and 
mounted in Mowiol. Images were made by using Bio-Rad MRC-1024 
confocal laser scanning microscopy (CLSM).
For the human kidneys, paraffin sections of 4 ^m thickness were cut, de- 
paraffinized and rehydrated. For Epac1 staining, antigen retrieval was 
achieved by boiling sections in 10 mM Tris/1mM EDTA buffer at pH 8.0 for 
10 min, followed by 20 min of cooling. For Epac2 staining, antigen retrieval 
was achieved by boiling sections in 10 mM citrate buffer at pH 6.0 for 10 
min, followed by 20 min of cooling. Endogenous peroxidase was blocked by 
0.3 % H2O2. Subsequently, the sections were incubated with rabbit anti-Epac1 
(1:300), anti-Epac2 (1:150), or anti-AQP2 (1:50) for 1 hour. After being 
rinsed, the sections were incubated with anti-rabbit-Envision or anti-guinea 
pig-Envision (Dako, Glostrup, Denmark), developed with diaminobenzidine 
and Cu2SO4, and counterstained with hematoxylin. Subsequently, the sections 
were dehydrated using increasing ethanol concentrations, xylene and mounted 
in malinol.
To check for the specificity o f the anti-Epac 1 and 2 immunostaining on the 
rat sections, the Epac antibodies at the concentrations given above were 
incubated O/N at 4°C with their antigenic GST-ADEP-Epac1 (15mg/ml) or 
GST-ADEP-Epac2 (5mg/ml) recombinant proteins before application. For the 
human sections, the anti-Epac1 and anti-Epac2 antibodies were first serially
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diluted until the next one in two dilution step resulted in reduction of 
immunostaining. The dilution o f anti-Epac antibodies was incubated with a 
10-fold molar excess of either Epac1, or Epac2 recombinant protein for 4 
hours at 4°C, followed by immnostaining o f normal human kidney paraffin 
sections. Control sections were incubated with unabsorbed antibodies at the 
same dilution.
RESULTS 
Specificity of the Epac 1 and 2 antibodies
To test the specificity of rabbit polyclonal antibodies 2293 and 2295 for Epac
1 and 2, respectively, HEK293 cells were transiently-transfected with F- 
Epac1 or F-Epac2 expression constructs. After three days, the cells were fixed 
and subjected to immunoblotting using these antibodies. Confocal laser 
scanning microscopy (CLSM) revealed a clear staining with the Epac1 
antibodies in cells expressing F-Epac1, but not F-Epac2 (Fig. 1A top). 
Moreover, the Epac2 antibodies only stained F-Epac2, but not F-Epac1, 
transfected cells (Fig. 1A bottom). In parallel, cells were scraped and lysed to 
test our antibodies with immunoblotting. As shown in figure 1B, our Epac1 
antibodies specifically recognized a band at 96 kDa in the lane loaded with F- 
Epac1 transfected cell material, which is the anticipated size for F-Epac1. No 
signal was found in the lanes loaded with samples derived from mock or F- 
Epac2 expressing cells (Fig. 1B). In contrast, our Epac2 antibodies recognized 
a 116 kDa in the lane loaded with F-Epac2 expressing material, which is in 
line with the anticipated mass o f F-Epac2. No such signals were obtained in 
lanes loaded with lysates from mock or F-Epac1 expressing cells. 
Immunoblotting with Flag antibody recognized the same bands for Epac1 and
2 in the cells. Similar P-actin signals confirmed loading of protein equivalents 
in each lane (Fig. 1B). These data indicated that our rabbit polyclonal 
antibodies against Epac 1 and Epac2 specifically recognize Epac1 and Epac2, 
respectively, when used in immunocytochemistry and in immunoblotting.
To determine whether our Epac antibodies reveal specific signals in the rat 
kidney, neighbouring sections were incubated with 1 :1 0 0  dilutions o f these 
sera or their respective pre-immune sera. Subsequent CLSM analysis revealed 
clear signals with the anti-Epac1 antibodies and anti-Epac2 antibodies (Fig. 
1C, left, arrows indicating positively stained renal tubules), which were not
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Figure. 1. Specificity of the Epac1 and 2 antibodies. (A) F-Epac1 or F-Epac2 
expressing HEK293 cells (indicated) were immuno-stained with rabbit Epac1 or 
2 antibodies, followed by Alexa-488 conjugated goat-anti-rabbit secondary 
antibody. The cells were analyzed CLSM. Images are shown with a 180-fold 
magnification. (B) Lysates of mock-transfected (m) or F-Epac1(1) or F-Epac2 
(2) expressing HEK293 cells were separated by gel electrophoresis and 
immunoblotted for Epac1, Epac2 or the Flag tag (indicated), whereas 
immunoblotting for p-actin was done to check equal loading. (C). Rat kidneys 
were fixed with 3% PFA, cryo-sections were made and incubated with rabbit 
Epac1 or Epac2 antibodies, or rabbit pre-immune serum (indicated), followed by 
Alexa-488 conjugated goat-anti-rabbit secondary antibody. (D) Consecutive 
cryo-sections were immuno-stained as in C with the rabbit Epac1 or 2 
antibodies, or the antibodies pre-absorbed with their antigenic recombinant 
proteins (indicated). Images are shown with a 60-fold magnification. Arrows 
indicate the tubules of inspection.
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seen with their respective pre-immune sera (Fig. 1C, right, arrows indicating 
the same tubules as those in the left). These data indicated that both antibodies 
reveal specific Epac signals in the rat kidney. Furthermore, pre-absorption of 
the antibodies with their antigenic recombinant proteins fully blocked the 
fluorescent signal (Fig. 1D, arrows indicating the same tubules for both left 
and right panels), demonstrating the specificity of these antibodies.
Localization of Epac1 in rat kidney
To elucidate the renal segmental localization of Epac1 and 2, co- 
immunohistochemical staining of rat kidney sections for Epac1 or 2 with 
nephron segment marker proteins was performed. Proximal tubules (PT) and 
thin descending limb of Henle’s loop (tDLH) express AQP1, the thick 
ascending limb of Henle’s loop (TAL) expresses Tamm-Horsfall protein 
(THP), the distal convoluted tubule (DCT) and connecting tubule (CNT) 
express Calbindin-D28K, and principal cells of the collecting duct (CD) 
express AQP2. Double labelling of Epac1 with AQP1 revealed a co­
localization in about 30% of the AQP1 positive proximal tubules in cortex 
(Fig. 2A), but no expression of Epac1 in AQP1-positive segments of the outer 
medulla (Fig. 2B). Interestingly, in all tubules stained with Epac1, the signals 
were predominantly confined to the brush border membrane region of the 
cells (Fig. 2A arrows)[16;21]. In the inner medulla, AQP1 positive tDLH 
tubules did not show Epac1 specific staining (Fig. 2C). Co-labelling with THP 
showed that Epac1 was expressed in all TAL cells (Fig. 2D). In these cells, 
Epac1 expression was spread throughout the cells, with a somewhat stronger 
staining at the apical side of the cells (Fig. 2D arrows). In the DCT and CNT, 
Epac1 was found in all Calbindin-D28K positive cells at only the apical region 
of the cells, but its expression was clearly weaker than in the proximal tubules 
(Fig. 2E, arrows). In the collecting ducts, Epac1 expression was found all 
along the tubule (Fig. 2F-H; arrows indicate principal cells and arrow heads 
intercalated cells). In the cortex, Epac1 was found in intercalated cells, in 
which it was evenly distributed. In the outer medulla, Epac1 was mainly 
expressed in intercalated and to some extent in (AQP2 positive) principal 
cells. In the inner medulla, Epac1 was again mainly found in AQP2-negative 
cells.
Localization of Epac2 in rat kidney
Double labelling of Epac2 with AQP1 revealed a clear Epac2 expression in 
proximal tubules of the cortex and outer medulla (Fig. 3A-B; arrows). Its
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Figure. 2. Expression of Epac1 in the rat kidney. Renal sections were double­
labelled for Epac1 (green) and AQP1 (red, A-C), Tamm Horsfall protein (THP, 
red, D), Calbindin-D28K (red, E) or AQP2 (red, F-H) and analyzed by CLSM. 
Images are shown with a 10- and 60-fold magnification (indicated). Arrows 
indicate the tubules of inspection. Bold arrows indicate CD principal cells, and 
arrow heads indicate CD intercalated cells.
expression was somewhat dispersed over the cell, but was mainly localized at 
the brush border side and sometimes also at the basolateral side of the cells 
(double arrows). The identity of the Epac2-positive structures in the lumen of
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the proximal tubules is unclear. The AQP1 positive tDLH positive tubules of 
inner medulla didn’t show staining for Epac2 (Fig. 3C).
Similar to Epac1, extensive expression of Epac2 was found in the TAL as all 
THP positive cells stained for Epac2 (Fig. 3D). Moreover, it had a dispersed 
vesicular-like expression pattern and confinement to the apical side of the 
cells (arrows). Epac2 was also found in the DCT and CNT, because it was 
expressed in all Calbindin-D28K positive tubular cells and intercalated cells 
(Fig 3E, arrows and arrow heads). In these cells Epac2 was found in the apical 
(arrow) and basolateral (double arrow) region of the cells. In the collecting 
duct, all AQP2-positive cells stained for Epac2 (Fig. 3F-H; arrows). In all 
segments, Epac2 was also mainly found at apical regions of the cells, with 
some expression throughout and at the basolateral side of both intercalated 
and principal cells.
Localization of Epac1 and Epac2 in the human kidney
To determine the localization of Epac1 and 2 in the human kidney, it was first 
tested whether the antibodies would yield specific staining. Indeed, following 
pre-absorption of the antibodies with their antigenic recombinant proteins, a 
complete absence (Epac1) or a marked reduction (Epac2) of Epac1 and Epac2 
staining on human kidney was observed (Fig. 4A). However, virtually no 
inhibition of staining was observed, when anti-Epac1 antibodies were 
incubated with Epac2, or vice versa (not shown). The subsequent 
immunoperoxidase staining using our Epac antibodies showed that the 
localization of Epac1 and Epac2 was essentially similar to that in the rat 
kidney (Fig. 4B). Epac1 was found in both proximal and distal epithelial cells, 
TAL, and CD with a predominant apical distribution. Glomerular epithelium 
only showed a weak staining. Peritubular capillaries and glomerular 
endothelium were negative. Epac2 staining was observed in a similar apical 
distribution in renal epithelia, but in addition showed some staining in visceral 
epithelial cells in glomeruli. To investigate whether Epac2 in the CD localized 
to principal or intercalated cells, consecutive staining of Epac 2 and AQP2 
was performed (Fig. 4C). Similar to that in the rat kidney, Epac2 positive 
staining was observed in both AQP2-positive (principal) and AQP2- 
negative(intercalated; double arrow heads) cells in the collecting ducts, with a 
predominant expression to the apical membrane.
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Figure. 3. Expression of Epac2 in the rat kidney. Renal sections were double­
labelled for Epac 2 (green) and AQP1 (red, A-C), Tamm Horsfall protein (THP, 
red, D), Calbindin-D28K (red, E) or AQP2 (red, F-H) and analyzed by CLSM. 
Images are shown with a 10-, 30-, 60-, 120- and 180-fold magnification 
(indicated). Arrows indicate the tubules of inspection and apical membrane of 
the tubular cells, whereas double arrows indicate basolateral membrane. Arrow 
heads indicate CNT intercalated cells.
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Figure. 4. Immunohistochemistry of Epac1 and Epac 2 in the human 
kidney. (A) Human renal sections were labeled by indirect immunoperoxidase 
for Epac1 and Epac2 (indicated) or the antibodies pre-incubated with their 
antigenic recombinant proteins (indicated). Magnification 10x. (B) Human 
kidney section of cortex and medulla were immune-labeled as in (A). Arrows 
indicate apical localization of Epac1 and 2 on distal tubular epithelium (left 
panel) and double arrows on collecting ducts (right panel). Bold arrows indicate 
cytoplasmatic Epac2 in proximal epithelium and arrow heads in glomerular 
visceral epithelium (left bottom). Magnification 20x. (C) Sequential human 
kidney sections were immunolabeled as in (A) with Epac2 and AQP2 antibodies. 
Arrow heads indicate CD intercalated cells. Magnification 100x.
DISCUSSION
During the last years, an alternative pathway for cAMP signalling has 
emerged with the identification of Epac1 and 2. Considering the important 
role that this cascade plays in the regulation of several different processes in 
the kidney, we set out to determine the Epac1 and Epac2 protein expression in 
the rat and human kidney. For this, we used rabbit polyclonal antibodies 2293 
and 2295, which were generated against human Epac1 and mouse Epac2, 
respectively. As shown in Fig. 1, these antibodies specifically recognized 
Epac 1 or 2 proteins without cross-reacting to each other. Furthermore, they 
also showed signals in the rat kidney, which were Epac-specific because 
neither the pre-immune sera nor the anti-sera after pre-absorption showed 
positive staining throughout the kidney. Immunostaining of both Epac 
isoforms in human and rat kidneys showed similar protein distribution.
Epac in the proximal tubule
Our immunohistochemistry revealed Epac1 and Epac2 expression throughout 
the nephron and collecting duct (Fig. 5). In line with the detected high 
expression of Epac1 mRNA [21] and the supposed functional implication of 
Epac1 in the cAMP-mediated regulation of the Na+/H+ exchanger 3 (NHE3) 
in the brush border[16;21] of mouse proximal tubule, we found a clear 
expression of Epac1 in the rat proximal tubule (Fig. 2A). The observed pattern 
for Epac1 (and Epac2) appeared similar as found for megalin, which is 
expressed in all three proximal tubule segments, but mainly segments 1 and 
2[22]. However, as the functional effects on NHE3 were deduced from the
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response to an Epac-specific agonist, and both Epac1 and Epac2 are found in 
the apical region of proximal tubules (Fig. 2A and 3A-B), the observed effect 
might have also been mediated by Epac2. Interestingly, angiotensin II has 
been shown to stimulate collagen synthesis in mouse mesangial cells through 
a novel Epac-mediated phosphoinositide 3-kinase-dependent pathway[23]. In 
the kidney, angiotensin II increases sodium and bicarbonate reabsorption in 
the apical membrane of the proximal tubule via ATj receptors, in which Epac1 
or 2 might also be involved. The structures in the center of the tubules was 
seen for both Epac1 and 2 staining, although more often for Epac2. At 
present, it is unclear to us whether these are erythrocytes and/or tubular cells. 
Some of these structures showed as cells with a round shape and are 
disconnected from the tubules around them. These may be erythrocytes, as 
these have been reported to express Epac[24]. Others are more irregular, are 
often connected with the tubules around them and may therefore be tubular 
microvilli.
Epac in the thick ascending limb
In the TAL, vasopressin induces apical sodium entry by increasing the 
expression and activation of the Na+-K+-2Cl- co-transporter (NKCC2) and 
activation of the Na+-K+-ATPase located in the basolateral membrane[25;26]. 
Whereas activation of the sodium pump is ascribed to PKA-mediated 
phosphorylation of its a-subunit[27], Epac1 and Epac2 might have a role in 
this process, as both are highly expressed throughout this nephron segment 
(Fig. 2D and 3D).
Epac in the distal convoluted and connecting tubule
In the DCT and CNT, several transport processes, such as the adenosine- 
induced uptake of magnesium and TRPV5-mediated calcium reabsorption, are 
known to be regulated by cAMP[28;29]. Both Epac1 and Epac2 are found in 
these nephron segments with the confinement at the cell membrane (Fig. 2E 
and 3E). It has to be established whether they have a role in these processes.
Epac in the collecting duct
In the kidney collecting duct, several processes have been suggested to 
involve Epac. In microdissected rat cortical collecting ducts, Laroche-Joubert 
et al demonstrated that the H+/K+-ATPase is activated through a cAMP- 
Epac1-Rap1-Raf-B-ERK cascade in Ia intercalated cells[21]. Involvement of 
Epac1, however, was again deduced from using an Epac1/2-specific agonist.
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Figure. 5. Summary of Epac1 and 2 localization in the kidney tubular cells.
Epac1 and 2 loclizationsare listed in renal segments and cell types for rat (A) and 
human (B). G: glomerular cells; PT: proximal tubule cells of cortex (c) or outer 
medulla (o); tDLH: thin descending limb of Henle’s loop cells; TAL: thick 
ascending limb of Henle’s loop cells; DCT/ CNT: distal convoluted tubular and 
connecting tubular cells; CCD: cortical collecting duct cells; OMCD: outer 
medullary collecting duct cells; IMCD: inner medullary collecting duct cells; 
mCD: medullary collecting duct cells. none: no staining observed.
As we find expression of both Epac proteins in these cells (Fig. 2F and 3F), 
our data suggest that the observed effect could be mediated by Epac1 and/or 
Epac2.
Following incubation of rat inner medulla sections with the Epac agonist 8 - 
pCPT-2’-O-Me-cAMP, Yip[13;30] found that Epac is involved in the 
vasopressin-induced Ca2+ mobilization and translocation of AQP2 towards the 
apical membrane. Based on immunocytochemical detection using only Epac1- 
specific antibodies, Yip suggested that Epac1 mediates this response in the 
IMCD. In line with our data (Fig. 2H), however, close examination of the 
particular figure of Yip et al. reveals that his IMCD Epac1 expression is also 
mainly confined to AQP2-negative cells. Although an involvement of Epac1 
cannot be excluded at this stage, the complete overlap of Epac2 and AQP2 
expression in the IMCD cells (Fig. 3H) may suggest that Epac2, rather than 
Epac1, mediates the vasopressin-induced calcium mobilization and AQP2 
translocation in the IMCD.
Interestingly, several data suggest that sodium reabsorption through the 
epithelial sodium channel ENaC, which is expressed in the CNT and CD, 
might also involve Epac1 and 2. It has been shown that in rat pulmonary cells, 
dopamine increases the channel open probability (Po) of ENaC by a cAMP­
mediated alternative signalling pathway involving Epac and Rap1 [31]. 
Moreover, in Madin-Darby canine kidney cells stably expressing ENaC, 
cAMP has been shown to increase the short circuit current (ISC) by increasing 
the surface expression of ENaC, which is thought to occur through 
phosphorylation of ENaC[32]. In Xenopu laeviss oocytes, however, the 
stimulation by cAMP is abolished with the expression of recombinant ENaC 
mutated at ERK phosphorylation motifs, but not of PKA phosphorylation
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sites[33], which may suggest that cAMP stimulates ENaC functioning through 
an Epac/ERK-mediated phosphorylation of ENaC.
Epac in proliferation
Besides roles in mediating signalling cascades regulating ion channels and 
transporters, the role of Epac in cellular proliferation has also been suggested 
through its activation of Rap1 in various organisms[2;34-37]. Interestingly, 
several hormones, such as angiotensin II, AVP and endothelin, induce cellular 
renal proliferation through phosphorylation events. Moreover, cellular 
proliferation is a hallmark for polycystic kidney disease and lithium induced 
NDI, disorders of (mostly) the collecting duct in which cAMP has a critical 
role[38;39]. It remains to be established, however, whether Epac has a critical 
role in these physiological and patho-physiological processes of cellular 
proliferation.
In conclusion, we have established the renal localization of the two Epac 
isoforms, 1 and 2 . While the particular function of each of these isoforms 
awaits further investigation, our data provide a basis for further studies toward 
the elucidation of the role of PKA or Epac proteins in cAMP-mediated 
processes of ion transport and cellular proliferation in the kidney.
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ABSTRACT
Vasopressin regulates human water homeostasis by re-distributing 
homotetrameric aquaporin-2 (AQP2) water channels from intracellular 
vesicles to the apical membrane of renal principal cells, a process in which 
phosphorylation of AQP2 at S256 by cAMP-dependent protein kinase A 
(PKA) is thought to be essential. Dominant nephrogenic diabetes insipidus 
(NDI), a disease in which the kidney is unable to concentrate urine in 
response to vasopressin, is caused by AQP2 gene mutations. Here, we 
investigated a reported patient case of dominant NDI caused by a novel 
p.R254Q mutation. Expressed in oocytes, AQP2-p.R254Q appeared to be a 
functional water channel, but was impaired in its transport to the cell surface 
to the same degree as AQP2-p.S256A, which mimics non-phosphorylated 
AQP2. In polarized MDCK cells, AQP2-p.R254Q was retained and was 
distributed similarly to that of unstimulated wt-AQP2 or AQP2-p.S256A. 
Upon co-expression, AQP2-p.R254Q interacted with, and retained wt-AQP2 
in intracellular vesicles. In contrast to wild-type AQP2, forskolin did not 
increase AQP2-p.R254Q phosphorylation at S256 or its translocation to the 
apical membrane. Mimicking constitutive phosphorylation in AQP2-p.R254Q 
with the p.S256D mutation, however, rescued its apical membrane expression. 
These data indicate that a lack of S256 phosphorylation is the sole cause of 
dominant NDI here, and thereby, p.R254Q is a loss of function instead of a 
gain-of-function mutation in dominant NDI.
INTRODUCTION
Water and salt balance in the body is maintained within strict boundaries. 
With hypernatremia or hypovolemia, vasopressin (AVP) is released from the 
pituitary gland and transported to the kidney where it binds to the vasopressin-
2 receptor (AVPR2) located in the basolateral membrane of collecting duct 
principal cells. This G-protein coupled receptor subsequently activates 
adenylyl cyclase to turn ATP into cAMP, which in turn increases protein 
kinase A (PKA) activity. PKA is then thought to phosphorylate several 
proteins, among which the aquaporin-2 (AQP2) water channel that resides in 
intracellular vesicles. Phosphorylation of at least three out of four monomers 
of an AQP2 tetramer at serine 256 (S256) is sufficient to redistributing AQP2
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homotetramers from storage vesicles to the apical membrane of the principal 
cells, consequently rendering the cells permeable to water[1;2]. Driven by the 
transcellular osmotic gradient, urinary water then enters the cells via AQP2 
and leaves the cells via AQP3 and AQP4, which are constitutively expressed 
in the basolateral membrane. This solute-independent reabsorption of water 
from urine restores isotonicity and euvolemia, which leads to a diminished 
AVP release from the pituitary and re-distribution of AQP2 from the plasma 
membrane to intracellular vesicles [3;4].
Congenital nephrogenic diabetes insipidus (NDI), which is characterized by 
the inability of the kidney to concentrate urine in response to AVP, is caused 
by defects in the AVPR2 (MIM# 300538) or the AQP2 gene (MIM# 107777). 
Mutations in the AVPR2 gene cause the X-linked recessive form of NDI, 
whereas autosomal recessive and dominant traits of NDI are caused by 
mutations in the AQP2 gene[5-9]. Expression studies revealed that nearly all 
missense AQP2 mutants encoded in recessive NDI are misfolded and retarded 
in the endoplasmic reticulum (ER). In contrast, AQP2 mutants identified in 
dominant NDI, including AQP2-c.761G>T (p.R254L), AQP2-c.772G>A 
(p.E258K), AQP2-c.721delG, AQP2-c.727delG, c.763_772del, c.812_818del, 
and AQP2-c.779_780insA, are properly-folded but missorted to different 
subcellular destinations depending on the mutation[7;10-15]. These mutants 
exert their dominant effect by inhibiting the proper sorting of wt-AQP2 to the 
apical membrane after the formation of heteroligomers[11;13].
A novel mutation in AQP2, p.R254Q, has been reported to result in dominant 
NDI in a 5 years old girl (pedigree reviewed but not shown[16]. Sequencing 
revealed that this mutation was caused by a 761G>A substitution in one allele 
of the AQP2 gene, while no mutation was found in her AVPR2 gene. This 
patient exhibited unusual thirst from birth, was noted to be polyuric at 18 
months and was diagnosed DI at her 5 years age. There was no history of DI 
in her mother, father or only sibling (a 9 year old girl). Her physical 
examination, including height and weight were normal for her age (50th 
percentile). Her DI did not respond to standard therapeutic doses of 
desmopressin. On ad libitum intake of fluids, her basal plasma osmolality, 
sodium, potassium, urea and creatinine were within normal limits. However, 
her plasma vasopressin (Pvp) was slightly elevated (4.3 pg/ml), her urine 
osmolality (Uosmo) was very low (58 mOsmo/kgH2O) and her 24 hour urine 
volume (Uvol) was high (280 ml/kg weight), indicating she had moderately
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severe NDI. When deprived of fluid for 5 hours, she developed mild 
hypertonic dehydration and raised her Pvp and Uosmo to 22.3 pg/ml and 220 
mOsmo/kgH2O. When rehydrated and given a supra-physiologic dose of 
desmopressin (6.3 ^g intravenous in 20 minutes), her Uosmo rose to 258 
mOsmo/kgH2O after 2 hours, confirming a partial antidiuretic response to 
stimulation of the V2 receptors.
To identify whether AQP2-p.R254Q can be causal to NDI and to determine 
the underlying mechanism of this mutation in dominant NDI, we here 
expressed AQP2-p.R254Q in oocytes and polarized epithelial MDCK cells 
and analyzed these in detail.
MATERIAL AND METHODS 
Constructs
The constructs encoding pT7Ts-AQP2, pT7Ts-AQP2-p.R187C, pT7Ts- 
AQP2-p.S256A, pT7Ts-wt-AQP2-F, and G-AQP2 were as described 
[6;7;11;17]. The cDNA coding for AQP2-p.R254Q or AQP2-p.R254Q- 
p.S256D were made by introducing the mutations into pT7Ts-AQP2 
(GenBank reference sequence: NM_000486.5) with the Altered Sites 
mutagenesis kit (Promega, Madison, WI) using the primers 5’- CGAGG 
TGCGACGTCAGCAGTCGGTGG-3’ and 5 -  CGAGGTGCGACGTCA 
ACAGGACGTGGAGCTGC-3’, respectively. Nucleotide numbering reflects 
cDNA numbering with +1 corresponding to the A of the ATG translation 
initiation codon in the reference sequence, according to journal guidelines 
(www.hgvs.org/mutnomen). The initiation codon is codon 1. Introduction of 
only the desired mutations was confirmed by DNA sequence analysis. To 
generate pCB6-AQP2-p.R254Q or pCB6-AQP2-p.R254Q-p.S256D, AQP2- 
p.R254Q and AQP2-p.R254Q-p.S256D were digested from pT7Ts-AQP2- 
p.R254Q or pT7Ts-AQP2-p.R254Q-p.S256D with BglII and <SpeI and ligated 
into the BglII andXbaI sites of the eukaryotic expression vector pCB6 .
To generate FLAG-tagged AQP2 expression constructs, pBluescript-FLAG- 
wtAQP2 [11] was cut with NotI, blunted and digested with HindIII, and the 
FLAG-tagged AQP2 (F-AQP2) cDNA fragment was isolated. In pCB7, which 
is similar to pCB6 , but contains a hygromycin instead of neomycine 
resistance gene, the BamHI site was cut, blunted and re-ligated. Next, the F-
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AQP2 fragment was ligated into the blunted KpnI site and the HindIII of 
pCB7-ABamHI to yield pCB7-ABamHI-F-AQP2. To generate pCB7-F- 
AQP2-p.R254Q, pT7Ts-AQP2-p.R254Q plasmids were digested with BamHI 
and KpnI, a 300 bp fragment isolated and cloned into the corresponding sites 
of pCB7-ABamHI-F-AQP2.
Oocytes
The obtained pT7Ts constructs were linearized with SalI. Transcription of 
pT7Ts-constructs and analysis of their integrity was done as described[7]. 
cRNA injection of oocytes and analysis of their water permeability in a 
standard swelling assay were done as reported[6 ]. Statistical significance was 
determined using the Student’s T-test and was considered significant when 
p<0.05. Total and plasma membranes were isolated as described[18].
MDCK cells
MDCK cells were cultured and stably transfected with expression constructs 
using the calcium-phosphate precipitation technique as described[19]. 
Selection of G418-resistant clones and immunocytochemistry of transfected 
MDCK cells was done as described[20]. MDCK cell lines stably expressing 
wt-AQP2 (wt-10), AQP2-p.S256A or GFP-tagged AQP2 were as 
described[2;17;21].
Monoclonal antibodies against FLAG (m2) and Golgi 58K were purchased 
from Sigma (St Louis, MO, USA) and against early endosome antigen-1 
(EEA1) from BD Transduction Laboratories (Lexington, KY, USA). 
Polyclonal antibodies against the Golgi marker proteins GOS28 and Giantin 
were obtained from Dr. Y. Ikehara, Fukuoka University School of Medicine 
and against the ER marker protein PDI from Ineke Braakman, University of 
Utrecht[22]. Monoclonal antibody (clone AC17) against the late 
endosomal/lysosomal marker Lamp2[14] were kindly provided by Dr. Le 
Bivic, Marseille, France. Anti-rabbit and anti-mouse secondary antibodies 
coupled to Alexa 488 or 594 were purchased from Molecular Probes (Eugene, 
OR, USA). Images were obtained with a Bio-Rad confocal laser-scanning 
microscope (CLSM) using a 60x oil-immersion objective and a 3-fold 
magnification.
Transient transfections of MDCK type I cells have been performed using 
LipofectAMINETM 2000 reagent (Invitrogen, CA, USA) according to the
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manufacturer’s protocol.
Immunoblotting, immunoprecipitation and densitometrical analysis
Immunoblotting, immunoprécipitations and orthophosphate labelling of 
MDCK cells were done as described[2;11]. To semi-quantify AQP2 amounts 
or the level of phosphorylation of AQP2-p.R254Q relative to that of wt- 
AQP2, immunoblot and [32P]-orthophosphate signals were semi-quantified by 
measuring the integrated optical densities (IOD) of the film signals using the 
Image-Pro Plus analysis software (Media Cybernetics, Silver Springs, CO). 
These signals were compared with those of two-fold dilution series of wt- 
AQP2, which were blotted in parallel or separated by SDS-PAGE and 
autoradiographed, respectively. Background IOD values were determined at 
unexposed areas of the film and subtracted from obtained IOD values for the 
different proteins. To determine the relative amounts of phosphorylated 
AQP2-p.R254Q protein, the level of phosphorylation was normalized for the 
amount of immunoprecipitated AQP2 and expressed as a percentile of 
phosphorylated wt-AQP2 protein under unstimulated condition, which was set 
at 1 0 0 %.
RESULTS 
Functional analysis of AQP2-p.R254Q in oocytes
Several expression studies have shown that phosphorylation of AQP2 at S256 
is essential for its AVP-induced translocation from vesicles to the plasma 
membrane, because AQP2-p.S256A, which mimics non-phosphorylated 
AQP2, is retained in vesicles [1;2;23;24]. R254 in AQP2 is part of the PKA 
phosphorylation consensus site (R-R254-X-S). Earlier, we showed that AQP2- 
p.R254L likely causes dominant NDI, because of its retention in intracellular 
vesicles due to an impaired phosphorylation at S256[15]. We hypothesized 
that the mechanism underlying NDI for the present mutation, p.R254Q, would 
be similar.
To determine whether the identified missense mutation could be the 
underlying cause for NDI in this patient, it was introduced into the AQP2 
cDNA sequence and transcribed. Then, oocytes were injected with cRNA 
encoding AQP2-p.R254Q, wt-AQP2 or AQP2-p.S256A. Determination of the 
water permeability (Pf) revealed that the Pfs of oocytes expressing AQP2- 
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p.R254Q (25.9±4.2; n=8 ) and AQP2-p.S256A (22.4±12; n=8 ) from 1 ng 
injections were significantly higher than those of controls (p=4x10-3), which 
showed that both mutants are functional water channels (Fig. 1A). To relate 
the obtained Pfs to the amount of expressed AQP2, total membranes and 
plasma membranes were isolated from the same batches of oocytes. 
Subsequent immunoblotting for AQP2 and densitometric scanning of the 
signals revealed that the expression levels of AQP2-p.R254Q and AQP2- 
p.S256A with 1 ng injections were similar and in between that of wt-AQP2 
expressing oocytes, injected with 1 and 3 ng cRNA (Fig. 1B, TM). In the 
plasma membranes of these oocytes, however, the expression levels of AQP2- 
p.R254Q and AQP2-p.S256A were about 6 -fold less than that found for wt- 
AQP2 (Fig. 1B, PM). Consistently, the total expression of AQP2-p.R254Q 
from 1 ng injections was higher than that of oocytes injected with 0.3 ng wt- 
AQP2 cRNA, but their plasma membrane expression levels were less. As 
reported for AQP2-p.S256A[1], these data indicated that AQP2-p.R254Q and 
AQP2-p.S256A were impaired in their trafficking to the plasma membrane. 
The similar level of retention of AQP2-p.S256A and AQP2-p.R254Q could 
indicate that the molecular cause of their retention in oocytes is identical.
AQP2-p.R254Q heteroligomerizes with wt-AQP2
To determine whether AQP2-p.R254Q would form heteroligomers with wt- 
AQP2 and thereby exert a dominant negative effect as other AQP2 mutants in 
dominant NDI do[10-12;14], it was co-expressed with flag-tagged wt-AQP2 
(F-AQP2) in oocytes and subjected to immunoprecipitation using Flag 
antibodies. Previously, we have shown that this N-terminal FLAG tag does 
not interfere with proper plasma membrane expression of wt-AQP2[11]. As a 
negative control, AQP2-p.R187C was taken along, which is an ER-retained 
AQP2 mutant in recessive NDI and does not heteroligomerize with wt- 
AQP2[11]. Two days after cRNA injections, membranes of oocytes 
expressing combinations of F-AQP2 with AQP2-p.R254Q or AQP2-p.R187C 
were solubilized and subjected to immunoprecipitation. Immunoblotting of 
total membranes using anti-AQP2 antibodies revealed clear expression of the 
31 kDa band of F-AQP2, the 29 kDa bands of AQP2-p.R254Q and AQP2- 
p.R187C, and the 32 kDa high-mannose glycosylated band of AQP2- 
p.R187C, which migrates slightly slower than F-AQP2 (Fig. 1C, TM). 
Immunoblot analysis of the FLAG immunoprecipitates showed that AQP2- 
p.R254Q, but not AQP2-p.R187C, co-precipitated with F-AQP2 (Fig. 1C, IP).
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Figure 1. Expression of AQP2-p.R254Q in oocytes. A) Water permeability. Three 
days after injection of the indicated amounts of wt-AQP2, AQP2-p.R254Q or 
AQP2-p.S256A cRNA, oocytes were subjected to a standard swelling assay. Non­
injected oocytes were taken as a control (C). Mean water permeabilities (Pf) and 
SEM of 8 oocytes are shown. B) AQP2 expression. From 12 oocytes injected as 
described above, total membranes (TM) or plasma membranes (PM) were 
isolated. Subsequently, equivalents of one (TM) or four (PM) oocytes were 
immunoblotted for AQP2. C) Heteroligomerization of AQP2-p.R254Q with wt- 
AQP2. Of 30 oocytes expressing combinations of F-AQP2 with AQP2-p.R254Q 
or with AQP2-p.R187C, total membranes (TM) were isolated. Equivalent 
fractions were solubilized in deoxycholate and subjected to immunoprecipitation 
(IP) using FLAG antibodies. Subsequently, total membranes and IPs were 
immunoblotted for AQP2. Molecular masses (in kDa) are indicated on the right.
Also, no AQP2 was detected in the immunoprecipitates from oocytes 
expressing untagged AQP2 only, which showed that the 
immunoprecipitations were specific for Flag-tagged proteins (not shown). 
Therefore, from these results it could be concluded that AQP2-p.R254Q forms 
heteroligomers with wt-AQP2.
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Localization of AQP2-p.R254Q in MDCK cells
Though oocytes are a good cell system to establish functionality and 
interacting ability of AQP2 mutants in NDI, they are not polarized as with 
collecting duct cells. Also, we were unable to study the level of 
phosphorylation of AQP2-p.R254Q in these cells. Madin-Darby Canine 
kidney (MDCK) cells are polarized, and heterologously-expressed AQP2 in 
these cells is redistributed from intracellular vesicles to the apical membrane 
upon forskolin treatment[21]. Therefore, to study AQP2-p.R254Q further, a 
eukaryotic expression construct encoding AQP2-p.R254Q was generated and 
transfected into MDCK cells. Single clones were grown to confluence, 
incubated with or without forskolin, and subjected to immunocytochemistry 
using a-AQP2 antibodies. MDCK-wt-AQP2 cells were taken along as 
controls. CLSM analysis revealed that AQP2-p.R254Q localized to 
intracellular vesicles and that this distribution was not changed upon 
incubation with forskolin (Fig. 2A, upper panel). In contrast and as shown 
before[21], wt-AQP2 was translocated from intracellular vesicles to the apical 
membrane (Fig. 2A, lower panel). The AQP2-positive vesicles in 
unstimulated MDCK-AQP2 and MDCK-AQP2-p.R254Q cells, however, 
were of similar size and were mainly located on the apical side of the cell, 
which is also similar to that found for AQP2-p.S256A[2]. To further identify 
the subcellular organelles in which AQP2-p.R254Q resides, representative 
cell lines were tested for co-localization with various marker proteins for 
subcellular organelles. MDCK-AQP2 and MDCK-AQP2-p.S256A cell lines 
were taken along as controls. None of the studied AQP2 proteins appeared to 
co-localize with marker proteins for the ER (PDI), cis-Golgi (GOS28), 
median-trans-Golgi (Giantin) or late endosomes/lysosomes (Lamp2; not 
shown). However, AQP2-p.R254Q, wt-AQP2 and AQP2-p.S256A appeared 
to partially co-localize with the early endosomal marker protein EEA1 (Fig. 
2B, arrows). Semi-quantification of the signals revealed an overlap of 9, 15 
and 12% for AQP2-p.R254Q, wt-AQP2 and AQP2-p.S256A respectively, 
which indicated that they co-localized to a similar level with EEA1.
AQP2-p.R254Q impairs trafficking of wt-AQP2 to the apical membrane
Since AQP2-p.R254Q was retained in intracellular vesicles in MDCK cells, 
we next wanted to investigate whether AQP2-p.R254Q exhibit a dominant 
negative effect on the trafficking of wt-AQP2. For this, MDCK cells stably- 
expressing GFP-tagged wt-AQP2 (GFP-AQP2) was transiently transfected
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with FLAG-tagged AQP2-p.R254Q (F-AQP2-p.R254Q), which resulted in 
cells expressing GFP-AQP2 alone as well as together with F-AQP2-p.R254Q. 
Immunocytochemistry and CLSM analysis of cell monolayers revealed that in 
cells expressing GFP-AQP2 and AQP2-p.R254Q, both proteins co-localized 
in intracellular vesicles (Fig. 2C; arrows). In contrast and as reported 
before[17], cells only expressing GFP-AQP2 showed a dispersed expression 
pattern, which is typical for apical membrane expression (Fig. 2C; asterisks; 
see also forskolin-treated wt-AQP2 in Fig. 2A). These data revealed that 
AQP2-p.R254Q exert a dominant-negative effect on wt-AQP2 in that it 
interferes with its trafficking to the apical membrane.
Phosphorylation of AQP2-p.R254Q in MDCK cells
Since the p.R254Q mutation destroys the phosphorylation consensus sequence 
of PKA, we next tested whether AQP2-p.R254Q could be phosphorylated at 
S256. For this, MDCK cells expressing wt-AQP2, AQP2-p.R254Q or AQP2- 
p.S256A were subjected to orthophosphate labeling in the presence or absence 
of forskolin. Subsequently, AQP2 proteins were immunoprecipitated and
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Figure 2. Localization of wt-AQP2 and AQP2-p.R254Q in MDCK cells. A
and B) MDCK cell lines stably-expressing or wt-AQP2, AQP2-p.R254Q or 
AQP2-p.S256A (indicated) were grown to confluence on semi-permeable filters 
and incubated O/N with indomethacin to reduce basal cAMP levels (A, non­
stimulated; B). Subsequently, cells were treated for 45 minutes with forskolin in 
the presence of indomethacin (A, stimulated). After fixation and 
permeabilization, the filters were incubated with rabbit anti-AQP2 antibodies 
and monoclonal antibodies recognizing the early endosomal marker protein 
EEA1, followed by Alexa 488 conjugated anti-rabbit and Alexa 594 conjugated 
anti-mouse antibodies. XY and XZ images were obtained using confocal laser 
scanning microscopy. Co-localization of the AQP2 proteins (green) and EEA1 
(red) is indicated by arrows. C) Dominant effect of AQP2-p.R254Q on GFP- 
AQP2. MDCK cells expressing GFP-tagged wt-AQP2 (GFP-AQP2) and 
(transiently) FLAG-tagged AQP2-p.R254Q (F-AQP2-p.R254Q) were grown to 
confluence, stimulated with forskolin as described above, fixed and 
permeabized. The filters were incubated with mouse FLAG antibodies and 
subsequently Alexa 594 conjugated anti-mouse antibodies. Upon co-expression, 
GFP-AQP2 and F-AQP2-p.R254Q co-localize (asterisks) in intracellular 
vesicles, while GFP-AQP2 expressed alone is found in the apical membrane 
(indicated by arrows).
equivalents were immunoblotted for AQP2 (Fig. 3A, IB) or loaded on a gel 
and exposed to a film for 3 days (Fig. 3A, 32P). Analysis of the autoradiogram 
revealed that wt-AQP2 and AQP2-p.R254Q were already phosphorylated in 
the absence of forskolin stimulation. In contrast, AQP2-p.S256A was not
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phosphorylated, although the cells were stimulated with forskolin and AQP2- 
p.S256A was expressed at high levels (Fig 3A, IB). This indicated that the 
basal phosphorylation of wt-AQP2 and AQP2-p.R254Q was at S256. Semi­
quantification of the [32P] signals and normalization for the expression levels, 
however, revealed that the basal level of phosphorylation of AQP2-p.R254Q 
was only about 5% of that of unstimulated wt-AQP2 (Fig. 3B). Upon 
treatment with forskolin, phosphorylation of wt-AQP2 was about 2.5-fold 
increased, whereas the level of AQP2-p.R254Q phosphorylation was not 
increased. With forskolin stimulation, the level of AQP2-p.R254Q 
phosphorylation was thus only 2% of that of wt-AQP2. These data revealed 
that AQP2-p.R254Q was impaired in its forskolin-induced phosphorylation at 
S256, in contrast to wt-AQP2.
To test whether the lack of phosphorylation is the only determinant for the 
retention of AQP2-p.R254Q, we introduced the p.S256D mutation into 
AQP2-p.R254Q, generating AQP2-p.R254Q-p.S256D. Previously, we have 
shown that the p.S256D transition in wt-AQP2 mimics constitutively- 
phosphorylated AQP2 in that this AQP2-p.S256D is located in the apical 
membrane of MDCK cells, independent of stimulation by forskolin[2]. 
Following transient transfection of MDCK cells, growth to confluent layers 
and immunocytochemistry, CLSM analysis indeed revealed that AQP2- 
p.R254Q-p.S256D was localized in the apical membrane, independent of 
forskolin treatment (Fig. 3C), which indicated that the retention of AQP2- 
p.R254Q in intracellular vesicles is solely due to the lack of phosphorylation 
of S256.
DISCUSSION 
AQP2-p.R254Q is a typical mutant in dominant NDI and lack of S256 
phosphorylation is likely the molecular cause
As shown previously, AQP2 mutants in dominant NDI are 1) functional water 
channels of 29 and 40-45 kDa, 2) missorted to other subcellular 
organellesthan wt-AQP2, and 3) able to form heteroligomers with wt-AQP2. 
Because of these characteristics, they cause missorting of wt-AQP2[7;10- 
12;14;17]. In contrast, AQP2 mutants in recessive NDI are misfolded, 
retained in the ER and unable to interact with wt-AQP2[6;17;25]. Indeed, like
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Figure 3. Phosphorylation of AQP2-p.R254Q in MDCK cells. A) MDCK cells 
expressing wt-AQP2, AQP2-p.R254Q or AQP2-p.S256A were grown and 
independent triplicates from the cell lines were treated with indomethacin (I), or 
indomethacin/forskolin (IF), as described in the legend of Fig. 2 and subjected to 
[32P]orthophosphate labelling. After cell lysis, the AQP2 proteins were 
immunoprecipitated, split into two portions of which one was separated on SDS- 
PAGE and autoradiographed (upper panel), while the second portion was 
immunoblotted for AQP2 (lower panel). Wt-AQP2 shows a clear increase in 
phosphorylation with forskolin, while AQP2-p.R254Q is phosphorylated to low 
extent, with or without forskolin treatment. AQP2-p.S256A is not labelled with 
forskolin. B) Relative phosphorylation levels. The [32P] signals of the blots under 
A were densitometrically scanned and normalization for the particular AQP2 
protein expression levels. Bars represent the ratio of phosphorylated AQP2 
versus the total amount of AQP2 protein. C) Apical localization of AQP2- 
p.R254Q-p.S256D in MDCK cells. MDCK cells transiently expressing AQP2- 
p.R254Q-p.S256D mutant were incubated without forskolin, fixed, and 
immunostained for AQP2 proteins using rabbit anti-AQP2 and Alexa-488 
conjugated anti-rabbit antibodies. XY and XZ images were made with a 
confocal laser-scanning microscope.
other mutations in dominant NDI [7;10;12;14], upon expression in oocytes 
and MDCK cells, AQP2-p.R254Q was observed to be a functional water 
channel of 29 and 40-45 kDa and retained in the cell, but not in the ER, as
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revealed by the absence of 32 kDa high-mannose bands (Fig. 1). Also, AQP2- 
p.R254Q formed heteroligomers with wt-AQP2 and impaired the further 
trafficking of wt-AQP2 to the plasma membrane (Figs. 1C and 2C). 
Therefore, similar to other mutants in dominant NDI, AQP2-p.R254Q is 
likely to cause dominant NDI in this particular NDI patient by inhibiting the 
trafficking of enough wt-AQP2 to the apical membrane of the principal cells. 
And due to this dominant negative feature of p.R254Q mutation, presence of 
wt-AQP2 in the heterozygous patient would not rescue the phenotype by 
providing simply 50% of functional channels.
In oocytes, wt-AQP2 is always maximally phosphorylated. Similar to 
polarized cells, however, phosphorylation of AQP2 at S256 is also essential in 
these cells, because AQP2-p.S256A is retained in vesicles, whereas AQP2- 
p.S256D, which mimics continuously phosphorylated AQP2, is completely 
localized in the plasma membrane[1]. Consistent with an impaired 
phosphorylation of S256 in AQP2-p.R254Q, this protein was retained to a 
similar extent in oocytes as AQP2-p.S256A (Fig. 1). Also, immunoblotting of 
membranes of injected oocytes with antibodies recognizing S256- 
phosphorylated AQP2[26] did not reveal any signal for AQP2-p.R254Q, 
whereas wt-AQP2 was well detected (not shown).
Additional evidence was obtained from transfected MDCK cells. First, the 
distribution and size of AQP2-p.R254Q-containing vesicles was alike those of 
wt-AQP2 in unstimulated cells and of AQP2-p.S256A (Fig. 2B[2]). 
Moreover, neither one of these proteins co-localized with marker proteins of 
the ER, cis-median Golgi complex, TGN, late endosomes/lysosomes or 
basolateral membrane (not shown), but showed a similar level of co­
localization with the endosomal marker protein EEA1 (Fig. 2B). Most 
convincingly, however, forskolin treatment did not increase phosphorylation 
of AQP2-p.R254Q or AQP2-p.S256A, in contrast to wt-AQP2 (Fig. 3A), and 
introduction of the ‘constitutive phosphorylation’ mutation p.S256D, which 
resulted in the steady state apical membrane localization when introduced in 
wt-AQP2[2], also rescued the apical membrane expression of AQP2-p.R254Q 
(Fig. 3C).
It has been well-accepted that phosphorylation of S256 is essential for AQP2 
trafficking. Non-phosphorylatable AQP2-p.S256A mutant showed impaired 
trafficking to the plasma membrane in several cell culture studies[1;2;23;27]. 
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Using antibodies recognizing phosphorylated AQP2, it has been also been 
shown that AQP2 is phosphorylated at S256 in vivo[24;26]. Same as AQP2- 
p.R254L, AQP2-p.R254Q is only impaired in its phosphorylation of S256 and 
causes dominant NDI, suggesting the fundamental importance of AQP2 
phosphorylation at S256 in vivo.
The p.R254Q mutation is a dominant NDI due to a loss of function 
mutation
Different AQP2 mutants in dominant NDI are missorted to different locations 
within the cell. Except AQP2-p.R254L, all six other AQP2 mutants described 
are thought to be missorted due to a signal introduced with the mutation. In 
oocytes, AQP2-p.E258K is retained in the Golgi complex region. Deletion of 
the region surrounding E258, however, greatly restored its plasma membrane 
expression, which indicated that the introduction of a Lys instead of the loss 
of E258 caused the dominant feature[7]. AQP2-c.779_780insA, which leads 
to a +2 reading frame shift of the AQP2 C-tail was targeted to the basolateral 
membrane, because of two introduced basolateral sorting signals in its mutant 
C-terminal tail[10]. Although starting at different positions, the other four 
described mutations (c.721delG, c.727delG, c.763_772del and c.812_818del) 
introduce a +1 reading frame shift, which results in a similar extended C- 
terminal tail. Studies in polarized cells, revealed that AQP2-727delG 
accumulates in late endosomes/lysosomes and, to some extent, in the 
basolateral plasma membrane of MDCK cells[14], whereas the other three 
mutants have been reported to localize to the basolateral membrane. Since the 
extended tail in AQP2-812_818del starts only at the stop codon of wt-AQP2 
and the extended tails contain a di-leucine motif, which is a known basolateral 
membrane targeting motif[28], the dominancy of these mutants in NDI is 
suggested to be due to this introduced basolateral sorting signal.
In contrast to the above mutants which introduce a missorting signal, AQP2- 
p.R254Q caused dominant NDI, same as AQP2-p.R254L, is due to the loss of 
function of wt-AQP2, namely the phosphorylation at S256. Consistent with 
this, AQP2-p.R254Q seems to accumulate in the vesicles in which 
unstimulated wt-AQP2 and AQP2-p.S256A also reside, and upon stimulation 
impairs the trafficking of wt-AQP2 to the similar level as AQP2-p.S256A 
(Fig. 2 ).
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However, many, if not all, membrane proteins are continuously transported 
between several organelles along microtubular and actin cytoskeletal systems 
[29-31]. The predominant subcellular localization of the protein in such a 
dynamic equilibrium is then determined by several factors, including the 
activity of protein kinases and phosphatases[32;33]. In parallel, it has been 
shown that in renal collecting duct and/or transfected cells, AQP2 is 
continuously shuttled between intracellular vesicles and the apical plasma 
membrane[34;35] and that the predominant localization of AQP2 
(intracellular vesicles or plasma membrane) in a steady state (without or with 
AVP stimulation, respectively) is determined by whether AQP2 is 
phosphorylated or not[4;27;36]. Indeed, AQP2-p.S256A, which mainly 
resided in intracellular vesicles of LLC-PK1 cells, appeared to continuously 
cycle between these vesicles and the plasma membrane, as blocking 
endocytosis resulted in its accumulation at the plasma membrane[37;38]. 
AQP2-p.R254Q, which seemed to accumulate in storage vesicles that also 
harbour non-phosphorylated wt-AQP2 or AQP2-p.S256A, is therefore also 
likely to cycle to the plasma membrane. This is partly underscored by the 
partial co-localization of wt-AQP2, AQP2-p.S256A and AQP2-p.R254Q with 
EEA1 (Fig. 2), which is known to regulate the endosome docking and fusion 
with the plasma membrane in the exocytotic process[39].
Fluid deprivation test and dDAVP infusion have been reported to increase 
renal AQP2 expression[40;41]. Although this will presumably not result in 
increased phosphorylation of AQP2, and thus not in a changed distribution of 
AQP2-p.R254Q/wt-AQP2 complexes in the renal cells, the increased wt- 
AQP2 and AQP2-p.R254Q expression levels will result in higher total 
amounts of wt-AQP2/AQP2-p.R254Q complexes in the apical membrane. 
This might provide an explanation for the weak ability of the AQP2-p.R254Q 
patient to concentrate her urine, from 58 to 220 and 258 mOsmo/ kgH2O, 
upon the fluid deprivation test and dDAVP infusion, respectively (Fig. 4).
Furthermore, McDill et al. reported that due to the lack o f S256 
phosphorylation by PKA, a p.S256L mutation in AQP2 caused congenital 
NDI in mice[42]. Interestingly, although both result in the loss of 
phosphorylation at S256, the p.S256L mutation causes recessive NDI in mice, 
whereas the R254 mutations cause dominant NDI in humans. In contrast to 
our in vitro experiments, a considerable portion of wt-AQP2 (and possibly 
AQP2-S256L) was found in the apical membrane of the AQP2-p.S256L 
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Figure 4. Hypothesis to explain the increased urine osmolality in the dominant 
NDI patient. Besides continuous cycling, AQP2 translocates from intracellular 
vesicles to the apical membrane under antidiuretic conditionin in healthy 
individuals (upper panel). In the AQP2-p.R254Q dominant NDI patient, 
translocation of AQP2 to the apical membrane is impaired (lower left panel), 
which can be rescued upon dehydration, or administration of dDAVP (lower 
right panel).
heterozygote. This clearly indicates that with AQP2 mutants interacting with 
wt-AQP2, the relative strength of the apical sorting signal in wt-AQP2 vs. the 
missorting signal in the AQP2 mutant determines recessive or dominant NDI, 
and that the mutation and its location within the AQP2 C-tail determines the 
strength of the apical sorting signal.
In conclusion, we identified that the mutation AQP2-p.R254Q causes 
dominant NDI, due to a lack of AVP-induced phosphorylation of S256 in the 
mutant protein and translocation to the plasma membrane. These data also
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illuminate that AQP2 phosphorylation at S256 is important for its 
translocation to the apical membrane in vivo and reveal that in this reported 
patient the dominant NDI is caused by a loss of function mutation instead of a 
gain of disfunction. As a dominant negative mutant, AQP2-p.R254Q likely 
retains complex wt-AQP2 in storage vesicles from which they likely recycle 
to a low extent to the apical membrane. Therefore, the slightly-improved urine 
concentrating ability and reduced polyuria with the dehydration and dDAVP 
treatment may be explained by increased wt-AQP2/AQP2-p.R254Q 
expression levels.
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ABSTRACT
In antidiuresis, vasopressin (AVP) occupation of V2 receptors (V2R) in renal 
collecting ducts activate adenylyl cyclase, resulting in increased intracellular 
cAMP levels, which activates protein kinase A (PKA). PKA phosphorylates 
both the cAMP responsive element binding protein (CREB), which induces 
aquaporin-2 (AQP2) transcription, and AQP2, which is then translocated to 
the apical membrane, allowing urine concentration. Lithium treatment often 
causes nephrogenic diabetes insipidus (NDI), which co-incides with decreased 
Aquaporin-2 expression and which is generally ascribed to reduced adenylyl 
cyclase activity. However, the underlying mechanism by which lithium causes 
NDI is poorly understood.
Here, we demonstrated that the mouse cortical collecting duct mpkCCDc14 
cells are a good model, as the dDAVP-induced endogenous AQP2 expression 
and plasma membrane localization was time-dependently reduced by 
treatment with clinically-relevant lithium concentrations. Lithium did not 
affect AQP2 stability, but decreased its mRNA levels.
Surprisingly, the effect of lithium was cAMP independent, as it did not alter 
AVP-stimulated cAMP production or PKA-dependent phosphorylation of 
AQP2 or CREB. In vivo, kidney tissue of lithium-NDI rats indeed generated 
less dDAVP-induced cAMP than that of controls, but this could be due to 
elevated blood AVP levels in lithium-NDI rats. Indeed, Brattleboro rats, 
which lack endogenous AVP, with clamped blood dDAVP levels, showed no 
difference in dDAVP-generated cAMP generation between kidneys of 
lithium-NDI and control rats.
In conclusion, we set up a first proper cell model to study lithium-NDI and 
demonstrated that the lithium-induced down-regulation of AQP2 and 
development of NDI occur independently of adenylyl cyclase activity in vitro 
and in vivo.
84
AQP2 down-regulation in lithium-induced NDI is cAMP-independent
INTRODUCTION
Lithium is the drug of choice for treating bipolar disorders and is prescribed to 
1 in 1000 of the population[1;2]. Besides, it is currently under consideration 
as a therapeutic for alcoholism, Alzheimer’s disease[3], schizoaffective 
disorders and AIDS[4], and cluster headaches[5]. In 30-40% of the patients 
taking this medication, however, lithium causes nephrogenic diabetes 
insipidus (NDI), a disease in which the antidiuretic effect of the hormone 
arginine-vasopressin (AVP) is impaired[6 ], and is therewith the most common 
acquired form of NDI. Besides, lithium-induced NDI imposes the patient to 
an increased risk of dehydration-induced lithium toxicity. At present, 
however, it is still unclear how lithium affects the AVP-induced water 
reabsorption in the kidney.
In the normal regulation of water homeostasis, hypovolemia or hypernatremia 
cause the release of AVP from the posterior pituitary into the circulation (for 
review, see[7]). In the kidney, AVP binds its vasopressin type 2 receptor 
(V2R) located in the basolateral membranes of the collecting duct principal 
cells. V2R occupation causes activation of adenylyl cyclase and a subsequent 
rise in intracellular cAMP levels. The increased cAMP concentration activates 
protein kinase A (PKA), which has at least two targets involved in the 
regulation of the aquaporin-2 (AQP2) water channel. First, PKA 
phosphorylates AQP2 itself, which is thereby translocated from vesicles to the 
apical plasma membrane to allow the reabsorption of water from the pro­
urine. Second, cAMP increases AQP2 transcription through phosphorylation 
of the cAMP responsive element binding protein (CREB), which then binds 
and activates the AQP2 gene promoter[8;9].
Lithium-induced NDI is associated with decreased AQP2 protein and mRNA 
levels, attenuated apical targeting of AQP2 in rats[10-12], and decreased urine 
AQP2 excretion in humans[13]. As isolated collecting ducts or kidneys of rats 
chronically treated with lithium show a decreased generation of cAMP in 
response to AVP[14-17], and lithium interfered with the activation of 
adenylyl cyclase in renal LLC-PKj cells[18], it is generally agreed upon that 
lithium-NDI is due to reduced AQP2 levels caused by the inhibition of 
adenylyl cyclases by lithium[1].
85
Chapter 4
However, partly due to the lack of a renal principal cell line expressing 
endogenous AQP2 in response to AVP, the mechanism by which lithium 
causes NDI is poorly understood. Recently, however, a mouse cortical 
collecting duct cell line (mpkCCDc14) was generated[19;20], which has 
retained many of the hallmarks of principal cells from native epithelium, 
including the expression of endogenous AQP2 when stimulated with 
physiological levels of AVP[19-21].
Here, we show that this cell line is an ideal model to study the mechanism 
underlying lithium-induced NDI and demonstrate in detail that in this cell line 
the administration of therapeutically-relevant concentrations of lithium 
reduces AQP2 expression independently from cAMP generation. Moreover, 
our rat studies reveal that the reduced AQP2 levels at early stages of lithium- 
NDI are also cAMP-independent in vivo.
M ATERIALS AND M ETHODS  
Experimental animals
Male Wistar rats were obtained from the University Animal Facility, while 
Brattleboro rats were purchased from Harlan Laboratories (Harlan Sprague 
Dawley, Indianapolis, IN). Rats, weighing 250-350 g, were maintained on a 
standard rodent diet and had free access to water prior to the experiment. For 
lithium therapy, lithium chloride was added to the chow to give a 
concentration of 40 mmol/kg dry food for the first week, and 60 mmol/kg 
thereafter, according to the methods of Marples et al.[11]. All rats receiving 
lithium had access to water ad libitum and a salt block. Water intake was 
monitored continuously. Wistar rats received lithium until development of 
NDI was established. Mini-osmotic pumps (ALZET®, Model 2001), releasing 
1 ^l/h for 7 days at 37°C were filled with 200 ^l of 5 ng/^l dDAVP in 0.9% 
sterile saline and implanted in the back of the neck of the Brattleboro rats at 
day eight. These were replaced at day fifteen with new ones. Proper function 
of the pumps was revealed by the reduction of urine output and up-regulation 
of AQP2 expression (see results). For the last 24 h of the experiment, the rats 
were housed in metabolic cages in order to measure water intake, and urine 
output and osmolality. All animal treatments were reviewed and approved by
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the Animal Experiments Committee of the Radboud University Medical 
Centre.
Tissue preparation
Rats were anaesthetized by isofluorothane after which blood was removed by 
heart puncture. The rats were then killed by cervical dislocation and the 
kidneys rapidly removed. The inner medulla, outer medulla and cortex were 
dissected out and similar-sized tissue samples were minced using a scalpel. 
One kidney was used to make samples for immunoblotting, while the other 
was used for drug treatment and cAMP analysis.
For immunoblotting, the tissue was homogenized in 1 ml of ice-cold sucrose 
dissecting buffer (300 mM sucrose, 25 mM imidazole, 1 mM EDTA and 
protease inhibitors) and cleared from nuclei and unbroken cells by 
centrifugation at 4,000 g for 15 min and diluted to 0.5 - 1 ^g/^l in Laemmli 
buffer.
For drug treatment and cAMP analysis, the tissue was suspended in 1 ml 
modified Krebs-ringer buffer (140 mM NaCl, 5 mM KCl, 1.2 mM MgSO4, 
0.8 mM CaCl2, 10 mM NaOAc, 20 mM Tris, 2 mM NaH2PO4 and 10 mM 
glucose (pH=7.4)) containing 0.001% DNase I, pre-warmed to 37oC. In this 
buffer, tissue was incubated for 5 min in IBMX at 37oC, followed by an 
addition of 1 nM (Wistar rats) or 1 ^M (Brattleboro rats) dDAVP for 10 min 
at 37oC. The tissue was spun down at 800 g and lysed in 300 ^l of 0.1 M HCl 
for 15’ at room temperature. Left over tissue was spun down and the 
supernatant was used in a colorimetric competitive immunoassay to measure 
cAMP (Sigma, St. Louis, MO), and was analyzed by PAGE and coomassie 
brilliant blue staining to normalize for the amount of lysed tissue.
Blood and urine analyses
From the collected blood, serum was prepared by incubation in the cold, 
followed by brief centrifugation at 600 g, while urine was spun down to 
remove sediment. Both serum and urine samples were analyzed for osmolality 
and sodium, potassium, lithium, creatinin and urea concentrations by standard 
procedures of the General Clinical Chemical laboratory the RUNMC 
Nijmegen.
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Cell Culture
MpkCCD cells (clone 14; passages 26-35) were grown as described [19]. For 
growth on semi-permeable filters (Transwell®, 0.4 ^m pore size, Corning 
Costar, Cambridge, MA), exponentially growing cells were trypsinized and 
seeded at a density of 1.5x105 cells/cm2. 1 cm2 filters were used for 
immunoblotting, immunocytochemistry or cAMP assays, and 4.7 cm2 filters 
for RNA isolation. In all experiments, the cells remained in culture for a total 
period of 8 days before being analyzed. Unless stated otherwise, the cells 
were treated for the last 96 h with 1 nM dDAVP to only the basolateral side, 
to maximally induce AQP2 expression. Lithium (1mM or 10mM) was 
administered to the apical and 1 mM lithium to the basolateral side. 
cycloheximide (50 ^M), IBMX (0.25 mM) and ATP (10 ^M) were 
administered to both the apical and basolateral sides, for the indicated time 
points.
cAM P Assay
cAMP levels were assayed using a direct cAMP enzyme immunoassay kit 
from Sigma. MpkCCD cells were filter seeded and drug treated as described 
above. Following drug treatments filters were rapidly excised from their 
plastic supports and immersed in 150 ^l of 0.1 M HCl and incubated for 15 
min at room temperature. The samples were then centrifuged at 600 g for 5 
min at room temperature; 1 0 0  ^l of the supernatant was drawn off and used 
directly in the assay, which was done according to the manufacturer’s 
instructions. Data are based on at least two independent experiments in which 
triplicates per condition were taken.
Im m unoblotting and imm unocytochem istry
MpkCCD cells from one cm2 filter were lysed in 200 ^l Laemmli buffer and 
15 ^l samples were analyzed, while 5-10 ^g of kidney material was analyzed. 
PAGE, blotting and blocking of the PVDF membranes were done as 
described[22]. Membranes were incubated O/N with 1:3,000-diluted affinity- 
purified rabbit AQP2 antibodies[23], 1:250-diluted affinity-purified rabbit 
anti-phosphorylated AQP2 antibodies (gift from Dr. S. Nielsen, Aarhus 
University, Denmark), 1:100,000 diluted mouse anti-tubulin antibodies (gift 
from Dr. Kreis, University of Geneva, Switzerland), or 1:2,000 diluted rabbit 
anti-CREB and p-CREB antibodies (Sigma, St. Louis, MO) in TBS-T 
supplemented with 1% non-fat dried milk. Blots were incubated for 1 h with 
1:5,000-diluted goat anti-rabbit IgG’s or 1:2,000 Goat anti-mouse IgG’s 
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(Sigma, St. Louis, MO) as secondary antibodies coupled to horseradish 
peroxidase. Proteins were visualized using ECL (Pierce, Rockford, IL). 
Immunocytochemistry was done as described[24]. Data are based on at least 
two independent experiments in which triplicates per condition were taken.
Northern blotting
Total RNA was isolated from filter-seeded mpkCCD cells using TriZOL 
reagent (Invitrogen, Carlsbad, CA) according to the manufacturer’s protocol. 
Parallel to a two-fold dilution series of a known RNA sample for semi­
quantification, 20 ^g of RNA of the experimental conditions were subjected 
to a 1% agarose-formaldehyde electrophoresis. Subsequent Northern blotting 
was performed as described[25]. The blot was hybridized with full-length |c:- 
32P]dCTP-labeled probes of rat AQP2 or GAPDH, washed and exposed to 
high-performance film (Amersham). Data are based on three independent 
experiments in which duplicates per condition were taken.
Data Analysis
Films were scanned using a Bio-Rad 690c densitometer and analyzed using 
Bio-Rad software. Two-fold dilution series of protein or mRNA were blotted 
in parallel to allow semi-quantification. Following densitometric analysis of 
the Western- or Northern blots, samples were corrected for differences in 
loading by being normalized to the corresponding amounts of tubulin or 
GAPDH (in arbitrary units), respectively. Statistical comparisons were made 
using the Student's paired t-test. p values <0.05 were considered significant.
RESULTS  
Lithium causes down-regulation of AQP2 expression in mpkCCD cells
To determine the time point at which maximal expression of AQP2 in 
mpkCCD cells was reached, confluent monolayers were incubated with 1 nM 
deamino-8  D-arginine vasopressin (dDAVP) for 0, 24, 48, 72 and 96 h and 
lysed. Subsequent immunoblot analysis showed no AQP2 expression in 
unstimulated cells, whereas cells incubated with dDAVP showed a time- 
dependent increase in the expression of unglycosylated (29 kDa) and complex 
glycosylated (35-45 kDa) AQP2 (Fig. 1A). Immunoblotting for tubulin
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revealed that equivalent cell samples were loaded. Semi-quantification of the 
signals (Fig. 1B) revealed that AQP2 expression stabilized after 72 h of 
dDAVP treatment. To exclude variable AQP2 expression due to dDAVP 
incubation times, all subsequent experiments were therefore done for a total 
period of 96 h stimulation with dDAVP.
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29—  ----------------------------- —  _  _  _
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Figure 1. Aquaporin-2 expression in mpkCCD cells by dDAVP is time- 
dependent. A) MpkCCD cells were grown to confluence, treated for the 
indicated times with 1 nM dDAVP and subjected to immunoblotting for AQP2 
or tubulin (indicated). Molecular masses (in kDa) are indicated on the left. 
Complex-glycosylated (35-45 kDa) and non-glycosylated (29 kDa) forms of 
AQP2 are detected. B) The signals from A) were densitometrically quantified 
and AQP2 signals were normalized for tubulin. Mean values of normalized 
AQP2 expression per time point (indicated) are given in arbitrary units. Values 
that are significantly different (p<0.05) from untreated cells (-) are indicated by 
an asterisk.
In patients undergoing lithium therapy, 1 mM serum and 1-10 mM urinary 
concentrations of lithium are commonly observed[1]. Therefore, to test 
whether lithium affects AQP2 expression, mpkCCD cells were treated with or 
without lithium for the last 24 or 48 h within the dDAVP treatment. Lithium 
was administered in 1 mM concentration to both the basolateral and apical 
compartment, or 1mM basolateral and 10 mM apical, which is further referred 
to as 1 mM or 10 mM lithium, respectively. Immunoblotting and semi-
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quantification revealed that lithium treatment resulted in a time and dose 
dependent reduction in AQP2 expression, with an almost complete down- 
regulation of AQP2 with 10 mM lithium for 48 h (Fig. 2). Cytotoxic effects of 
lithium could be excluded, because the transepithelial resistance of the 
monolayer was not affected (not shown) and tubulin expression levels were 
similar for all samples (Fig. 2A). Altogether, these data indicated that 
mpkCCD cells are a valuable cell model to investigate the cellular 
mechanisms underlying lithium-induced NDI.
Figure 2. Effects of lithium on dDAVP-stimulated AQP2 expression in 
mpkCCD cells. A) Confluent mpkCCD monolayers were treated for a total 
period of 96 h with 1nM dDAVP in the absence (-) or presence of lithium (Li+). 
Cells were incubated with 1 mM lithium at the basolateral side and 1 mM or 10 
mM (indicated) at the apical side for the last 24 or 48 h (indicated). Cells were 
lysed and immunoblotted for AQP2 or tubulin. Molecular masses (in kDa) are 
indicated on the left. B) Semi-quantification of the AQP2 signals and statistical 
analysis was done as described in the legend of Figure 1. Mean normalized 
AQP2 expression values are given as a percentage of the control (-) sample.
Lithium treatm ent alters the cellular localization of AQP2 in mpkCCD  
cells
To establish the effects of lithium on the cellular redistribution of AQP2, 
lithium-treated mpkCCD cells were subjected to immunocytochemistry and
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confocal laser scanning microscopy. Consistent with an earlier study[19] and 
in agreement with the need of dDAVP for AQP2 expression, no AQP2 could 
be detected in untreated cells (Fig. 3a), while cells stimulated for 96 h with 1 
nM dDAVP showed AQP2 expression at the apical and basolateral 
membranes (Fig. 3b).
In cells co-treated with 1 mM lithium for the last 24 h, plasma membrane 
staining of AQP2 was decreased, while the intracellular AQP2 staining was 
increased (Fig. 3c). This effect was even more pronounced with cells co­
treated with 1 mM lithium for 48 h, or 10 mM lithium for 24 or 48 h (Fig. 3 d­
f). In the latter situation, AQP2 plasma membrane staining was virtually 
absent.
Figure 3. Effects of lithium on the cellular distribution of AQP2 in mpkCCD 
cells. Confluent mpkCCD monolayers were left untreated (a), treated with 1 nM 
dDAVP for 96 h (b), or treated with both dDAVP for 96 h and either 1 mM (c: 
24 h; d: 48 h) or 10 mM (e: 24 h; f: 48 h) of lithium, as described in Figure 2. 
Then, cells were subjected to AQP2 immunocytochemistry and analyzed by 
confocal laser scanning microscopy.
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Lithium does not alter the stability of the AQP2 protein
AQP2 downregulation can be due to increased degradation or decreased 
synthesis of AQP2 protein and/or mRNA. To examine at what level lithium 
exert its effect, we first studied its effects on AQP2 protein degradation. 
dDAVP-stimulated mpkCCD cells were treated with the protein synthesis 
inhibitor cycloheximide and incubated in the absence or presence of 1 or 10 
mM lithium for different time periods. Immunoblotting for AQP2 revealed 
that with or without lithium a reduction in AQP2 expression becomes 
apparent at 6  h of cycloheximide treatment, which increases at longer 
incubation times (Fig. 4A-B). Semi-quantification of the signals after 
normalization for tubulin revealed that the relative reduction of AQP2 
expression in time was not different between incubations with or without 
lithium (Fig. 4C). This indicated that lithium does not decrease the stability of 
the AQP2 protein.
A CHX B CHX + Li*
Oh 2h 4h 6h 8h 12h Oh 2h 4h 6h 8h 12h
i S i t ;  v r - ------ S - - —
AQP2
tubulin
c
— I— .— I— I— .— *
0 2 4 6 8 10 12 
CHX treatment (h)
Figure 4. Effects of lithium on AQP2 protein stability in mpkCCD cells. 
A,B) Confluent mpkCCD monolayers were treated with 1 nM of dDAVP for 96 
h, followed addition of 50 cycloheximide, without (CHX) or with 10 mM of 
lithium (+Li+) for the indicated times. C) Semi-quantification of the AQP2 
signals in A) and B) was done as described in Figure 2.
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Lithium decreases AQP2 mRNA expression
To investigate whether lithium affects AQP2 mRNA expression, total RNA 
was isolated from mpkCCD cells that were treated with dDAVP for 0, 24, 48 
or 96 h, or for 96 h dDAVP in the presence of 1 or 10 mM lithium for the last 
24 or 48 h. In line with AQP2 protein levels (Figure 1), subsequent Northern 
blotting revealed that dDAVP treatment increased AQP2 mRNA levels to a 
maximal level at 72 h, which was sustained at 96 h (Fig. 5A). Lithium 
treatment appeared to affect the AQP2 mRNA levels as it resulted in a dose- 
dependent decrease in AQP2 (Fig. 5A). As the intensity of the GAPDH 
signals was similar in all lanes, indicating equal loading, semi-quantification 
of the signals and normalization for GAPDH confirmed these observations 
(Fig. 5B).
A  dDAVP 0h_ 24h 48h 72h _______ 96h________
1 mM Li+10 mM Li*
_  24h 48h 24h 48h
1.6 - . . . .  AQP2
1.4 - GAPDH
1 mM Li* 10 mM Li*
Figure 5. Effects of lithium on AQP2 mRNA levels in mpkCCD cells. A)
Confluent mpkCCD monolayers were treated with 1 nM of dDAVP for the 
indicated times in the absence or presence of the indicated concentrations and 
times of lithium (Li+), as described in Figure 2. Subsequently, total RNA was 
extracted and subjected to Northern blotting using AQP2 and GAPDH probes 
(indicated). The approximate lengths of the messengers (in kb) are indicated on 
the left. B) For the 96 h dDAVP treatments without (-) or with lithium, AQP2 
and GAPDH signals from three independent experiments were densitometrically 
quantified. The AQP2 mRNA levels were normalized for GAPDH. Data are 
given and statistically analyzed as described in Figure 2.
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Lithium does not decrease adenylyl cyclase activity in mpkCCD cells
In line with the current dogma, the lithium-induced reductions in AQP2 
protein and mRNA levels could be due to decreased cAMP levels. To 
investigate this in mpkCCD cells, filter-seeded cells were pre-treated for 24 h 
with 0, 1 or 10 mM lithium. During the last 10 min, the phosphodiesterase 
inhibitor IBMX was added to inhibit cAMP degradation, while 1 nM dDAVP 
was added or not for the last two min. Finally, the cells were lysed and 
subjected to cAMP assays. In the absence of lithium, dDAVP caused a four­
fold increase in the cAMP concentration (Fig. 6 ), indicating activation of 
adenylyl cyclase via the V2R signaling cascade. Surprisingly, however, 
dDAVP-stimulated cells pre-treated with 1 or 10 mM lithium showed a cAMP 
accumulation that was even larger than of cells that had not been pre-treated 
with lithium. As a negative control, dDAVP addition in the presence of 10 
^M ATP, a known inhibitor of AVP-stimulated cAMP production in the 
collecting duct[26], showed a blunted cAMP accumulation compared to 
dDAVP alone.
Li+ (mM) - - 1 10 - 
dDAVP - + + + +
ATP _ _ _ _ +
Figure 6. Effects of lithium on dDAVP-stimulated cAMP production in 
mpkCCD cells. MpkCCD monolayers were left untreated (-) or treated for 24 h 
with the indicated concentrations of lithium (Li+), as described in Figure 2. All 
cells were pre-treated with 0.25 mM IBMX for ten min. Where indicated (+), 
cells were subsequently stimulated with 1 nM of dDAVP with or without 10 ^M 
ATP for two min, in the continuous presence of lithium where indicated. Cells 
were lysed and subjected to cAMP measurements. The mean cAMP 
concentration ([cAMP] +/- SEM (in pmol/ml)) was determined from three 
independent filters per condition. Significant differences (*; p < 0 .05) between 
different conditions are indicated.
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Because raised intracellular cAMP levels activate PKA, which phosphorylates 
AQP2 and CREB, analysis of the phosphorylation state of these proteins 
represent another indicator of adenylyl cyclase activity. Therefore, confluent 
mpkCCD monolayers were treated with 1 or 10 mM lithium for 24 or 48 h, 
lysed and immunoblotted for AQP2, phosphorylated AQP2, CREB, 
phosphorylated CREB and tubulin (Fig. 7). Lithium induced a similar down- 
regulation of phosphorylated AQP2 and total AQP2, without affecting the 
levels of tubulin, used as internal standard (Fig. 7A). In the absence of 
lithium, dDAVP caused a significant decrease in total CREB without reducing 
phosphorylated CREB levels (p=0.07; Fig. 7B). Consistent with the 
unaffected AQP2 phosphorylation with lithium, however, lithium did not 
reduce CREB phosphorylation when in the continuous presence of dDAVP 
(Fig. 7B/C). Altogether, these data reveal that lithium does not affect V2R- 
mediated activation of adenylyl cyclase in mpkCCD cells.
Lithium does not affect adenylyl cyclase activity in vivo
To analyze whether adenylyl cyclase activity is affected in lithium-induced 
NDI (i.e. in vivo), three Wistar rats were fed with chow containing lithium to 
induce NDI, while three control rats were fed with normal chow. After twelve 
days, significant differences in urine volumes and osmolalities between 
lithium-fed (106 ± 4  ml/24 h; 146 ± 9  mOsm) and control rats (13 ± 2  ml/24 
h; 457 ± 39 mOsm) indicated that lithium-NDI had developed. At this point, 
the serum lithium concentration in lithium-fed animals was 0.71 ± 0.19 mM, 
while that of control animals was below the detection limit of 0.05 mM. The 
rats were killed and their kidneys were removed immediately. As anticipated, 
immunoblotting of membranes from one kidney inner medulla per rat for 
AQP2 and tubulin revealed a marked reduction of AQP2 in the lithium-treated 
rats (Fig. 8A). The inner medullas of the contra-lateral kidneys were used to 
measure cAMP accumulation after treatment with IBMX or IBMX combined 
with 1 nM dDAVP. In the presence of IBMX, dDAVP increased intracellular 
cAMP levels nearly three-fold in the control rats, while it only increased 
cAMP levels twofold in lithium-fed rats (Fig. 8 B). Thus, lithium treatment of 
rats clearly decreased dDAVP-stimulated cAMP accumulation in kidneys 
isolated from these animals.
However, in rats that have lithium-induced NDI, the blood AVP levels are 
elevated[27] and, as shown for numerous receptors in vitro[28], including the
96
AQP2 down-regulation in lithium-induced NDI is cAMP-independent
* ____________ dDAVP_________
_______1mM Li+
-  - _________ 24h________48h
45------------------------------------------—  —  — -------------
45—  —  mm m m ---------------- —  —  — -------------
50—  -------------------------------------------- — -------------
P-AQP2
AQP2
tubulin
p-CREB
CREB
tubulin
Figure 7. Effects of lithium on AQP2/CREB phosphorylation in mpkCCD 
cells. Confluent mpkCCD cells were treated for 96 h with 1 nM dDAVP in the 
absence (-) or presence of the indicated concentrations and times of lithium (Li+), 
as described in Figure 2. Then, cells were lysed and immunoblotted for (A) 
phosphorylated AQP2 (p-AQP2), AQP2 and tubulin, or (B) for the cAMP 
responsive element binding protein (CREB), its phosphorylated form (p-CREB), 
and tubulin. C) Semi-quantification of the CREB and p-CREB signals and 
statistical analysis was done as described in the legend of Figure 1. Mean 
normalized CREB and p-CREB expression values are given as a percentage of 
the control (-) sample. Molecular masses (in kDa) are indicated on the left.
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A - Li'
Li* - Li* - Li'
IBMX IBMX + dDAVP
Figure 8. Effects of lithium on AQP2 expression and dDAVP-stimulated 
cAMP production in rat inner medulla. A) Three Wistar rats were fed a 
normal diet (-) and three a diet containing lithium (Li+). After 12 days, lithium- 
induced NDI was confirmed, the rats were killed and kidneys were instantly 
removed. Membranes from one kidney inner medulla per rat were solubilized an 
immunoblotted for AQP2 and tubulin (indicated). Molecular masses (in kDa) are 
indicated on the left. B) The other kidney inner medulla of each rat was finely 
minced and divided into three portions, which were left untreated, treated with 
0.25 mM IBMX (indicated) for 10 min, or treated with IBMX followed by 
stimulated with 1 nM of dDAVP for 10 min (IBMX + dDAVP). The tissue was 
lysed, subjected to cAMP measurements, and cAMP values were corrected for 
protein content. Values are means +/- SEM of the corrected cAMP concentration 
([cAMP] (in pmol/ml)) from three rats. Significant differences (*; p < 0.05) 
between different groups are indicated.
V2R[29;30], an increased receptor occupancy results in their activation, 
internalization and degradation. Therefore, the decreased cAMP accumulation 
with renal tissue of lithium-fed rats after dDAVP treatment might be 
accounted for by a decreased V2R availability. To test this hypothesis, we 
repeated the experiment above with Brattleboro rats, which lack endogenous 
AVP, and of which blood AVP levels were clamped using implanted mini­
pumps releasing continuous levels of dDAVP. Establishment of a reduced 
urine volume (not shown) before the diuretic effects of lithium treatment 
became apparent illustrated proper release of dDAVP from the minipumps. 
Eighteen days after the onset of feeding rats with food with or without
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lithium, urine volume and osmolalities of lithium-fed rats (108 ± 18 ml/24 h; 
192 ± 36 mOsm) differed significantly from those of dDAVP-infused control 
rats (23 ± 9 ml/24 h; 1807 ± 359 mOsm), which indicated that NDI had 
developed. Lithium-fed rats had a serum lithium concentration of 1.20 ± 0.23 
mM, while that of control rats was undetectable. As anticipated, 
immunoblotting revealed a markedly reduced AQP2 expression in the cortex, 
outer medulla and inner medulla of lithium-treated animals compared to 
controls (Fig. 9). The dDAVP-induced cAMP accumulation after 1 ^M 
dDAVP treatment, however, was not different for the cortex (p=0.21), outer 
medulla (p=0.36) or inner medulla (p=0.134) between lithium-NDI rats and 
their controls. This indicated that also in vivo lithium does not affect cAMP 
generation by AVP-activated adenylyl cyclases and that the lithium-induced 
down regulation of AQP2 occurs independent from cAMP.
DISCUSSION  
M pkCCD cells represent a proper model to study lithium -induced down- 
regulation of AQP2
The major handicap for deciphering the mechanism by which lithium induces 
NDI at the cellular level has been the lack of a cell line that expresses AQP2 
endogenously in response to physiological levels of AVP, and of which the 
AQP2 expression is sensitive to therapeutically-relevant lithium levels. We 
demonstrated that the mpkCCD cell line fulfils these requirements, as 1 and 
10 mM concentrations of lithium cause a time and concentration-dependent 
decrease in AQP2 protein levels (Fig. 2), and the plasma membrane 
expression of AQP2 was decreased in response to lithium (Fig. 3). These 
observations are in close agreement with the findings of Marples et al. [1 1], 
who demonstrated the correlation between the onset of lithium-induced NDI 
and AQP2 down-regulation in rats, and the work from Dousa et al.[31], who 
showed that lithium affects microtubule assembly in the renal medulla, 
thereby inhibiting the AVP-induced AQP2-mediated antidiuretic effect. As 
lithium often results in hypercalcaemia, which can cause NDI by itself, the 
observed down regulation of AQP2 in mpkCCD cells with lithium under 
normocalcaemic conditions clearly reveal that lithium also affects AQP2 
expression directly.
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Figure 9. Effects of lithium on AQP2 expression and dDAVP-stimulated 
cAMP production in kidneys of dDAVP-clamped rats. Six Brattleboro rats 
were fed a normal diet (-) and six a diet containing lithium (Li+). From day eight 
onwards, all rats were implanted with dDAVP-filled minipumps. On day 
eighteen, lithium-induced NDI was confirmed, the rats were killed and kidneys 
were instantly removed. Membranes from one kidney inner medulla (A), outer 
medulla (B) and cortex (C) per rat were solubilized and immunoblotted for 
AQP2 and tubulin (indicated). The other kidney inner medulla (A), outer 
medulla (B) and cortex (C) of each rat was finely minced and divided into two 
portions, and analyzed for their ability to generate cAMP in response to dDAVP 
as described in Figure 8, except that here 1 ^M dDAVP was used. Values and 
statistical analysis was done as described in the legend of Figure 8.
Lithium affects A Q P2 gene transcription in mpkCCD cells
The lithium-induced reduction in AQP2 expression, as found in mpkCCD 
cells, could be due to increased AQP2 protein/mRNA degradation and/or 
reduced AQP2 translation/transcription. Using the protein synthesis inhibitor 
cycloheximide, no difference in the level of AQP2 degradation was observed 
with or without lithium (Fig. 4). As the pulse (chase) labeling assay did not 
yield enough product, which is common for polarized cells, we were not able 
to determine the effect of lithium on the speed of AQP2 translation. However, 
lithium caused a strong down regulation of the AQP2 mRNA levels (Fig. 5). 
As the AQP2 protein levels usually follow AQP2 mRNA levels, the lithium- 
induced down regulation of AQP2 protein in mpkCCD cells likely originates 
from effects on AQP2 transcription and/or mRNA degradation. It remains to 
be established which factors mediate the effect of lithium on AQP2 mRNA 
levels.
Lithium-induced reduction of AQ P2 expression in lithium-NDI is cAMP 
independent
Our results reveal that both in mpkCCD cells and in vivo the lithium-induced 
down regulation of AQP2 occurs independent from AVP-induced cAMP 
levels. In mpkCCD cells, pre-incubation with lithium did not affect the cAMP 
response generated by physiological levels of AVP (Fig. 6 ). Consistent with 
this, while lithium reduced dDAVP-induced AQP2 expression levels, the 
relative level of the cAMP-dependent AQP2 phosphorylation was not reduced 
(Fig. 7A). In addition, lithium did not affect CREB expression levels or its 
level of phosphorylation (Fig. 7B, C), of which the latter is cAMP
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dependent[32]. These findings do not corroborate with the observation that 
lithium interferes with the activation of adenylyl cyclase in LLC-PK 
cells[18]. However, LLC-PKi cells originate from the renal proximal tubule, 
while lithium-NDI is caused by insufficient functioning of collecting-duct 
principal cells. The mpkCCD cells used in this study are derived from 
principal cells, show a reduced AQP2 expression after lithium treatment and, 
therefore, are a better model to study the mechanism of lithium-NDI.
As reported by many others[14-17] and as found in this study (Fig. 8 ), 
comparing the cAMP generating response to AVP of renal tissue from 
lithium-NDI rats versus controls suggest that lithium reduces AVP-induced 
cAMP generation. However, as blood AVP levels are increased in lithium- 
NDI rats[27], the reduced amount of generated cAMP in lithium-NDI renal 
tissue could just be due to a reduced number of available V2Rs, which is a 
common negative-feedback response of cells to increased agonist levels[28]. 
Indeed, when the effects of a difference in endogenous AVP levels were 
excluded by implanting dDAVP-filled minipumps in AVP-deficient 
Brattleboro rats, differences in dDAVP-induced cAMP generation in the renal 
cortex, outer medulla and inner medulla of lithium-NDI rats and control rats 
were no longer observed, whereas the AQP2 levels were clearly reduced in 
the lithium-NDI rats (Fig. 9).
Of note is that the obtained plasma lithium levels were higher in the 
Brattleboro rats than in the Wistar rats, which underscores our hypothesis that 
the cause by which lithium causes NDI is cAMP independent, as then one 
would expect to see a more pronounced difference in generated cAMP 
between the lithium and non-lithium groups of Brattleboro rats than of Wistar 
rats.
Also, to clamp blood vasopressin levels in the Brattleboro rats, we used 
minipumps releasing dDAVP, giving a sub-maximal level of urine 
concentrating ability[33]. As the obtained blood dDAVP levels in these rats 
were likely increased compared to our Wistar rats, and the level of receptor 
occupancy by an agonist (here AVP/dDAVP) and, consequently, its removal 
from the cell surface is depending on the concentration of the agonist, the 
cAMP generating ability of Brattleboro rat kidney homogenates had to be 
tested with a higher dDAVP concentration than used with Wistar rats. 
Considering the fact that dDAVP can not be measured using the standard
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assays, 1 M dDAVP seemed to be a well-chosen concentration, because it 
generated moderate cAMP responses within the range for sensitive detection 
of differences (10-200 pmol/ml). One could question whether this higher 
concentration of dDAVP would affect our results. Although we can not 
exclude this possibility, this is rather unlikely for several reasons. First, 
dDAVP activates the V2R and V1b receptor at high potency, but in the rat 
kidney only V1a and V2R are expressed[34;35]. Secondly, 1 uM of dDAVP 
does not appear to activate V1aRs, because treatment of V1aR-expressing rat 
brain septum tissue with 1 or even 10 uM dDAVP did not result in an 
increased inositol-phosphate production [36]. Thirdly, the control and lithium- 
NDI Brattleboro groups were similarly infused with dDAVP. All together, we 
believe that these and our mpkCCD cell line data strongly indicate that 
lithium-induced down regulation of AQP2 and thus lithium-NDI occurs 
independent from adenylate cyclase activity. Our findings are in line with the 
finding that in rats treated for only 7 days with lithium, their lithium-induced 
polyuria was not interrupted by low doses of AVP, but also not by cAMP[37].
Lithium-NDI development
Based on our data and that of others, lithium-NDI might develop as follows: 
During the onset of lithium-NDI development (about 10 days in rats), 
collecting duct morphology is not changed, but AQP2 protein levels are 
decreased[38]. Our data are model for this early onset, as the mpkCCD cells 
were treated with lithium for maximally 48 h, and did not show a change in 
the number of cells, nor appearance of the intercalated cell marker H+-ATPase 
(not shown; see below). Also, our rats were treated for maximally 18 days 
with lithium and had a normal collecting duct morphology (not shown). Our 
data indicate that the lithium-induced down regulation of AQP2 in this period 
is cAMP and adenylyl cyclase independent and is due to the reduction of 
AQP2 mRNA. Presumably due to the toxic effect of lithium on principal cells, 
chronic lithium therapy (> 4 weeks in rats) further results in a decreased 
number of principal cells to the benefit of intercalated cells [39], which will 
additionally contribute to a reduced dDAVP-induced cAMP generation in 
kidneys of lithium-NDI rats. Recently, COX2 expression has been suggested 
to be involved in lithium-induced NDI [40], but this was debated by 
others[41]. Although our study does not exclude a role of COX-2 in 
development of lithium-NDI, the lithium-induced AQP2 down regulation in 
our mpkCCD cells, which are grown in the absence of COX2-producing
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interstitial cells, indicate that COX2-derived prostaglandins are not necessary 
for lithium-NDI development.
Although highly debated[42;43], it needs to be noted that several studies 
revealed that abnormalities of cAMP signaling in the brain underlie bipolar 
disorders[44]. Also, lithium treatment for more than 1 week reduced receptor- 
mediated cAMP formation through inhibition of a Ca2+/calmodulin-sensitive 
adenylyl cyclase, and diminished phosphorylation of the CREB transcription 
factor in brain tissue and cells[2;45;46]. As such, our data that the onset of 
lithium-NDI is cAMP independent might not be of relevance to the brain.
CONCLUSION
Our in vitro and in vivo data indicate that we have established the first 
appropriate cell model to unravel the mechanism underlying lithium-induced 
NDI, that lithium-induced down regulation is due to diminished AQP2 mRNA 
levels, likely through reduced AQP2 gene transcription, and that the onset of 
lithium-induced AQP2 degradation and NDI development occurs 
independently from the activity of principal cell adenylyl cyclase activity. As 
such, it resets the scope of the cellular signaling pathway(s) by which lithium 
causes AQP2 down regulation and NDI development. Several studies in brain 
report that the positive effect of lithium in bipolar disorders might be 
mediated through inhibition of glycogen synthase kinase 3 and/or phospho- 
inositol kinases[42;43]. It remains to be established whether these pathways 
and proteins underlie lithium-induced NDI. Future studies will focus on the 
identification of the pathways and proteins involved in lithium-NDI, for 
which mpkCCD cells appears an ideal model system, and which may become 
important pharmacological targets to reduce development of NDI in lithium- 
treated patients with bipolar disorders.
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ABSTRACT
Lithium therapy frequently induces nephrogenic diabetes insipidus; amiloride 
appears to prevent its occurrence in some clinical cases. Amiloride blocks the 
epithelial sodium channel (ENaC) located in the apical membrane of principal 
cells; hence one possibility is that ENaC is the main entry site for lithium and 
the beneficial effect of amiloride may be through inhibiting lithium entry. 
Using a mouse collecting duct cell line, we found that vasopressin caused an 
increase in Aquaporin 2 (AQP2) expression which was reduced by clinically 
relevant lithium concentrations similar to what is seen with in vivo models of 
this disease. Further amiloride or benzamil administration prevented this 
lithium-induced downregulation of AQP2. Amiloride reduced transcellular 
lithium transport, intracellular lithium concentration, and lithium-induced 
inactivation of glycogen synthase kinase 3b. Treatment of rats with lithium 
downregulated AQP2 expression, reduced the principal-to-intercalated cell 
ratio, and caused polyuria, while simultaneous administration of amiloride 
attenuated all these changes. These results show that ENaC is the major entry 
site for lithium in principal cells both in vitro and in vivo. Blocking lithium 
entry with amiloride attenuates lithium-induced diabetes insipidus, thus 
providing a rationale for its use in treating this disorder.
INTRODUCTION
Lithium is regularly used to treat psychiatric diseases, such as bipolar disorders, 
schizoaffective disorders, and depression. Lithium is prescribed to 0.1% of the 
population[1]. Approximately 20% of patients develop nephrogenic diabetes 
insipidus (NDI), a disorder characterized by polyuria and polydipsia because of 
renal insensitivity to the antidiuretic hormone, arginine vasopressin (AVP)[2]. 
Thus, lithium-NDI is the most common form of NDI. Lithium-NDI patients are 
at risk for dehydration-induced lithium toxicity, and prolonged lithium 
treatment might lead to end-stage renal disease[1]. However, as the symptoms 
of the underlying psychiatric disorder have a high impact on the quality of life, 
cessation of lithium therapy is not an option for most patients.
The kidney is the main organ for regulating water homeostasis. In the state of 
hypernatremia or hypovolemia, AVP is released from the pituitary gland. 
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Binding of AVP to the vasopressin type-2 receptor in the basolateral membrane 
of renal collecting duct principal cells results in the redistribution of 
aquaporin-2 (AQP2) water channels from intracellular vesicles to the apical 
membrane. Driven by an osmotic gradient, water will enter the principal cells 
through AQP2 and will exit through AQP3 or AQP4 in the basolateral 
membrane, resulting in the concentrated urine. Besides this short-term 
regulation, AVP also exerts a long-term regulation by increasing AQP2 
expression[3].
From studies in rats, it became clear that lithium-NDI develops in two stages. In 
the short term (10 days), lithium-NDI coincides with AQP2 downregulation 
and natriuresis, without gross changes in renal morphology[4-6]. Chronic 
lithium treatment (4 weeks), however, also leads to a severe decrease in the 
fraction of principal cells. This is ‘compensated’ by an increase in the fraction 
of intercalated cells, which are involved in acid/base balance regulation[7;8].
Presently, it is unclear how lithium causes NDI and whether lithium-NDI can 
be attenuated. Some data, however, suggest that lithium may exert its effects by 
entering principal cells through the epithelial sodium channel (ENaC). First, 
NDI is due to an impaired water reabsorption in the connecting tubules and 
collecting ducts principal cells[9], where ENaC is expressed[10]. Second, 
ENaC has a higher permeability for lithium than for sodium[11]. Third, lithium 
inhibits amiloridesensitive sodium reabsorption in the toad urinary bladder and 
rat collecting duct, tissues known to express ENaC[12-14], and the 
ENaC-blocker triamterene increases lithium excretion[15]. Moreover, it was 
shown in a limited number of lithium-NDI patients that blocking ENaC with 
amiloride significantly reduces urine volume and increases urine 
osmolality[16-18]. The decreased urine volume is classically explained by an 
amiloride-induced hypovolemia, followed by an increased proximal sodium 
and water retention. The increased urine osmolality was suggested to be caused 
by an amiloride-induced reduction of sodium reabsorption[16;17].
On the basis of the above, we hypothesized that lithium enters the principal 
cells through ENaC and that blocking ENaC by amiloride would reduce 
cellular entry of lithium, AQP2 downregulation, and alterations in the cellular 
composition of the collecting duct and the lithium-NDI phenotype.
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M ATERIALS AND M ETHODS  
Cell culture
Mouse mCCDc11 and mpkCCDcl4 cells were essentially grown as 
described[19;20]. Cells were seeded at a density of 1.5 X 105 cells/cm2 on 
semi-permeable filters (Transwell, 0.4 ^m pore size; Corning Costar, 
Cambridge, MA, USA) and cultured for 8 days. Unless stated otherwise, the 
cells were treated for the last 96 h with 1 nM dDAVP to the basolateral side, to 
induce AQP2 expression. Lithium and zinc chloride were administered as 
indicated. A concentration of 10 ^M of amiloride or benzamil, concentrations 
specifically blocking ENaC[21;22], were administered to the apical side, unless 
indicated otherwise. BIO-Acetoxime (Calbiochem, San Diego, CA, USA) was 
used indicated. Medium with reduced sodium concentrations was prepared 
identical to the standard medium except that lower amounts of NaCl were 
added.
Lithium assays
To determine transcellular lithium transport, mCCDc11 cells were grown on 
1.13 cm2 filters. After 24 h treatment with 10 mM lithium in the presence or 
absence of amiloride at the apical side, the basolateral and apical media were 
collected and the lithium concentrations were determined with a flame 
photometer (Eppendorf 6341, Hamburg, Germany).
Intracellular lithium concentrations were determined essentially as 
described[23]. Briefly, mCCDc11 cells were grown on 4.7 cm2 filters. To 
determine the extent of lithium contamination from the extracellular side, 
fluorescein isothiocyanate dextran (FITC-dextran) was added to the 
lithium-containing medium to a final concentration of 10  ^M just before 
harvesting, after which the medium was mixed. Then, the filters were washed 
three times with iso-osmotic sucrose (pH 7.3) at 40C and cells were lysed by 
sonication in 1 ml Milli-Q water. Of the 800 ^l sample, the amount of lithium 
was determined by flame photometry, from which the total amount of lithium in 
the sample was calculated.
Of the 100 ^l sample, the amount of FITC-dextran was measured using 
spectrofluorophotometry (Shimadzu RF-5301, Kyobo, Japan) at 492 nm 
(excitation) and 518 nm (emission) wavelengths. By comparing the obtained
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values with a two-fold FITC-dextran dilution series, the FITC-dextran 
concentration in each sample was determined, from which the extent of 
extracellular Li+ contamination was calculated and subtracted from the total 
amount to obtain the intracellular lithium amount. With the used FITC-dextran 
concentration, a contamination above 1:5,000 would be detected. To correct for 
differences in cellular yield, the intracellular lithium amounts were normalized 
for the protein amount in each sample, which was determined using the 
Bio-Rad Protein Assay (Munchen, Germany). The intracellular lithium 
concentration (in millimolar) was estimated by calculating the cellular water 
content, on the basis of the assumption that 2 0 % of the cell weight consists of 
cellular proteins and the remaining 80% is water[24].
Experimental animals
Male Wistar rats (200-300 g) were obtained from the Animal Facility of the 
RUNMC (Radboud University Nijmegen Medical Centre). The rats were 
treated with lithium as described[5].
Control rats received normal rodent diet (ssniff R/M-H V1534, ssniff 
Spezialdiaten GmbH, Soest, Germany; n = 6 ). For lithium therapy, lithium 
chloride was added to the chow to give a concentration of 40 mmol/kg for the 
first week and 60 mmol/kg dry food for the next 3 weeks. The rats were then 
killed (n = 6 ). For amiloride treatment, amiloride was added to the lithium 
chow to a concentration of 200 mg/kg dry food for the entire 4 weeks (n = 7). 
All rats had free access to water, food, and a sodium-chloride block[7]. For the 
last 48 h of the experiment, the rats were housed in metabolic cages to measure 
water intake and urine output during the last 24 h. All animal experiments were 
approved by the Animal Experiments Committee of the RUNMC.
Tissue preparation
Rats were anesthetized with isofluorothane, after which their blood was 
removed by a heart puncture. Then, the rats were killed by cervical dislocation 
and the kidneys rapidly removed. One kidney was fixed for 
immunohistochemistry by immersion in 1% (wt/vol) periodate-lysine- 
paraformaldehyde for 2 h and in 15% (wt/vol) sucrose in phosphate buffered 
saline overnight, whereas of the other kidney, the inner medulla, outer medulla, 
and cortex were dissected for immunoblotting as described[25].
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Blood and urine analyses
Blood serum was prepared by 16 h incubation at 40C, followed by 
centrifugation at 600 g for 2-3 min. Urine was centrifuged at 4000 g for 5 min 
to remove sediment. Both serum and urine samples were analyzed for 
osmolality, and for sodium and lithium concentrations by standard procedures 
of the General Clinical Chemical laboratory of the RUNMC.
Im munoblotting
mCCDc11 cells from the 1.13 cm2 filter were lysed in 200 ^l Laemmli buffer and 
15 ^l samples were analyzed, while 5-10 ^g of kidney material was also 
analyzed. Polyacrylamide gel electrophoresis, blotting, and blocking of the 
PVDF membranes were carried out as described[26]. The membranes were 
incubated for 16 h with affinity-purified rabbit AQP2 antibodies (1:3,000 
dilution)[27], affinity-purified rabbit anti-v1 H-ATPase antibodies 
(1:2,000-dilution; gift from Dr S Nielsen, Denmark), rabbit anti-Ser9-GSK3p 
(1:1,000 dilution; Cell Signaling Technology, Beverly, MA, USA), mouse 
anti-GSK3p (1:5,000 dilution; BD Transduction Laboratories, San Jose, CA, 
USA), or with mouse anti-tubulin antibodies (1:100,000 dilution; gift from Dr 
Kreis, Switzerland) in Tris-buffered saline Tween-20 supplemented with 1% 
non-fat dried milk. ENaC detection was carried out as described[19]. Blots 
were incubated for 1 h with goat anti-rabbit IgGs (1:5,000) or with goat 
anti-mouse IgGs (1:2,000) (Sigma, St Louis, MO, USA) as secondary 
antibodies coupled to horseradish peroxidase. Proteins were visualized using 
enhanced chemiluminescence (Pierce, Rockford, IL, USA). Films were 
scanned using a Bio-Rad 690c densitometer and signals were analyzed using 
Bio-Rad software. Two-fold dilution series of the respective proteins were 
blotted in parallel to allow semi-quantification. Equal loading of the samples 
was confirmed by parallel immunoblotting for tubulin or by staining of the 
blots with coomassie blue.
Im munohistochemistry
Immunohistochemical staining was performed on 7-^m-thick sections of fixed 
frozen kidney samples, following antigen retrieval. The sections were blocked 
in goat serum dilution buffer (GSDB: 16% goat serum, 0.3% Triton X-100, 0.3 
M NaCl in phosphate buffered saline) for 30 min and incubated for 16 h at 40C 
with rabbit anti-a4 H-ATPase antibodies (1:3,000, provided by Dr F Karet, 
UK). After washes and incubation with Alexa 488-conjugated goat anti-rabbit 
antibodies, the sections were incubated with affinity-purified guinea pig AQP2 
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antibodies (1:50)[28] for 1 h at room temperature and with Alexa 
594-conjugated goat anti-guinea pig secondary antibodies (Molecular Probes, 
Leiden, The Netherlands). TOTO-3 iodide (Invitrogen, Carlsbad, CA, USA) 
was used for counter-staining. Images were produced using Bio-Rad 
MRC-1024 confocal laser scanning microscopy.
Quantification of principal and intercalated cells was performed on the 
confocal images of the fluorescent kidney sections. Tubules in >5 randomly 
selected areas of each kidney region of each animal were included. Only cells 
with distinct TOTO-3 staining were counted. Cells stained with H-ATPase or 
AQP2 were considered as intercalated or principal cells, respectively.
Data analysis
Differences between groups were tested by Student’s t-test corrected by the 
Bonferroni multiple-comparisons procedure. Differences were considered 
statistically significant for P<0.05.
RESULTS  
mCCDcl1 cells as a model for lithium-NDI
To study the role of ENaC in lithium-NDI in vitro, a cell line needs to show (1) 
expression of all three ENaC subunits, (2) amiloride-inhibitable transcellular 
sodium transport, (3) deamino-8 -D-arginine vasopressin (dDAVP)-induced 
expression of AQP2, and (4) lithium-induced downregulation of AQP2.
mpkCCDcl4 cells show a lithium-induced AQP2 downregulation[25] and an 
amiloride-inhibitable transcellular voltage difference. However, immune- 
cytochemistry did not reveal ENaC expression in these cells (data not shown), 
in contrast to the novel mouse cortical collecting duct mCCDcn cell line[19]. 
Therefore, we tested mCCDcl1 cells as a model. To test whether dDAVP 
induces AQP2 expression in these cells, confluent cells were treated for 1-4 
days with 1 nM dDAVP. Immunoblotting revealed the typical 
non-glycosylated 29 and complex-glycosylated 40-45 kDa AQP2 bands, 
besides a nonspecific band of 35 kDa (Fig. 1a). Similar to mpkCCDc14 
cells[25], maximal expression of AQP2 was observed after 72-96 h. To have 
steady AQP2 expression, cells were therefore treated with dDAVP for 96 h in 
the following experiments.
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Figure 1. mCCDcn cells: a proper cell model to study lithium-NDI. (a)
mCCDcn cells were grown to confluence, treated for the indicated times (in hours) 
with 1 nM dDAVP, and subjected to AQP2 immunoblotting or, after blotting, 
stained with coomassie blue. Non-glycosylated (29 kDa) and complex-glycosylated 
(40-45 kDa) forms of AQP2, and an a-specific band of 35 kDa, are detected. (b) 
mCCDc11 cells grown as previously described were treated for 96 h with 1 nM 
dDAVP, and for the last 24 or 48 h, in the absence (-) or presence of 1 mM lithium 
at the basolateral side and 1 or with 10 mM lithium at the apical side. Cells were 
lysed and immunoblotted for AQP2. Blots were also stained with coomassie blue. 
Molecular masses (in kDa) are indicated on the left. The signals for 
non-glycosylated and complex-glycosylated AQP2 were densitometrically 
quantified and normalized for coomassie blue staining. Mean values of normalized 
AQP2 expression per condition are given as the percentage of control (±s.e.m.) and 
were determined from three independent filters per condition. Significant 
differences (P<0.05) from control (-) are indicated by an asterisk.
In patients on lithium therapy, the concentration of lithium is B1mM in serum 
and ranges between 1 and 10 mM in urine[1]. To test whether these 
concentrations affect AQP2 expression, cells were incubated with 1 mM 
lithium at the basolateral side and with either 1 or 10 mM lithium at the apical 
side for 24 or 48 h. Immunoblotting revealed that lithium reduced the AQP2 
expression in a time-and dose-dependent manner, with an almost complete 
absence of AQP2 after a 48-h incubation in 10 mM lithium (Fig. 1b). This 
concentration of lithium did not affect cell viability as indicated by similar
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coomassie-stained protein levels (Fig. 1b) and a consistent transcellular 
resistance of >1000 Q/cm2 (data not shown). Together, these data reveal that 
mCCDcl1 cells are a suitable model to investigate the role of ENaC in 
lithium-NDI.
The role of ENaC in AQP2 downregulation and transcellular lithium  
transport
ENaC is located in the apical membrane of collecting duct and mCCDcn 
cells[19], and its activity is blocked by amiloride. To test whether ENaC 
mediates AQP2 downregulation by lithium, mCCDc11 cells were treated for 48 
h with lithium at only the basolateral (1 mM) or the apical (10 mM) side with 
or without amiloride. Application of lithium at the apical side reduced AQP2 
expression to ~30% of control values, which was prevented by amiloride (Fig. 
2a). In contrast, the addition of lithium with or without amiloride to the 
basolateral compartment did not change AQP2 levels. Similar results were 
obtained with another ENaC blocker, benzamil (Fig. 2b).
If ENaC is the main entry site for lithium, cellular uptake of lithium and the 
lithium-induced downregulation of AQP2 should be influenced by the sodium 
concentration. In pilot experiments, mCCDc11 cells were grown in medium 
containing lower concentrations of sodium at the apical side for variable time 
periods. Incubation of the cells for 12 h in medium containing 60, 90, or 150 
mM sodium showed similar AQP2 expression, whereas lower concentrations 
of sodium or more prolonged incubations resulted in the reduction of AQP2 
expression (data not shown). Therefore, we incubated the cells with lithium for
12 h in the presence of 150, 90, or 60 mM sodium. Indeed, the AQP2 
expression negatively correlated to the sodium concentration (Fig. 2c), thus 
confirming competition between sodium and lithium, and indicating that 
lithium enters the cells through a sodium-transporting protein.
If ENaC is the apical entry site for lithium, amiloride should reduce 
transcellular transport and the intracellular concentration of lithium. To test 
this, cells were treated with 10 mM lithium at the apical side with or without 
amiloride. After 24 h, we observed a significant decrease in the lithium 
concentration at the apical side and an increase at the basolateral side, 
indicating that transcellular lithium transport occurred, which was inhibited by
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Figure 2. ENaC blockers reduce lithium-induced AQP2 downregulation in 
mCCDc11 cells. (a) Confluent mCCDc11 monolayers were treated for 96 h with 1 
nM dDAVP and incubated for the last 48 h in the absence (-) or presence (+) of 
lithium and/or with 10 ^M amiloride as indicated. At the basolateral and apical side, 
1 and 10 mM lithium were used, respectively. (b) Confluent mCCDc11 monolayers 
were treated described earlier with 10 mM lithium with/without 10 ^M benzamil 
(Li+Ben) at the apical side for the last 24 h. (c) mCCDc11cells were grown as 
previously described and treated for the last 12 h in medium containing a lower 
sodium chloride concentration at the apical side only, with or without lithium 
(indicated). (a-c) Cells were lysed and immunoblotted for AQP2. Molecular masses 
(in kDa) are indicated on the left. Semiquantification of the AQP2 signals, 
normalization, and statistical analysis were carried out as described in the Figure 1 
caption. Mean values were determined from three independent filters per condition. 
Significant differences (P<0.05) are indicated by an asterisk.
co-incubation with amiloride (Fig. 3a). We next determined intracellular 
lithium levels. A 24-h incubation of cells with 1 mM lithium at the basolateral 
side resulted only in an intracellular lithium concentration of 3 ±3 pmol lithium 
per mg protein, which corresponds to a [Li+] of 0.7 mM (Fig. 3b). This is well
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above that of control cells (below detection limit; data not shown), indicating 
that some lithium enters the cells from the basolateral side. Intracellular lithium 
concentrations were markedly higher when 1 or 10 mM lithium was also added 
to the apical side, resulting in concentrations of 3.0 and 26.0 mM, respectively. 
In the presence of amiloride, intracellular lithium concentrations were reduced 
by more than 75%. To determine whether the obtained data were cell 
line-specific, we repeated some of the above experiments in mpkCCDcl4 cells. 
In these cells, amiloride also reduced the intracellular lithium concentration and 
prevented lithium-induced downregulation of AQP2 (Supplementary Fig. S1).
Together, these data indicate that ENaC is the main cellular entry site for 
lithium in collecting duct cells and that blocking ENaC by amiloride prevents 
lithium-induced downregulation of AQP2.
Effects of lithium and amiloride on ENaC subunit expression
In vivo, it has been shown that lithium treatment results in the ENaC 
downregulation[29]. To see whether similar effects occurred in vitro, mCCDc11 
cells were treated with lithium for 12-48 h. Indeed, lithium reduced the 
expression of P-ENaC, but not of a- or y-ENaC (Fig. 3c). However, these cells 
showed an amiloride-dependent transcellular voltage (data not shown), 
indicating that ENaC was still functionally expressed. Amiloride partially 
prevented the downregulation of P-ENaC (Fig. 3d).
Effects of lithium and amiloride on GSK30
Rao et al. [30] showed a decreased glycogen synthase kinase (GSK)3P activity 
in lithium-treated rats, suggesting a possible involvement of GSK3P in the 
pathway leading lithium-NDI. To test whether GSK3P is also involved in the 
lithium-induced downregulation of AQP2, total GSK3P expression and the 
extent of GSK3P-inactivating phosphorylation at Ser9 were analyzed in 
conjunction with AQP2 expression. Although lithium treatment for 48 h again 
caused downregulation of AQP2, it did not change total GSK3P expression 
levels, but strongly increased the Ser9 phosphorylation of GSK3P (Fig. 4a). 
Zinc also inhibits GSK3P[31], and BIO-Acetoxime is a specific GSK3 
inhibitor[32;33]. Indeed, similar to lithium, 20 mM, but not 1 mM, zinc reduced 
AQP2 levels and increased phosphorylated GSK3P, but did not affect total
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Figure. 3. Amiloride blocks lithium transport. mCCDcn cells were grown as 
previously described. (a) After a 24-h treatment with 10 mM lithium with/without 
amiloride at the apical side, media from the apical and basolateral compartments 
were collected and lithium concentrations were determined. (b) mCCDc11 cells 
were treated for the last 24 h with the indicated concentrations of lithium at the 
basolateral (bl) and/or apical (ap) side in the absence or presence of 10 ^M 
amiloride. After 24 h, lithium concentrations were determined. Intracellular lithium 
concentrations were corrected for contamination with extracellular lithium and 
normalized for the amount of protein. (a,b) The mean lithium concentration ([Li+] 
±s.e.m. in mM (a) or in pmol/^g protein (b)) was determined from at least three 
independent filters per condition. Significant difference *P<0.05. (c) mCCDc11 
cells were treated with lithium on the apical (10 mM) and basolateral (1 mM) side 
for the indicated time periods, lysed, and analyzed for ENaC subunit expression. (d) 
mCCDc11 cells were treated as in panel c with or without amiloride for 24 h and 
analyzed for p-ENaC. (c and d) Molecular masses (in kDa) are indicated on the left. 
Significant differences (P<0.05) from control are indicated by an asterisk.
GSK3P levels (Fig. 4a). In line with an important role of GSK3p in AQP2 
expression, BIO-Acetoxime also decreased the expression of AQP2 (Fig. 4b).
As amiloride prevents lithium-induced downregulation of AQP2, we also 
tested whether amiloride reduced the effect of lithium on GSK3p. Indeed, 
although amiloride again protected the lithium-induced downregulation of
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Figure. S1 Effect of amiloride in mpkCCDcl4 cells. A) Confluent mpkCCDcl4 
monolayers were treated for 96 hrs with 1 nM dDAVP and incubated for the last 
24 hrs in the absence or presence of lithium and/or 10 ^M amiloride as indicated.
At the basolateral and apical side, 1 mM and 10 mM lithium was used, 
respectively. Proteins were immunoblotted for AQP2, of which the mass is 
indicated on the left (in kDa). Mean values of normalized AQP2 expression per 
condition are the mean of three independent experiments and are given as 
percentage of control (+/- SEM). B) Confluent mpkCCDcl4 monolayers were 
treated as in A. 24 hrs after start of the lithium treatment, intracellular lithium 
concentrations were determined. These were corrected for contamination with 
extracellular lithium and normalized for the amount of protein. The mean lithium 
concentration ([Li+] ± SEM in pmol/^g protein) was determined from three 
independent filters per condition. For A and B, asterisks indicate a significant 
difference (p < 0.05).
AQP2, it did not affect total GSK3P expression, but significantly reduced the 
extent of lithium-induced phosphorylation of GSK3P at Ser9 (Fig. 4c).
Together, these data strongly suggest that in mpkCCDcl4 cells, lithium affects 
AQP2 expression by inactivating GSK3P through the phosphorylation at Ser9, 
which is attenuated by amiloride.
The effect of amiloride on the development of lithium-NDI in rats
To analyze whether amiloride can prevent the development of lithium-NDI in 
vivo, rats were fed on lithium chow for 4 weeks, with or without amiloride, 
whereas control rats fed on normal chow. All rats had free access to a salt 
block to compensate for the sodium losses that occur in lithium-NDI[34].
As anticipated[7;8], the rats treated with lithium developed severe polyuria
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Figure 4. Effects of lithium on GSK30. Confluent mpkCCDcl4 monolayers were 
treated for 96 h with 1 nM dDAVP. (a) Cells were treated with 1 mM lithium at the 
basolateral side and 10 inM lithium at the apical side, or with 20 and 1 P-M zinc at 
both sides for the last 48 h and subjected to AQP2, GSK3 f-1 , and 
phospho-GSK3 P(Ser9) immunoblotting or, after blotting, stained with coomassie 
blue. (b) mpkCCDcl4 cells were treated with a specific GSK3-inhibitor 
(BIO-Acetoxime) for the last 48 h and subjected to AQP2 immunoblotting. 
Concentrations are expressed in nanomolar. (c) Cells were incubated for the last 
48 h in the absence or presence of lithium with or without 10 ^M amiloride as 
indicated. At the basolateral and apical side, 1 and 10 mM lithium were used, 
respectively. Molecular masses (in kDa) are indicated on the left. 
Semiquantification, normalization, and statistical analysis were carried out as 
described in the legend of Figure 1. Significant differences (P<0.05) from control 
are indicated by an asterisk.
with reduced urine osmolality (Table 1). Amiloride treatment attenuated this 
polyuria and increased urine osmolality compared with lithium only. Serum 
lithium  concentrations found in the lithium  (0.69±0.08 mM) and 
lithium-amiloride (0.57±0.08 mM) groups were similar and in the therapeutic 
range, whereas serum lithium concentrations in control rats were below the 
detection limit (0.05 mM; Table 1). As observed more often[7;35-38],
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Table 1. Blood and urine parameters
- Li Li+Am
Body weight (g) 287±11 212±7* 232±8*
Plasma osmolality (mOsm) 283±5 304±5* 288±3**
Plasma lithium (mmol/l) / 0.69±0.08 0.57±0.08
Plasma sodium (mmol/l) 141±1 142±2 141±2
Plasma urea (mmol/l) 5.9±0.3 4.0±0.3* 5.6±0.7
Plasma creatinine (^mol/l) 43±3 41±1 41±2
Urine volume (ml/day) 13±2 189±15* 108±24***
Urine osmolality (mOsm) 1537±158 98±25* 400±93*,>*
Total lithium excretion (mmol/24 h) / 0.38±0.10 0.61±0.10
Total sodium excretion (mmol/24 h) 1.5±0.3 4.7±0.2* 11.4±1.9*,>*
Total potassium excretion (mmol/24 h) 3.2±0.5 2.4±0.4 3.0±0.3
Total urea excretion (mmol/24h) 10.9±0.2 6.8±0.5 8.6±1.3
Osmolar excretion (mOsm/24h) 18.3±0.2 16.9±0.3 35.4±6.7
Creatinine clearance (ml/min) 0.93±0.05 0.42±0.09* 0.72±0.12
Urea clearance (ml/min) 1.31±0.25 1.20±0.07 1.15±0.17
Lithium clearance (ml/min) / 0.65±0.10 0.98±0.25
Am, amiloride; Li, lithium.
Values are means ±s.e.m.
*Significant differences between control (-) and other groups.
“ Significant differences between the lithium (Li) and lithium+amiloride group (Li+Am). 
/ Below detection limit.
lithium-treated rats had a slightly lower body weight. We observed no 
differences in serum sodium or serum creatinine concentrations. However, 
there were differences in the urinary excretion of the various solutes. Lithium 
treatment resulted in increased sodium losses, which was further exaggerated 
by amiloride, confirming the need for the salt block. To investigate whether 
there were differences in food intake, the excretion of potassium and urea was 
measured. Urinary excretion of these solutes was numerically, although not 
significantly, lower in rats treated with lithium only. In rats treated with lithium 
and amiloride, values were similar to controls. Furthermore, creatinine 
clearance was lower in lithium-treated rats than in control rats. This was not the 
case in the amiloride-lithium-treated rats.
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The effect of amiloride on the renal collecting duct in lithium-NDI rats
Lithium-NDI is characterized by a decreased fraction of AQP2-expressing 
principal cells with a parallel increase of H-ATPase-expressing intercalated 
cells[7]. We evaluated the effect of amiloride treatment on AQP2 and 
H-ATPase expression and on the cellular composition in different regions of 
the kidney. We observed a significantly reduced expression of AQP2 in the 
cortex of lithium-treated animals (Fig. 5; Table 2). Amiloride significantly 
attenuated this decrease, but did not restore the AQP2 expression to the level 
of untreated rats. Similar results were obtained for the outer and inner medulla 
(Table 2). With respect to the expression of H-ATPase, we noted an increased 
expression in the cortex of lithium-treated rats, which was prevented by 
amiloride (Fig. 5). Similar data were obtained for the outer and inner medulla 
(Table 2).
To investigate whether amiloride treatment also affects the ratio of principal 
and intercalated cells, kidney sections were labeled with antibodies against 
AQP2, H-ATPase, and nuclear TOTO-3. In agreement with earlier studies[7;8] 
and with the immunoblot data, lithium treatment resulted in a decreased density 
of AQP2-expressing cells and an increased density of H-ATPase-expressing 
cells (Fig. 6 a). Amiloride treatment attenuated these changes.
Figure 5. Amiloride prevents effects of lithium on AQP2 and H-ATPase 
expressions in lithium-NDI rats. Wistar rats were fed a normal diet (-; n=6), a diet 
containing lithium (Li; n=6), or a diet containing lithium and amiloride (Li+Am; 
n=7). After 4 weeks, one kidney was divided in the cortex, outer medulla, and inner 
medulla segments and solubilized. An equal amount of protein of the cortex of each 
rat was immunoblotted for AQP2, H-ATPase, or tubulin (indicated). Molecular 
masses (in kDa) are indicated on the left.
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Table 2. Effect of amiloride on collecting duct marker protein expression
AQP2 H-ATPase
- Li Li+Am - Li Li+Am
Cortex 100±6 4±2* 22±4*” 100±42 303±23* 150±19*
OM 100±5 30±9* 53±6*” 100±30 179±17* 121±40
IM 100±4 6±4* 42±4*” 100±29 129±13 65±20**
Am, amiloride; Li, lithium.
Mean values (±s.e.m.) are expressed as percentages of the controls.
*Significant differences between control (-) and other groups.
**Significant differences between the lithium (Li) and lithium+amiloride group (Li + Am)
We quantified the changes by calculating a principal/ intercalated cell ratio. 
Lithium treatment significantly reduced the ratio in the cortex, an effect that 
was fully prevented by amiloride (control: 1.72±0.09; lithium: 0.83±0.06; and 
lithium-amiloride: 1.78±0.15; Fig. 6 b).
Similar results were obtained for the outer medulla (control: 2.21±0.15; 
lithium: 1.02±0.07; and lithium-amiloride: 1.98±0.13) and the inner medulla 
(control: 2.66±0.56; lithium: 1.16±0.12; and lithium-amiloride: 1.91±0.07), 
indicating that amiloride prevents the change in the ratio of principal/ 
intercalated cells.
DISCUSSION  
mCCDc11 cells are a proper model to study lithium -induced AQP2 
downregulation
A major impediment to the study of lithium-NDI at the cellular level was the 
lack of a suitable model. Our study indicates that mCCDc11 cells are an 
appropriate model for the following reasons. First, mCCDc11 cells express all 
three ENaC subunits in the apical membrane and show amilorideinhibitable 
sodium transport[19]. Second, and similar to collecting duct cells in vivo, 
mCCDc11 cells show a dDAVP-dependent increase in the expression of 
endogenous AQP2 (Fig. 1a). Third, and in line with in vivo findings[5], 
mCCDc11 cells show a time-and concentration-dependent decrease in the
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Figure 6. Amiloride prevents cell conversion in lithium-NDI rats. (a) Of the rats 
described in the Figure 5 caption, one kidney was removed and fixed. Cryosections 
were prepared and incubated with rabbit H-ATPase (green) and guinea pig AQP2 
(red) antibodies, followed by Alexa-488-conjugated goat-anti-rabbit and 
Alexa-594-conjugated goat anti-guinea pig antibodies. TOTO-3 (blue) was used to 
counterstain the sections. Images were produced with confocal laser scanning 
microscopy. Bars=10 ^m. (b) Of >5 defined areas of the kidney cortex of each 
control (n=6), lithium (n=6), and lithium+amiloride (n=7) rats, cells positive for 
AQP2 or H-ATPase were counted and expressed as the ratio of principal and 
intercalated cells (±s.e.m.) (total cells control (-): 1244; Li: 1393; Li+Am: 2064). 
Significant differences * P<0.05.
AQP2 expression in response to therapeutically relevant lithium 
concentrations (Fig. 1b).
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ENaC is the main entry site for lithium and blocking ENaC prevents 
lithium-induced GSK30 inactivation and AQP2 downregulation in vitro 
With 1 mM lithium added to the basolateral side of mCCDc11 cells, a small but 
significant increase in the intracellular lithium concentration was observed 
(Fig. 3b). As the cells formed a tight monolayer, this indicated that lithium can 
enter through a basolateral site. Although the identity of this entry pathway 
remains to be established, it did not reduce AQP2 expression (Fig. 2a).
Upon addition of 1 mM lithium to the apical compartment, intracellular lithium 
concentrations increased about 3.5-fold to 3.0 mM (Fig. 3b), which resulted in 
slightly, but not significantly, reduced AQP2 levels (Fig. 1b). The addition of 
10 mM lithium together with amiloride to the apical compartment resulted in 
similar intracellular lithium concentrations (Fig. 3b) and in normal AQP2 
levels (Fig. 2a). In contrast, the AQP2 expression was strongly reduced with 10 
mM lithium at the apical side in the absence of amiloride (Fig. 1c), which 
coincided with an intracellular lithium concentration of 26 mM (Fig. 3b). The 
observed AQP2 reduction suggests that within 24 h, AQP2 expression is 
downregulated with a threshold of intracellular lithium concentrations between 
3 and 26 mM, which are obtained with lithium concentrations of 1 mM at the 
basolateral side and 10 mM at the apical side. However, at prolonged 
incubation times, AQP2 downregulation may be induced with lower 
extracellular lithium concentrations, as illustrated by the reduced AQP2 levels 
upon incubation with 1mM lithium for 48 h (Fig. 1b). In agreement with an 
important role of GSK3P activity in lithium-NDI mice[30] and the protective 
effect of amiloride on lithium-induced down-regulation of AQP2, lithium, and 
also other GSK3P inhibitors, increased inactivating GSK3P phosphorylation 
and downregulation of AQP2 expression in mpkCCDcl4 cells, which was 
partially prevented by co-treatment with amiloride (Fig. 4).
The observed intracellular lithium concentration of 26 mM is higher than the 
concentration in the extracellular fluid, which has been observed before. 
Immunocytochemistry did not show the difference in cell size between[23] 
lithium-treated and control cells, and, in similar experiments, intracellular 
potassium levels were not different between control, lithium-and lithium • 
amiloride-treated cells, indicating that this is not because of an increased 
intracellular volume in the lithium-treated cells. More likely, the strong 
inwardly directed electrochemical potential for lithium and the fact that lithium
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is a poor substitute for sodium with Na/K-ATPase to be transported to the 
extracellular fluid[39] cause intracellular accumulation of lithium.
Overall, our study provides strong evidence that ENaC is the major cellular 
entry pathway for lithium and that blocking ENaC reduces lithium-induced 
GSK3P inactivation and prevents AQP2 downregulation.
Co-treatment with amiloride attenuates lithium-NDI
As reported[5;7], lithium also induced NDI in our experiments, as indicated 
by the increased urine volume and decreased urine osmolality (Table 1). Our 
data furthermore reveal that amiloride treatment decreased urine volume and 
increased urine osmolality (Table 1). Although these changes point to a better 
urine-concentrating ability, the observed changes could theoretically be due to 
differences in solute intake or extracellular volume: an increased solute intake 
increases urine volume because of osmotic diuresis, whereas hypovolemia 
will reduce urine volume and increase urine osmolality. However, our data 
clearly indicate that the effects of amiloride cannot be explained by these 
factors. First, the urinary excretion of osmolytes was higher in the amiloride­
lithium group than in the group receiving lithium only. Second, if anything, 
volume depletion was more likely to be present in lithium-only-treated rats as 
suggested by the lower body weight, and the reduction in creatinine clearance.
Consistent with this and the protective effect of amiloride in mCCDc11 cells, 
rats treated with amiloride and lithium had significantly increased AQP2 and 
decreased H-ATPase expression compared with rats treated with lithium only 
(Fig.s 5 and 6 ; Table 2), and the lithium-induced change in the 
principal/intercalated cell ratio was completely prevented (Fig. 6 ). Taken 
together, our data indicate that amiloride has a protective effect on lithium-NDI 
development by preventing the lithium-induced change in the cellular 
composition and partial protection of AQP2 downregulation, leading to a 
preserved concentrating ability of the collecting duct.
The complete prevention of the change in the cell ratio and the partial 
protection of AQP2 downregulation by amiloride suggests that AQP2 
expression is more sensitive to lithium than the integrity of the principal cells, 
which is in agreement with the fact that AQP2 downregulation precedes the 
fractional decrease in principal cells in lithium-NDI development[4;8]. It 
furthermore suggests that the used amiloride concentration did not completely
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prevent the deleterious effect of lithium, and it is unclear whether a residual 
effect of lithium can explain the fact that the concentrating ability of 
amiloride-treated rats is still lower than in control rats. One explanation for the 
reduced concentrating ability is that blockage of sodium reabsorption by 
amiloride could lead to a decrease in osmolality in the interstitium. However, 
considering the small contribution of sodium transport through ENaC to the 
interstitial osmolality, which is even less when NaCl is given ad libitum as done 
here, this is rather unlikely.
Alternatively, this could be due to an incomplete block of ENaC by amiloride 
in the kidney or due to cellular lithium influx through (an) other 
transporter(s)/channel(s). Amiloride was added to the food of the rats at a 
concentration of 200 mg/kg dry food, which is equivalent with 5 mg of 
amiloride. Assuming a volume of distribution of 3.4 l/kg and a tlA of 21 h, and a 
bioavailability of 10%[40;41],this will lead to a plasma concentration of 3 ^M. 
Amiloride clearance has been estimated to be about three times the creatinine 
clearance[42], leading to a amiloride excretion of 9 mmol/day and an end-urine 
concentration of 84 ^M, which, as the IC50 of amiloride is 0.1-0.5 ^M[21], very 
likely completely blocks ENaC. If these calculations hold for our rats, our data 
suggest that, in line with our in vitro data, some lithium may enter principal 
cells through a protein other than ENaC.
In our lithium-induced NDI rats and as observed by others[8 ], we observed an 
increased expression of H-ATPase, which can be partly attributed to an 
increase in the number of intercalated cells (Fig.s 5 and 6 ). It has been 
suggested that the observed reduction in AQP2 expression with lithium is 
partially due to a loss of principal cells, either by differentiation of principal 
cells to intercalated cells or by selective cell death of principal cells[7;8]. 
Occasionally, and as observed by others[7], we observed cells to stain positive 
for both AQP2 and H-ATPase, which may suggest that the change of the 
principal/intercalated cell ratio in lithium-NDI is (partly) due to a transition of 
principal to intercalated cells. However, the numbers were too low to influence 
the counting of the principal/intercalated cell ratio. In line with a loss of 
principal cells, Christensen et a/.[8 ] found an increased number of 
apoptosis-inducing factor-labeled collecting duct cells in the inner medullary 
collecting duct after 10 and 15 days of lithium treatment, suggesting that 
apoptosis of principal cells may be involved, at least in part, in the changes in 
cellular composition in lithium-induced NDI. However, they also found an
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increased proliferation of not only intercalated cells but also principal cells, 
and, therefore, the change in cell composition could be the result of an 
increased number of intercalated cells without a loss of principal cells. If so, the 
reduced expression of AQP2 could be the result of a decreased expression per 
cell only. The exact underlying mechanism awaits further experiments.
Lithium-NDI also coincides with reduced expression of urea transporters 
UT-A1 and UT-B, and Bedford et a/.[43;44] recently showed that amiloride 
treatment also signifcantly increases UT-A1 expression and conserves the 
osmotic gradient compared with rats treated with lithium only. Considering our 
data, the changes in UT-A1 expression and osmotic gradient with lithium and 
lithium-amiloride, respectively, could be due to a decreased/increased 
expression per cell, but are likely (partially) explained by the changes in the 
principal/intercalated cell ratio.
In conclusion, our data reveal that mCCDc11 cells form a proper model to study 
lithium-NDI. We show that ENaC forms the major entry pathway for lithium 
into principal cells, and that blocking ENaC with amiloride reduces the 
lithium-induced AQP2 downregulation, protects the cellular composition of the 
collecting duct, and thereby attenuates lithium-NDI. As such, our data provide 
a rationale for the use of amiloride in treating lithium-NDI patients.
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ABSTRACT
It is anticipated that gene expression profiling of kidney inner medullary 
collecting duct cells from rats at the first signs of lithium-induced 
Nephrogenic diabetes insipidus (NDI) will reveal the genes changed early on 
and involved in the development of lithium-induced NDI, because, at later 
time points, transcriptome changes due to adaptive changes will also be 
encountered. In the present study, we determined that 3 days lithium treatment 
is the earliest moment at which lithium induced the earliest significant 
increase of urine output, reduction of urine osmolality, and reduction in 
aquaporin-2 (AQP2) protein and mRNA levels in rats. Subsequent cDNA 
microarray analysis of inner medulla collecting duct (IMCD) transcripts of 3 
days lithium-treated and control rats yielded 1271 distinct genes with or 
without changes of expression compared between lithium-treated and control 
rats, of which 146 and 8 8  genes were more than 2-fold down- or up-regulated, 
respectively. Ingenuity pathway analysis of these 234 altered genes identified
13 significant gene networks (p<0.001), with the top-scoring networks mostly 
associated with DNA replication, recombination, and repair, cancer, cell 
cycle, cellular movement, nucleic acid metabolism, renal and urological 
disease, inflammatory response, cellular growth and proliferation. 
Furthermore, our data showed that the genes that suppress apoptosis and 
stimulate proliferation were upregulated by lithium treatment, whereas the 
pro-apoptotic genes were downregulated, indicating a stimulation of cell 
proliferation and reduced apoptosis in the IMCD. We also demonstrated 
increased expression of genes involved in AQP2 trafficking in lithium-treated 
rats, suggesting an early effect of lithium on AQP2 trafficking. Genes of 
significantly altered expression reported in the previous gene profiling study 
of rat inner medulla after 4 week lithium treatment were not detected in our 
data, indicating an importance of using purified inner medulla collecting duct 
cells. At last, the immunoblotting of iKBa, the inhibitory unit of transcription 
factor NFkB, showed that lithium downregulated IKBa, suggesting an 
activation of NFkB in response to lithium in the rat IMCD. In conclusion, the 
present study demonstrated an induced proliferation rather than apoptosis by 
lithium at the early stage, early effect of lithium on AQP2 trafficking, and 
NFKB might mediate lithium-induced downregulation of AQP2 in the rat 
IMCD.
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INTRODUCTION
Lithium is the drug of choice for treating bipolar disorders, and is prescribed 
to 1 in 1000 of the population[1]. Besides, lithium is used for treating 
schizoaffective disorders and depression and is currently under consideration 
as a therapeutic for alcoholism, Alzheimer’s disease[2], AIDS[3] and cluster 
headaches[4]. Unfortunately, development of Nephrogenic Diabetes Insipidus 
(NDI) is a common side effect of lithium therapy. Since 0.1% of humans are 
on lithium therapy and this side effect presents in approximately 2 0 % of the 
patients[5], lithium-NDI is the most common acquired form of NDI. 
Considering the narrow therapeutic index of lithium (0.6 to 1.2 mEq/L) and 
the increased risk of toxicity with the severe dehydration that is associated 
with this disorder, lithium-induced NDI is a problem of significant clinical 
magnitude and can lead to permanent renal damage.
Many studies have focused on investigating the molecular basis of lithium- 
induced NDI. In 1995, Marples et al. reported that lithium-induced NDI is 
associated with decreased levels of collecting duct water channel protein 
Aquaporin-2 (AQP2)[6]. Subsequent studies revealed that the severity of 
lithium-induced NDI is time-dependent: two weeks of lithium exposure 
resulted in downregulation and reduced trafficking of AQP2 to the apical 
membrane of the principal cells without significant morphological changes in 
the collecting ducts; after 2  weeks, a major change in cell distribution along 
the collecting duct was observed, with the proportion of intercalated cells 
increased at the expense of principal cells[7-10]. Along these, reduced 
expression of epithelial sodium channel (ENaC) subunits[11;12], urea 
transporters UTA-1 and UT-B[13], and acid-base transporting proteins H+- 
ATPase and the anion exchange type 1 (AE1)[8] were found, which could 
possibly attribute to the development of lithium-induced NDI. Furthermore, 
cDNA microarray[14] and a proteomic analysis[15] have been done to 
identify the molecular changes in lithium-induced NDI. In the microarray 
screening of the rat inner medulla after chromic lithium treatment (4 weeks), 
most genes with significantly altered expression were demonstrated to be 
mainly linked to changes of morphology, cellular proliferation, and 
remodelling and changes in interstitial osmolality. These include 1ip- 
hydroxysteroid dehydrogenase type 2 (11P-HSD2), inhibitory protein of 
cyclin-dependent kinases p27 (p27/KIP) and heat shock protein 27 (Hsp27).
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The more recent proteomic analysis, using inner medulla collecting ducts 
(IMCD) isolated from rats of 1 and 2 weeks of lithium treatment, identified 6  
and 74 proteins with altered expression, respectively. These proteins were 
mainly involved in processes such as apoptosis, cell proliferation and 
maintenance of cell morphology.
Most microarray and proteomics studies of diseases in general, including the 
ones above, are done at stages when the disorder is already fully or to a great 
extent developed. These studies have the inherent drawback that many 
genes/proteins identified to be changed in their expression are likely adaptive 
changes to the changed situation and, therefore, are not the most suitable to 
find (changes in) proteins causing the disease. The early changes in 
mRNA/protein expression, which are at the basis and likely directly involved 
in causing the development of the disease, will be overshadowed by adaptive 
changes and may even have already disappeared.
Therefore, to obtain information on the early changes in mRNA expression in 
lithium-NDI with the goal to identify the cause(s) of lithium-induced NDI, we 
set out to determine the earliest moment of development of lithium-induced 
NDI in rats, and to identify the mRNAs changed in their expression using 
microarray analysis.
M ATERIALS AND M ETHODS  
Animal protocol
Pathogen-free male Sprague-Dawley rats weighing 200-250g (Taconic Farms 
Germantown, NY) had free access to ad libitum drinking water and normal 
rodent chow before experiment (National Heart, Lung, and Blood Institute 
Animal Care and Use Committee approved protocol nr. H-0110)[16]. After 
two days adaption in metabolic cages, rats were treated with lithium as 
previously described[6 ] for 1, 2, 3 or 4 days. For lithium treatment, lithium 
chloride was added to the chow to give a concentration of 40 mmol/kg dry 
food (n=6 /time point), while sodium chloride of 40 mmol/kg dry food were 
given to the control rats (n=6 /time point).
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IM CD preparation
IMCD and non-IMCD cells were prepared from whole inner medullas as 
previously described[17;18]. In brief, rats were euthanized by decapitation 
and the kidneys were removed rapidly. The renal inner medullas were 
dissected and minced to obtain 1 mm tissue pieces. The tissue was then 
digested in the digestion solution (3 mg/ml collagenase B, 2,000 U/ml 
hyaluronidase, 250 mM sucrose, 10 mM triethanolamine, pH 7.6) at 37 0C for 
75 minutes. Homogenous digestion mixture was subjected to centrifugation 
at 5 g for 10 seconds (Jouan C412) to remove large undigested tissue pieces. 
IMCD cells in the supernatant were harvested by centrifugation at 70 g for 30 
seconds at 40C and washed 3 times with sucrose resuspension solution (250 
mM sucrose, 10mM triethanolamine, pH 7.6). Non-IMCD cells were 
harvested from the supernatant of the above centrifugation steps. The final 
pellet of IMCD cells were subjected to total RNA isolation. A small aliquot of 
IMCD and non-IMCD cells was lysed in Laemmli buffer for immunoblotting.
RNA isolation and real-time PCR
In order to yield enough RNA for the to-be-performed microarray assays, 
IMCD cells isolated from two identically treated rats were pooled and the 
total RNA was extracted using TriZOL® reagent (Invitrogen, Carlsbad, CA) 
following the manufacturer’s protocol. The total RNA was treated with 
DNase and heat inactivation followed by isopropanol precipitation. The 
concentration of total RNA was measured using a Nanodrop 
spectrophotometer (NanoDrop Technologies, Wilmington, DE). The quality 
of the total RNA was analyzed by an Agilent 2100 Bioanalyzer (Agilent 
Technology Inc, Santa Clara, CA).
200 ng of RNA was reverse-transcribed using SuperScript® II First-Strand 
Synthesis SuperMix (Invitrogen, USA). This cDNA was used to semi- 
quantify Aqp2 mRNA levels with ribosomal RNA as an endogenous control 
using Platinum® SYBR® Green qPCR SuperMix-UDG (Invitrogen, USA). 
PCR primers used for Aqp2 were 5’-gactgtgcttagtgcatctca -3’ and 5’- 
tgaggaaaagaaatacgcgga -3 ’. Real-time PCR was performed and quantified on 
an ABI Prism 7700 Sequence Detection System (PE Biosystems, Rotkreuz, 
Switzerland).
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Protein sample preparation and immunoblotting
In order to assess purity of IMCD samples and to detect the protein 
abundance, aliquots from the whole inner medulla (IM), IMCD and non- 
IMCD pellets were loaded onto SDS-polyacrylamide gels and 
immunoblotting was carried out as described[16;17]. Affinity-purified 
polyclonal anti-AQP2 K5007 detecting the COOH terminus[19] and anti- 
AQP1[17] antibodies were used.
cDNA array analysis
Hybridization probes (labelled cDNAs corresponding to the transcripts) were 
prepared and hybridized to the microarrays according to the manufacturer’ s 
protocols (NHLBI Gene Expression Core Facility). Briefly, 0.5~1 ^g of total 
RNA was used to generate double-stranded cDNA using the One-Cycle 
cDNA Synthesis Kit and the oligo(dT) 24 primer (Affymetrix Inc, Santa 
Clara, CA), a primer which contained a 3' T7 RNA polymerase promoter site. 
Biotin-labelled cRNA probes were produced from cDNA using the in vitro 
transcription (IVT) labelling kit (Affymetrix Inc, Santa Clara, CA). The 
probes were purified and fragmented (Standard protocol of Affymetrix for 
cleanup of cRNA after IVT labelling; Fragmentation by metal-induced 
hydrolysis). Fragmented RNA was assessed for relative length (RNA 
fragment sizes from approximately 35 to 200 bases) on the Agilent 2100 
bioanalyzer and hybridized to Affymetrix Rat Genome 230 2.0 microarrays 
(Affymetrix, Santa Clara, CA) for 16 hours. Microarrays were washed and 
fluorescently labelled using Affymetrix Genechip Fluidics Station 450. The 
fluorescence signal was measured using the Affymetrix Genechip scanner.
M icroarray data analysis and identification of IM CD transcribed genes
The total number of genes with the Affymetrix Detection p-value consistent 
with a “Present Call” (detected) was about 1,316 features in the Affymetrix 
rat 230 2.0. [Each Affymetrix GeneChip® probe set contains 8 to 16 paired 
perfect matches (PM) and mismatch (MM) 25-mer probes, which are used to 
determine whether a given gene is expressed and to measure the expression 
level (signal). The Affymetrix Microarray Suite version 5 (MAS5) algorithm 
uses a non-parametric statistical test (Wilcoxon signed rank test) of whether 
significantly more perfect matches show more hybridization signal than their 
corresponding mismatches to produce the detection call (Absent (A), Present 
(P) or Marginal (M)) for each probe set[20].] These 1,316 features 
corresponded to about 1,271 distinct genes. The remaining 45 features were
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identified to be “unknown” or “weakly similar” to the 1,271 distinct genes. 
Intensities of each probe set were normalized by median-transformed 
normalization.
Ingenuity Pathway Analysis
Data sets containing the Affymetrix probe set identifiers and fold changes 
were uploaded into Ingenuity's online server for Ingenuity Pathway Analysis 
(IPA; https://analysis.ingenuity.com/; Ingenuity® Systems, Mountain View, 
CA). A cut-off of the fold change equals 2 was applied to the gene list and 
therefore only genes with at least 2  fold changed expression levels were 
included in the pathway analysis. The IPA program searches the Ingenuity 
Pathway Knowledge Base (IPKB) for interactions between the uploaded 
genes and all other genes contained in IPKB and generates a series of 
networks[21] (Ingenuity® Systems, www.ingenuity.com). Fisher's exact t test 
was used to assign statistical significance, and each network's score was 
displayed as -log (p value). Biological functions were also assigned to each 
network.
Scores of the pathways of highly interconnected genes represent statistical 
likelihoods using the following equation:
where N  is the number of genes in the genomic network, of which G are focus 
genes, for a pathway of 5 genes, f  of which are focus genes.
RESULTS  
Short-term lithium treatm ent in rats induced polyuria
To determine the earliest moment at which rats develop lithium-induced NDI, 
the Sprague-Dawley rats received standard rat chow containing 40 mmol 
lithium/kg food for 4 days, while control rats received 40 mmol sodium/kg 
food. After 1 day treatment, serum lithium concentration of rats receiving 
lithium chow reached 0.40 ± 0.04 mM and remained similarly up to 4 days 
treatment (Table 1# page 157). In line with previous findings[15], 4 days lithium 
treatment established a marked polyuria and decreased urine osmolality in rats
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(Fig. 1, day 4). During these 4 days treatment, urine volumes changed 
correspondingly, and a clear increase of urine volume and a significant 
decrease of urine osmolality were observed as early as of 3 days lithium 
treatment (Fig. 1).
Figure 1. Effects of lithium treatment on urine concentrating ability.
Sprague-Dawley rats were fed a sodium diet (control) or lithium diet (lithium) 
for 1, 2, 3 or 4 days (n=6/time point/diet). The last 24 hours urine volume (A) 
and osmolality (B) were measured. Asterisk indicates significant difference 
between lithium-treated and control rats of the same time point (*, P< 0.05).
In order to assess purity of IMCD samples that were prepared from the rat IM 
and would be used for later analysis, aliquots from the whole IM, IMCD and 
non-IMCD pellets were loaded onto SDS-PAGE gels and immunoblotted for 
the protein markers of the vasa recta and thin descending limbs of Henle 
(AQP1) and collecting duct (AQP2), respectively. The blots showed 
pronounced AQP2 expression in the IMCD fraction, less pronounced in the 
whole IM and least in the non-IMCD fraction, indicating that AQP2 was 
indeed highly enriched in the IMCD fraction and depleted from the non- 
IMCD fraction (Fig. 2A). Meanwhile, the AQP1 expression was seen only 
pronounced in the non-IMCD fraction but not in IMCD fraction, indicating 
that the de-enrichment of the non-IMCD cells from the IMCD fraction was 
also successful (Fig. 2B). Furthermore, the AQP2 expression level was clearly 
reduced by lithium in the IMCD samples, whereas the lithium-induced 
downregulation of AQP2 in the whole IM was less significant. These 
confirmed the enrichment of the AQP2 expressing IMCD fraction in the
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whole IM, and indicated that the lithium-induced AQP2 downregulation in the 
IMCD cells was not affected by the preparation protocol.
Figure 2. Expression of AQP1 and AQP2 in the IMCD and non-IMCD 
fractions. A) Sprague-Dawley rats were fed a sodium diet (control) or lithium- 
diet (lithium) for 3 days (n=4). IMCD and non-IMCD cell fractions were 
prepared from whole inner medullas of control (C; pooled samples from 2 rats) 
and 3 days lithium-treated rats (L; pooled samples from 2 rats). The cells and the 
inner medullas were solubilized and equal amount of protein from these samples 
were immunoblotted for AQP2. B) Immunoblot loaded the same as A and 
probed with AQP1 antibody. C and L indicating control and lithium rat samples, 
and number 1 and 2 indicating experiment 1 and its repeat experiment 2, 
respectively. Molecular masses in kDa are indicated on the left.
Next, the IMCDs isolated from 1 to 4 days lithium-treated rats were 
immunoblotted for AQP2. Consistent to the observed changes in urine volume 
and osmolality, AQP2 protein expression of the rat IMCD showed a 
significant reduction after 4 days lithium treatment (Fig. 3A-B).
To assess whether Aqp2 mRNA levels were also reduced after 4 days or even 
earlier, we performed real-time PCR against the isolated IMCD RNA. Despite 
it seemed that Aqp2 mRNA levels were slightly higher in lithium treated rats 
after 1 and 2 days, a clear decrease of Aqp2 mRNA levels was observed after 
3 and 4 days (Fig. 3C), indicating the first moment effect of lithium in the 
rats.
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Figure 3. Effects of lithium treatment on AQP2 protein and mRNA levels.
A) Of the rats described in Figure 1, inner medullas of two rats from the same 
time point were pooled, and the IMCD cell fractions were prepared and 
solubilized. Equal amount of protein of the IMCD samples were then 
immunoblotted for AQP2. Representative blot of one sample per time point is 
shown. C and L indicate control and lithium rat samples, respectively. B) Semi­
quantification of the immunoblots of all IMCD samples (n=3; each sample is 
from two rats) including the one shown in A. AQP2 expression levels of lithium- 
treated rats are shown in percentage of control rats. Asterisk indicates significant 
difference between lithium-treated and control rats of the same time point (*, P<
0.05). C) Of the IMCD samples described in A, total RNA were isolated and 
subjected to real-time PCR analysis to detect Aqp2 mRNA levels. Aqp2 mRNA 
levels of lithium-treated rats are shown in percentage of control rats. Asterisk 
indicates significant difference between lithium-treated and control rats of the 
same time point (*, P< 0.05).
Expression M icroarray analysis
To assess the first moment lithium-induced changes in gene expression in the 
IMCD, we performed microarray analysis with rat IMCD RNA samples of 3 
days treatment by using the Affymetrix Rat Genome 230 2.0 microarrays. 
The data presented are calculated from the results of six microarray chip sets, 
i.e., three pairs of lithium IMCD vs. control IMCD transcripts. Total RNA for
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each pair was isolated from two rats (4 inner medullas). The Microarray
analysis detected 1,271 distinct genes in total, and a full listing of the 1,271
genes was shown in Table 2(# page 158-178). The genes were also grouped and
listed according to their function type, such as protein kinases (Table 3# page
178-179), transcription factors (Table 4# page 179-181), cytokines (Table 5# page 181),
and G-protein-coupled factors, growth factor and ion channels (Table 6 # page 
181-182^
Of genes with changed expression in response to lithium, 146 genes showed a 
>2 -fold decrease and 88  genes a >2 -fold increase in gene expression 
compared to control (Table 7# page 182-185). To explore the functional roles of 
the genes of changed expression in lithium-treated rats and to build a 
signalling pathway that may underlie establishment of lithium-induced NDI, 
these 234 genes were analyzed by Ingenuity Pathway Analysis software. The 
analysis identified 13 significant gene networks (p< 0.001), with the top- 
scoring networks mostly associated with DNA replication, recombination, and 
repair, cancer, cell cycle, movement, morphology and assembly, nucleic acid 
metabolism, renal and urological disease, inflammatory response, cellular 
growth and proliferation (Table 8 # page 186).
Lithium induced activation of NFkB
As shown in Table 3, the kinases of which their mRNAs were most 
downregulated were cdc2 , cks2 , bub1, chek1 and plk1, which are all 
implicated in the network dealing with cancer, respiratory disease and cell 
cycle (Network 4 in Table 8 and Fig. 4). Interestingly, this network showed an 
interaction with the NFkB regulatory complex (Fig. 4) and a study recently 
demonstrated that NFkB activation decreased AQP2 mRNA and protein 
abundance in a time- and dose-dependent manner[22]. The NFkB 
transcription factor is present in the cytosol in an inactive state complexed 
with the inhibitory IkB proteins [23;24]. Activation of NFkB occurs via 
phosphorylation of iKBa, which targets iKBa for ubiquitination and 
degradation and in turn results in the release and nuclear translocation of 
active NFkB. Therefore, to test whether the activation of NFkB coincides with 
the lithium-induced altered protein expression in rat IMCD, we examined 
whether the abundance of the NFkB inhibitory protein IKBa was reduced with 
lithium. Indeed, immunoblot analysis revealed that our short-term lithium 
treatment reduced IKBa expression in the rat IMCD (Fig. 5).
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Figure 4. Network 4 identified by Ingenuity Pathway Analysis. Network 
contains genes of altered expression and identified around N FkB gene. Top 
functions of the genes are related to cancer, respiratory disease and cell cycle. 
Legends of the Node (gene) and edge (gene relationship) symbols are described 
next to the figure. The intensity of the node colors indicated the degree of 
downregulation (green) and upregulation (red). Genes in uncolored notes were 
not identified as differentially expressed in our experiment and were integrated 
into the computationally generated networks on the basis of the evidence stored 
in the IPA knowledge memory indicating a relevance to this network.
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Figure 5. Effects of lithium treatment on the expression of iKBa in rat
IMCD. Inner medullas and IMCD protein samples were prepared as described 
in the legend of Figure 2A. Equal amount of protein from these samples were 
immunoblotted for IKBa using a mouse monoclonal or a rabbit polyclonal 
antibody (indicated). C and L indicate control and lithium rat samples, and 
number 1 and 2 indicate experiment 1 and its repeat experiment 2, respectively. 
Molecular masses in kDa are indicated on the left.
DISCUSSION
In the present study, we used a microarray approach to profile the gene 
expression in the IMCD of rats treated with lithium for the shortest period of 
time possible to develop NDI. The microarray data were further coupled with 
pathways analysis to identify key signalling pathways that are possibly 
involved in the earliest responses to lithium, and immunoblotting was done to 
verify the protein expressions.
Previous studies on rats of short-term lithium treatment have shown 
significantly-reduced AQP2 expression after 7 days, 12 days or longer time 
period of lithium diet[15;25]. Here we demonstrated that using a similar 
protocol, 3-4 days of lithium treatment already induced a significant decrease 
of AQP2 protein and mRNA expression in the rat IMCD (Fig. 3). Consistent 
with the effects of lithium on the urinary concentrating mechanism, the 
decrease of AQP2 expression coincided with an increase in urine volume and 
a decrease in urine osmolality (Fig. 1). Therefore, this time period was 
considered to be appropriate for the microarray analysis.
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The microarray gene profiling detected 1,271 distinct genes, and among them 
234 genes showed more than 2-fold changes in abundance in response to 
lithium. The detected genes with altered expression levels appeared to be 
related to a broad range of networks and functions as shown in Table 8 .
Proliferation rather than Apoptosis is induced with short-term lithium  
treatment
Both proliferation and apoptosis are increased in the more long-term 
studies[10;14;15;26]. Several of our data, however, indicate that 3 days 
lithium treatment induced proliferation and suppressed apoptosis in the rat 
IMCD:
1) Phosphorylation/activation of the serine/threonine kinase Akt was 
increased in the IMCD cells of 1 or 2 weeks lithium-treated rats[15]. 
Akt plays a critical role in controlling the balance between cell 
survival and apoptosis. Increased phosphorylation/activation of Akt, 
and a concomitant reduction in phosphatase and tensin homologue 
deleted on chromosome 10 tumor suppressor gene (PTEN), a protein 
that normally inhibits the activation of Akt, are known to promote 
renal carcinogenesis[27]. In the current study, both Akt1 and PTEN 
gene expression were downregulated by 3-day lithium treatment 
(Table 2; Akt1 Li/Con=0.81, PTEN Li/Con=0.59). It’s unknown 
whether the expression level of Akt1 is relevant to its function, but 
PTEN has been shown to negatively regulate the Akt/PKB signaling 
pathway. Therefore the clear downregulation of PTEN would likely 
lead to or coincide with an increased activation of Akt after lithium 
treatment, which in turn triggers cell proliferation.
2) Previous studies demonstrated that inhibition of c-Raf by 
phosphorylation at S259 inhibited ERK1/2 activation and MEK1/2 
phosphorylation. As reported, c-Raf inhibition may be mediated by 
PKA[28;29] or Akt[30]. Increased abundance or increased 
phosphorylation of JNK, P38, and MAPK/ERK after 1 or 2 weeks 
lithium treatment was also demonstrated, together with an increased 
phosphorylation of Akt[15]. In our data set, the gene expression of 
Araf (Li/Con=2.51), a member of the Raf family, was shown to be 
upregulated by lithium. Raf family kinases are known to activate
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MEK1/2 and promotes cell growth[31]. Thus, an increase of Araf 
expression also may enhance cell proliferation.
3) Lithium was shown to increase phosphorylation of GSK3P and 
thereby inhibit GSK3P activity in the renal collecting ducts in vitro 
and in vivo[15;32;33]. GSK3P can be phosphorylated by PKA and 
Akt[34;35]. Upregulated Akt activity can result in phosphorylation 
and inhibition of GSK3P, leading to an activation of signalling 
pathways that are blocked by GSK3P, such as that of the NFAT 
transcription factor family[36] (Table 8 , Network 2). Indeed, a gene 
of which its expression is induced by NFAT, the fibroblast growth 
factor 18 (FGF18), was upregulated by lithium (Li/Con=2.56, Table
2). FGF18 is one of the fibroblast growth factors that is known to 
stimulate proliferation in various tissues[37]. These data support an 
early stimulation of proliferation by lithium in the rat IMCD. GSK3P 
may also play a direct role in mediating lithium-induced 
downregulation of AQP2, as implicated in our previous study[33].
4) E2F1 expression has been shown to induce apoptosis in cooperation 
with p53 in various tissues[38] and inhibits anti-apoptotic signals. Our 
data showed that both E2f1 (Li/Con=0.36) and tumor protein p53 
genes were downregulated by lithium (Li/Con=0.62). Consistently 
shown in our data, one of the pro-apoptotic members of the Bcl-2 
family, Bak1, was downregulated by lithium (Li/Con=0.64).
5) Heat shock 27kDa protein 2 (Hspb2, Li/Con=1.80) and heat shock 
alpha-crystallin-related protein B6  (Hspb6 , Li/Con=2.02) were found 
increased in expression in our dataset (Table 2). These proteins 
belong to the heat shock protein 27 family, and share anti-apoptotic 
properties[39]. In the 2-D gel proteomic study, Hsp27 was detected 
only in rats of 2  weeks lithium treatment, in which it showed a 
decreased expression (Li/Con=0.5). Immunoblotting in that study, 
however, showed an increase of Hsp27 expression in 1 week lithium 
rats IMCD, which is consistent with our finding. The increased 
expression of Hsp27 after 3 days (our data) or 1 week (2-D gel 
proteomic study) again suggests a reduced apoptosis in the rat IMCD, 
and the reduced expression of Hsp27 after 2 weeks of lithium (2-D 
gel proteomic study) could be either due to a compensatory change in
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the cells or a development of the effects of lithium with long time 
period.
Short-term lithium treatm ent may affect AQP2 trafficking
The previous 2-D gel proteomic study of rats with 1 and 2 weeks lithium 
treatment showed an increased expression of heat shock 70kDa protein 5 
(Hspa5, also named as 78-kDa glucose-regulated protein or GRP78)[15]. Our 
data showed a similar increase of Hspa5 expression (protein Li/Con=1.6[15], 
gene Li/Con=1.54). This protein belongs to the heat shock protein 70kDa 
family (Hsp70). Besides Hspa5, heat shock 70kDa protein 2 (Hspa2, 
Li/Con=1.83) was found increased in our dataset, while heat shock 70kDa 
protein 1B and heat shock 70kDa protein 1-like were found altered 
(Li/Con=0.64/1.7, Li/Con=0.64, respectively) in the 2-D gel proteomic study. 
Hsp70 family proteins GRP78, Hsp70 protein 1 and 2 were shown to interact 
with AQP2 and the Ser-256 residue in the AQP2 C-tail is important for the 
direct interaction[40;41]. Thus, the upregulation of these proteins suggest an 
effect on AQP2 trafficking at the early stage of lithium treatment.
NFkB activation may form the direct link between lithium and reduced  
AQP2 transcription
Our previous studies on lithium-induced NDI showed that lithium decreases 
AQP2 expression possibly at the transcription level[25]. The involvement of 
transcription factors in lithium-induced AQP2 downregulation was thus of our 
interest. Using renal collecting duct principal mpkCCD? cells, it was reported 
that activation of transcription factor NFkB by LPS decreased AQP2 mRNA 
and protein levels in a time- and dose-dependent manner but did not decrease 
AQP2 mRNA stability, and that this effect was independent from intracellular 
cAMP levels[22]. These effects of activated NFkB (by LPS) on AQP2 
transcription is similar to the effects of lithium on AQP2 as we previously 
demonstrated using the same cells[25]. Indeed, in our IPA analysis, NFkB 
was implicated in Network 4 which deals with cancer, respiratory disease and 
cell cycle (Fig. 4 and Table 8) and immunoblotting showed downregulated 
IKBa expression in rat IMCD after 3 days of lithium treatment (Fig. 5), 
suggesting an activation of NFkB. Therefore, NFkB could be the direct target 
of lithium in the rat IMCD and the lithium-induced downregulation of AQP2 
transcription could be mediated by NFkB.
151
Chapter 6
We furthermore compared our data set with the reported gene profiling data in 
the study of rats with chronic lithium treatment[14]. Significantly altered 
transcription of three genes in response to lithium was investigated in the 
previous microarray study, i.e. 11P-HSD2 (increased), p27/KIP 
(decreased/undetected), and Ezrin (decreased), and changes of these proteins 
were concluded as linked to altered sodium and water transport, cell cycling 
and changes in interstitial osmolality. These genes, however, were not 
detected in our dataset. This could be due to the fact that the reported 
microarray used rat kidney inner medullas, which is different from the IMCD 
fraction of rats in our study. The existence of the intercalated cells in the 
kidney inner medulla might dilute or interfere the gene profiling of what is 
only relevant to AQP2 regulation.
Of importance, however, it has to be noted that although real-time PCR and 
immunoblot showed decreased mRNA and protein levels of AQP2 from day 
three onwards (Fig. 3C), our microarray analysis didn’t score a detectable 
level of AQP2 expression. This might be due to a lower sensitivity of 
microarray compared to real-time PCR, or to a high variation of AQP2 
expression between the RNA samples, preventing it to be detected as a 
‘present call’ signal by the microarray normalization. Therefore, the 
microarray analysis has to be repeated before further analysis of protein 
expression of the potential genes with interesting mRNA expression changes 
can be pursued.
Considering that changes in mRNA expression may or may not necessarily be 
accompanied by similar changes in protein expression, genes that are detected 
in the gene profiling and potentially involved in the development of NDI or 
involved in regulation of AQP2 need to be further investigated on their 
protein expression levels. However, if so, our data suggest that at the early 
stage, lithium induces proliferation and reduces apoptosis in the rat IMCD, 
which is in line with the finding that the loss of collecting duct principal cells 
is only observed at a later time point of lithium treatment (2 weeks)[10;33]. A 
comparison of collecting duct cell profiling between short (as done in our 
study) and long term lithium treatments might provide more insight on 
whether increased proliferation of principal collecting duct cells is the first 
process leading to development of lithium-induced NDI.
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Table 1. Physiological effects of lithium treated rats
Dav 1 
control lithium
Dav 2 
control lithium
Body weight, g 266±4 265±2 250 ±4 246±4
Serum osmolality, mOsmo/kg H2O 265±2 258±5 246 ±3 248±5
Serum lithium, mM < 0.20 0.40±0.04* < 0.20 i0.45±0.02*
Serum sodium, mM 3 6. 2. 2 3 6. 5 ± 2. 3 137.6± 1. 5 135.1±1.3
Serum creatinine, ^M 47.7±4.9 46.6±4.1 43.3±4.1 42.3±0.7
24h-water drunk, ml 16±2 16±2 13±1 17±2
24h-urine sodium excretion, mmol 2.1±0.1 1.9±0.2 1.3±0.3 1.2±0.2
Urine creatinine, mM 7.6±0.8 8.7±0.8 11.6±1.4 10.7±2.7
Creatinine clearance, ml/min 1.16±0.11
in.00.
-H9.0 0.96±0.12 1.04±0.11
Dav 3 Dav 4
control lithium control lithium
Body weight, g 243±4 244±5 246±5 240±1
Serum osmolality, mOsmo/kg H2O 240±4 243±4 243±5 240±2
Serum lithium, mM < 0.20 i0.60 ±0.11*: < 0.20 i0.52±0.07*
Serum sodium, mM 3 8. 3 ± 2. 3 .92.±.8
in2 .22.±.59.3.3±1.97.3
Serum creatinine, ^M 41.0±1.7 44.2±2.4 45.2±2.6 51.4±2.2
24h-water drunk, ml 14±1 21±4 13±2 47 ±6*
24h-urine sodium excretion, mmol 1.8±0.2 1.9±0.1 1.7±0.1 1.7±0.3
Urine creatinine, mM 10.7±1.5 7.7±2.0 12.2±1.7 2.6±0.5*
Creatinine clearance, ml/min 1.09±0.13 1. 17±0.13 1.09±0.14 1.08±0.06
Values are means ± SEM; 
n = 6 rats / groups;
*P< 0.05 lithium-treated compared to control rats of the same day
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Table 2. Genes detected in rat IM CD cells with changes in response to 3 
days lithium treatment
Gene Title Gene ID Li/Con(fold Changes)
neuronal guanine nucleotide exchange factor Ngef 9.18
G protein-coupled receptor 37 Gpr37 5.68
ATPase, H transporting, lysosomal V1 subunit B1 (predicted) Atp6v1b1_predicted 5.53
Src-like adaptor Sla 4.90
osteomodulin Omd 4.70
gamma-glutamyltransferase-like activity 1 Ggtlal 4.51
deoxyribonuclease I Dnasel 4.16
regulatory factor X-associated ankyrin-containing protein R&ank 4.10
cytochrome P450, family 4, subfamily b, polypeptide 1 Cyp4b1 4.06
angiotensin receptor-like 1 Agtrl1 3.78
fibrinogen-like 2 Fgl2 3.77
chloride intracellular channel 3 Clic3 3.65
similar to KIAA1183 protein (predicted) RGD1560435_predicted 3.63
Rhesus blood group-associated C glycoprotein Rhcg 3.41
vestigial like 1 homolog (Drosophila) (predicted) Vgll1_predicted 3.23
hypothetical protein LOC686432 LOC686432 3.07
hypothetical protein LOC689748 LOC689748 2.98
defensin beta 1 Defb1 2.95
crystallin, mu Crym 2.94
branched chain ketoacid dehydrogenase E1, alpha polypeptide Bckdha 2.91
EPS8-like 1 (predicted) Eps8l1_predicted 2.90
LRP16 protein Lrp16 2.83
slit homolog 2 (Drosophila) Slit2 2.78
similar to aldo-keto reductase family 1, member C12 (predicted) RGD1562954_predicted 2.68
period homolog 3 (Drosophila) Per3 2.68
similar to golgi-specific brefeldin A-resistance guanine nucleotide exchange 
factor 1 (predicted) RGD 1307160_predicted 2.60
transmembrane protein 86A (predicted) Tmem86a_predicted 2.59
fibroblast growth factor 18 Fgf18 2.56
microfibrillar-associated protein 3-like Mfap3l 2.53
v-raf murine sarcoma 3611 viral oncogene homolog Araf 2.51
similar to transmembrane protein 61 LOC688864 2.48
solute carrier family 6 (neurotransmitter transporter), member 17 Slc6a17 2.48
dicarbonyl L-xylulose reductase Dcxr 2.47
adenylate cyclase 3 Adcy3 2.46
Rab40b, member RAS oncogene family (predicted) Rab40b_predicted 2.41
glutathione S-transferase Yc2 subunit Yc2 2.38
pyruvate dehydrogenase phosphatase isoenzyme 2 Pdp2 2.35
coiled-coil domain containing 53 (predicted) Ccdc53_predicted 2.34
aldo-keto reductase family 7, member A3 (aflatoxin aldehyde reductase) Akr7a3 2.34
dynactin 6 (predicted) Dctn6_predicted 2.33
neuraminidase 1 Neul 2.33
polymerase (DNA-directed), delta 4 Pold4 2.31
steroid sulfatase Sts 2.31
aldo-keto reductase family 1, member C12 (predicted) Akr 1c 12_predicted 2.31
chaperone, ABC1 activity of bc1 complex like (S. pombe) Cabcl 2.28
similar to Histone H1.2 (H1 VAR.1) (H1c) LOC684681 2.27
platelet-derived growth factor receptor-like Pdgfrl 2.26
cathepsin F Ctsf 2.25
S100 calcium binding protein A5 (predicted) S100a5_predicted 2.25
adipose differentiation related protein Adfp 2.24
histone cluster 1, H4b Hist1h4b 2.23
prostaglandin-endoperoxide synthase 1 Ptgsl 2.21
catenin (cadherin associated protein), alpha-like 1 (predicted) Ctnnal1_predicted 2.21
premature ovarian failure 1B (predicted) Pof1b_predicted 2.20
aarF domain containing kinase 5 Adck5 2.20
alpha thalassemia/mental retardation syndrome X-linked homolog (human) Atrx 2.20
similar to trafficking protein particle complex 6A LOC680465 /// LOC686599 2.17
complement component factor H Cfh 2.16
hypothetical LOC287534 RGD1359691 2.16
158
Gene profiling o f lithium-induced downregulation o f AQP2
FK506 binding protein 14 Fkbp14 2.15
similar to Nuclear receptor ROR-gamma (Nuclear receptor RZR-gamma) 
(Thymus orphan receptor) (TOR) /// similar to leucine rich repeat neuronal 6D 
(predicted)
LOC368158 /// 
RGD1562025_predicted 2.15
similar to hypothetical protein FLJ32825 (predicted) RGD1564257_predicted 2.15
nuclear protein 1 Nupr1 2.14
similar to mKIAA1002 protein RGD1310066 2.12
ubiquitin specific peptidase 33 Usp33 2.11
calcium/calmodulin-dependent protein kinase kinase 2, beta Camkk2 2.11
mitogen activated protein kinase kinase kinase kinase 1 (predicted) Map4k1_predicted 2.11
interleukin enhancer binding factor 2 Ilf2 2.11
retinoblastoma binding protein 9 Rbbp9 2.11
Chromodomain helicase DNA binding protein 2 (predicted) Chd2_predicted 2.09
similar to CG4751-PA LOC681944 2.09
histone cluster 2, H2aa (predicted) /// similar to H2A histone family, member O Hist2h2aa_predicted /// LOC682560 /// LOC690131 2.08
monoglyceride lipase Mgll 2.07
FXYD domain-containing ion transport regulator 2 Fxyd2 2.06
ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-N- 
acetylgalactosaminide alpha-2,6-sialyltransferase 3 St6galnac3 2.06
pleckstrin homology domain containing, family B (evectins) member 1 Plekhb1 2.06
similar to germinal histone H4 gene LOC680097 /// LOC684887 2.06
similar to Breast carcinoma amplified sequence 3 homolog (K20D4) (predicted) RGD1560788_predicted 2.05
guanine nucleotide binding protein, alpha 15 Gna15 2.05
similar to yippee-like 3 (predicted) RGD1564579_predicted 2.04
ankyrin repeat and BTB (POZ) domain containing 1 Abtb1 2.03
tripartite motif protein 34 (predicted) Trim34_predicted 2.03
EGF-like-domain, multiple 6 Egfl6 2.03
RAB31, member RAS oncogene family Rab31 2.03
transmembrane 6 superfamily member 1 (predicted) Tm6sf1_predicted 2.02
heat shock protein, alpha-crystallin-related, B6 Hspb6 2.01
chordin Chrd 2.01
RGD1563912 (predicted) RGD1563912_predicted 2.00
homolog of zebrafish ES1 RGD1303003 2.00
histone H4 variant H4-v.1 (predicted) RGD1562378_predicted 1.99
Ly6/Plaur domain containing 2 (predicted) Lypd2_predicted 1.98
histone 2a H2a 1.97
pre-B-cell colony enhancing factor 1 Pbef1 1.97
WW domain binding protein 1 Wbp1 1.96
similar to RIKEN cDNA 5330414D10 (predicted) /// hypothetical LOC366300 LOC366300 /// RGD1307986_predicted 1.95
tropomodulin 4 (predicted) Tmod4_predicted 1.95
S100 calcium binding protein A13 (predicted) S100a13_predicted 1.95
glycoprotein hormone alpha 2 Gpha2 1.94
translocase of inner mitochondrial membrane 22 homolog (yeast) Timm22 1.93
DnaJ (Hsp40) homolog, subfamily B, member 1 (predicted) Dnajb1_predicted 1.92
NIMA (never in mitosis gene a)-related expressed kinase 3 (predicted) Nek3_predicted 1.91
homocysteine-inducible, endoplasmic reticulum stress-inducible, ubiquitin-like 
domain member 1 Herpud1 1.90
similar to Peroxisome assembly protein 10 (Peroxin-10) (Peroxisome biogenesis 
factor 10) (RING finger protein 69) LOC680424 1.90
phosphatidylinositol glycan, class P (predicted) Pigp_predicted 1.89
placental growth factor Pgf 1.89
dystonin (predicted) Dst_predicted 1.89
cysteine and histidine rich 1 Cyhr1 1.89
similar to 5(3)-deoxyribonucleotidase, cytosolic type (Cytosolic 5,3-pyrimidine 
nucleotidase) (Deoxy-5-nucleotidase 1) (dNT-1) LOC688261 1.87
similar to coiled-coil domain containing 9 LOC684934 1.87
6-pyruvoyl-tetrahydropterin synthase Pts 1.87
ring finger protein 141 rnf141 1.87
methionine aminopeptidase-like 1 (predicted) Metapl1_predicted 1.87
similar to Glucosylceramidase precursor (Beta-glucocerebrosidase) (Acid beta- 
glucosidase) (D-glucosyl-N-acylsphingosine glucohydrolase) LOC684536 1.87
regulator of G-protein signaling 6 Rgs6 1.86
similar to RIKEN cDNA 2810025M15 (predicted) RGD1304982_predicted 1.86
Rab acceptor 1 (prenylated) Rabac1 1.86
leukotriene B4 12-hydroxydehydrogenase Ltb4dh 1.86
similar to RIKEN cDNA 5730509K17 gene (predicted) RGD1561042_predicted 1.85
159
Chapter 6
RAB6B, member RAS oncogene family (predicted) Rab6b_predicted 1.85
arginine vasopressin receptor 2 Avpr2 1.85
enhancer of zeste homolog 1 (Drosophila) (predicted) Ezh1_predicted 1.84
pyruvate dehydrogenase kinase, isoenzyme 2 Pdk2 1.84
Similar to cDNA sequence BC006662 RGD1304748 1.84
heat shock 70kDa protein 2 Hspa2 1.84
dedicator of cytokinesis 9 Dock9 1.83
protein-L-isoaspartate (D-aspartate) O-methyltransferase domain containing 2 
(predicted) Pcmtd2_predicted 1.83
ADP-ribosylation factor-like 2 Arl2 1.82
WD repeat domain 45 Wdr45 1.82
dynamin 3 Dnm3 1.82
calcium binding and coiled coil domain 1 Calcoco1 1.82
transmembrane 7 superfamily member 2 Tm7sf2 1.82
crystallin, zeta Cryz 1.82
scavenger receptor cysteine rich domain containing, group B (4 domains) 
(predicted) Srcrb4d_predicted 1.82
lactate dehydrogenase D Ldhd 1.82
target of mybl homolog (chicken) Tom1 1.82
similar to hypothetical protein FLJ31413 RGD1306209 1.82
thyrotroph embryonic factor Tef 1.81
methionine sulfoxide reductase A Msra 1.81
enoyl coenzyme A hydratase 1, peroxisomal Ech1 1.81
heat shock 27kDa protein 2 Hspb2 1.80
oligophrenin 1 (predicted) Ophn1_predicted 1.80
glutathione peroxidase 3 Gpx3 1.80
Special AT-rich sequence binding protein 1 Satb1 1.79
hepsin Hpn 1.79
OMA1 homolog, zinc metallopeptidase (S. cerevisiae) (predicted) Oma1_predicted 1.79
basonuclin 2 (predicted) Bnc2_predicted 1.79
solute carrier family 22 (organic cation transporter), member 18 Slc22a18 1.78
wingless-type MMTV integration site 5A Wnt5a 1.78
CDC42 effector protein (Rho GTPase binding) 5 (predicted) Cdc42ep5_predicted 1.77
similar to solute carrier family 25, member 35 LOC497933 1.77
carbonic anhydrase 11 Car11 1.77
acetyl-Coenzyme A acyltransferase 1 /// similar to 3-ketoacyl-CoA thiolase B, 
peroxisomal precursor (Beta-ketothiolase B) (predicted) Acaa1 /// RGD1562373_predicted 1.76
similar to 9630058J23Rik protein (predicted) RGD1564833_predicted 1.76
NADH dehydrogenase (ubiquinone) flavoprotein 3-like Ndufv3l 1.76
MAWD binding protein Mawbp 1.76
arylsulfatase K Arsk 1.76
similar to 2700008B19Rik protein (predicted) RGD1566204_predicted 1.76
oxysterol binding protein-like 5 Osbpl5 1.76
similar to Methylmalonyl-CoA mutase, mitochondrial precursor (MCM) LOC688517 1.76(Methylmalonyl-CoA isomerase)
carbonic reductase 4 Cbr4 1.76
Ras-related C3 botulinum toxin substrate 1 Rac1 1.75
cysteine sulfinic acid decarboxylase Csad 1.75
acetyl-coenzyme A acetyltransferase 1 Acat1 1.75
Similar to FLJ00414 protein (predicted) RGD1304675_predicted 1.75
sulfotransferase family 1A, phenol-preferring, member 1 Sult1a1 1.74
sulfotransferase family, cytosolic, 2B, member 1 (predicted) Sult2b1_predicted 1.74
phosphodiesterase 1A, calmodulin-dependent Pde1a 1.74
malic enzyme 3, NADP(+)-dependent, mitochondrial (predicted) Me3_predicted 1.74
TBC1 domain family, member 17 (predicted) Tbc1d17_predicted 1.73
SYF2 homolog, RNA splicing factor (S. cerevisiae) Syf2 1.73
zinc finger CCCH type containing 6 (predicted) Zc3h6_predicted 1.73
ets homologous factor (predicted) Ehf_predicted 1.72
similar to praja1, RING-H2 motif containing LOC683077 1.72
similar to KIAA2026 protein RGD1311595 1.72
interferon regulatory factor 3 Irf3 1.72
hypothetical LOC366300 LOC366300 1.72
abhydrolase domain containing 14b Abhd14b 1.72
transmembrane protein 42 (predicted) Tmem42_predicted 1.72
PDZK1 interacting protein 1 Pdzk1ip1 1.72
complement component 8, gamma polypeptide (predicted) C8g_predicted 1.71
similar to apoptosis related protein APR-3; p18 protein (predicted) RGD1311605_predicted 1.71
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zinc finger protein 36 (KOX 18) MGC116363 1.71
microsomal glutathione S-transferase 2 (predicted) Mgst2_predicted 1.71
similar to putative phosphoinositide 5-phosphatase type II; C62 LOC287533 1.71
similar to Intersectin-2 (SH3 domain-containing protein 1B) (SH3P18) (SH3P18- LOC313934 1.70like WASP-associated protein)
aspartoacylase (aminoacylase) 3 Acy3 1.70
src family associated phosphoprotein 1 Scap1 1.70
prostate tumor over expressed gene 1 Ptov1 1.69
excision repair cross-complementing rodent repair deficiency, complementation Ercc5 1.69group 5
enoyl Coenzyme A hydratase domain containing 2 (predicted) Echdc2_predicted 1.69
similar to RIKEN cDNA 0610011N22 gene RGD735106 1.69
nudix (nucleoside diphosphate linked moiety X)-type motif 12 (predicted) Nudt12_predicted 1.69
cytoplasmic FMR1 interacting protein 2 (predicted) Cyfip2_predicted 1.69
RAS-like family 11 member B Rasl11b 1.69
dystrobrevin alpha (predicted) Dtna_predicted 1.68
vitamin K epoxide reductase complex, subunit 1 Vkorc1 1.68
A kinase (PRKA) anchor protein 2 Akap2 1.68
similar to open reading frame 5 RGD1305062 1.68
DnaJ (Hsp40) homolog, subfamily C, member 4 Dnajc4 1.68
leupaxin Lpxn 1.68
mannose-P-dolichol utilization defect 1 Mpdu1 1.67
transmembrane protein 50A (predicted) Tmem50a_predicted 1.67
bolA-like 1 (E. coli) (predicted) Bola1_predicted 1.67
similar to suppressor of Ty 3 homolog LOC685697 1.66
similar to 1110001K21Rik protein LOC497867 1.66
hypothetical protein LOC685756 LOC685756 1.66
kinesin light chain 4 Klc4 1.66
interleukin 3 receptor, alpha chain Il3ra 1.66
similar to RNA binding motif, single stranded interacting protein 3 isoform 1 LOC680726 1.66
RAB 11a, member RAS oncogene family Rab11a 1.65
hypothetical LOC304650 (predicted) RGD1310262_predicted 1.65
Heterogeneous nuclear ribonucleoprotein A2/B1 (predicted) Hnrpa2b1_predicted 1.65
kelch domain containing 8A Klhdc8a 1.65
SNAP-associated protein Snapap 1.65
similar to cell division cycle 2-like 1 (predicted) RGD1566355_predicted 1.64
excision repair cross-complementing rodent repair deficiency, complementation 
group 8 (predicted) Ercc8_predicted 1.64
disabled homolog 2 (Drosophila) Dab2 1.64
kelch-like 24 (Drosophila) Klhl24 1.64
Cell cycle progression 1 (predicted) Ccpg1_predicted 1.64
calpastatin Cast 1.63
WD repeat domain 33 (predicted) Wdr33_predicted 1.63
tRNA splicing endonuclease 2 homolog (S. cerevisiae) Tsen2 1.63
similar to Basic helix-loop-helix transcription factor scleraxis LOC680712 /// LOC684826 1.63
stannin Snn 1.63
elastase 1, pancreatic Ela1 1.63
acyl-CoA thioesterase 8 Acot8 1.63
similar to mKIAA1011 protein LOC366669 1.63
similar to chromosome 7 open reading frame 11 LOC678905 /// LOC684996 1.63
sorting nexin 17 Snx17 1.63
3-hydroxyisobutyryl-Coenzyme A hydrolase Hibch 1.62
kinesin family member 3C Kif3c 1.62
serine/arginine-rich protein specific kinase 2 (predicted) Srpk2_predicted 1.62
xeroderma pigmentosum, complementation group A (predicted) Xpa_predicted 1.61
FUN14 domain containing 1 Fundc1 1.61
BCL2/adenovirus E1B 19 kDa-interacting protein 3-like Bnip3l 1.61
nudix (nucleoside diphosphate linked moiety X)-type motif 14 (predicted) Nudt14_predicted 1.61
similar to RIKEN cDNA 2010106G01 (predicted) RGD1563001_predicted 1.60
similar to hypothetical protein MGC40499 (predicted) RGD1307636_predicted 1.60
lymphocyte cytosolic protein 1 Lcp1 1.60
similar to phospholysine phosphohistidine inorganic pyrophosphate phosphata MGC95092 1.60(5M590)
amiloride binding protein 1 (amine oxidase, copper-containing) Abp1 1.60
similar to membrane protein expressed in epithelial-like lung adenocarcinoma 
(predicted) RGD1307493_predicted 1.59
rabphilin 3A-like (without C2 domains) Rph3al 1.59
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vacuolar protein sorting 28 (yeast) (predicted)
ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-N-
acetylgalactosaminide alpha-2,6-sialyltransferase 2
similar to mKIAA0704 protein (predicted)
malate dehydrogenase 1, NAD (soluble)
similar to hypothetical protein FLJ23375 (predicted)
sulfatase modifying factor 1 (predicted)
similar to Ubiquitin ligase protein DZIP3 (DAZ-interacting protein 3 homolog) 
(predicted)
acyl-Coenzyme A dehydrogenase, very long chain 
oxysterol binding protein-like 1A 
propionyl coenzyme A carboxylase, beta polypeptide 
similar to hypothetical protein MGC14141 (predicted) 
presenilin enhancer 2 homolog (C. elegans)
WD repeat domain, phosphoinositide interacting 1 (predicted)
Thioredoxin domain containing 9 
inositol polyphosphate multikinase 
Arylsulfatase A
similar to RIKEN cDNA 4921520P21 
dodecenoyl-coenzyme A delta isomerase 
N-acylsphingosine amidohydrolase 3-like (predicted) 
galactosidase, alpha
similar to hypothetical protein FLJ14624 (predicted)
similar to DNA segment, Chr 14, ERATO Doi 436, expressed (predicted)
AT rich interactive domain 2 (Arid-r& like) (predicted) 
regucalcin
cysteine dioxygenase 1, cytosolic 
G protein-coupled receptor kinase-interactor 2 
similar to spermatogenesis associated 11 
mannosidase, alpha, class 1C, member 1 (predicted) 
transmembrane protein 77
pleckstrin homology domain containing, family G (with RhoGef domain) 
member 2 (predicted)
Max interacting protein 1
heat shock 70kDa protein 5 (glucose-regulated protein)
cyclin-dependent kinase (CDC2-like) 10
prolylcarboxypeptidase (angiotensinase C) (predicted)
similar to ctla-2-beta protein (141 AA) (predicted)
transmembrane protein 106C
ligase III, DNA, ATP-dependent
kinesin family member 12
similar to RIKEN cDNA 1300002A08
similar to CG1998-PA
similar to hypothetical protein FLJ14803
PDZ domain containing 11 (predicted)
similar to RIKEN cDNA 1810037C20 (predicted)
anaphase promoting complex subunit 2
interleukin 1 receptor accessory protein
ATPase, H transporting, lysosomal V1 subunit G1 (predicted)
similar to transmembrane 4 superfamily member 10 (predicted)
branched chain keto acid dehydrogenase E1, beta polypeptide
solute carrier family 39 (zinc transporter), member 13
metallophosphoesterase 1 (predicted)
Ufm1-conjugating enzyme 1 
sulfite oxidase
similar to hypothetical protein LOC284018 isoform b (predicted) 
protein tyrosine phosphatase-like A domain containing 2 (predicted) 
sorting nexin 13 (predicted)
similar to Methionine-R-sulfoxide reductase (Selenoprotein X 1) (Selenoprotein 
R)
similar to SMP3 mannosyltransferase 
flotillin 1
Similar to EHM2 (predicted) 
sodium channel, nonvoltage-gated 1 alpha 
nucleosome assembly protein 1-like 3 
similar to hypothetical protein D12Ertd771e 
similar to mKIAA0317 protein (predicted)
Vps28_predicted 1.59
St6galnac2 1.59
RGD1564287_predicted 1.58
Mdh1 1.58
RGD1305647_predicted 1.58
Sumf1_predicted 1.58
RGD1563278_predicted 1.57
Acadvl 1.57
Osbpl1a 1.57
Pccb 1.57
RGD1561492_predicted 1.57
Psenen 1.57
Wipi1_predicted 1.57
Txndc9 1.57
Ipmk 1.57
Arsa 1.57
MGC114388 1.56
Dci 1.56
Asah3l_predicted 1.56
Gla 1.56
RGD1560183_predicted 1.56
RGD1304610_predicted 1.56
Arid2_predicted 1.56
Rgn 1.56
Cdo1 1.55
Git2 1.55
LOC679944 /// LOC681562 1.55
Man1c1_predicted 1.55
Tmem77 1.55
Plekhg2_predicted 1.55
Mxi1 1.55
Hspa5 1.54
Cdk10 1.54
Prcp_predicted 1.54
RGD1565540_predicted 1.54
Tmem106c 1.54
Lig3 1.54
Kif12 1.54
RGD1305466 1.54
LOC686661 /// LOC691221 1.54
RGD1309682 1.54
Pdzd11_predicted 1.54
RGD1562076_predicted 1.54
Anapc2 1.54
Il1rap 1.54
Atp6v1g1_predicted 1.53
RGD1564799_predicted 1.53
Bckdhb 1.53
Slc39a13 1.53
Mppe1_predicted 1.53
Ufc1 1.53
Suox 1.53
RGD1565033_predicted 1.53
Ptplad2_predicted 1.52
Snx13_predicted 1.52
MGC105753 1.52
LOC684506 1.52
Flot1 1.52
RGD1562988_predicted 1.52
Scnn1a 1.52
Nap1l3 1.52
RGD1309550 1.52
RGD1307597_predicted 1.52
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a disintegrin and metalloprotease domain 10 Adam10 1.51
tropomyosin 1, alpha Tpm1 1.51
exosome component 4 (predicted) Exosc4_predicted 1.51
aldo-keto reductase family 7, member A2 (aflatoxin aldehyde reductase) Akr7a2 1.51
fission 1 (mitochondrial outer membrane) homolog (yeast) Fis1 1.50
N-myc downstream regulated gene 1 Ndrg1 1.50
ankyrin repeat domain 24 (predicted) Ankrd24_predicted 1.50
similar to chromatin modifying protein 1B LOC682926 /// LOC689364 1.50
similar to Vacuolar protein sorting 26 homolog (VPS26 protein homolog) LOC300472 1.50
aminoadipate-semialdehyde synthase (predicted) Aass_predicted 1.50
solute carrier family 44, member 4 Slc44a4 1.49
matrin 3 Matr3 1.49
similar to RIKEN cDNA 6530401L14 gene RGD1309107 1.49
tumor suppressor candidate 4 Tusc4 1.49
similar to talin 2 (predicted) RGD1565416_predicted 1.49
phosphatidic acid phosphatase type 2B Ppap2b 1.49
similar to general transcription factor IIH, polypeptide 5 (predicted) RGD1560991_predicted 1.49
WD repeat and FYVE domain containing 2 (predicted) Wdfy2_predicted 1.48
uroporphyrinogen decarboxylase Urod 1.48
hypothetical LOC362564 LOC362564 1.48
ATPase, Cu++ transporting, beta polypeptide Atp7b 1.48
pleckstrin homology domain containing, family A member 6 (predicted) Plekha6_predicted 1.48
Similar to MAPK-interacting and spindle-stabilizing protein (predicted) RGD 1311455_predicted 1.48
similar to RIKEN cDNA 4930455F23 RGD1309708 1.48
zinc finger protein 446 (predicted) Zfp446_predicted 1.48
RNA-binding region (RNP1, RRM) containing 2 Rnpc2 1.48
acetyl-Coenzyme A acyltransferase 2 (mitochondrial 3-oxoacyl-Coenzyme A 
thiolase) Acaa2 1.48
similar to KCCR13L (predicted) RGD 1310193_predicted 1.47
mitochondrial ribosomal protein L50 (predicted) Mrpl50_predicted 1.47
similar to RIKEN cDNA 2010200O16 (predicted) RGD1564454_predicted 1.47
mitochondrial ribosomal protein L16 Mrpl16 1.47
SCAN domain-containing 1 (predicted) Scand1_predicted 1.47
similar to Small EDRK-rich factor 2 (4F5rel) LOC502663 1.47
ligand of numb-protein X 1 (predicted) Lnx1_predicted 1.47
Cdc42 binding protein kinase beta Cdc42bpb 1.47
ceroid lipofuscinosis, neuronal 3, juvenile (Batten, Spielmeyer-Vogt disease) Cln3 1.47
similar to Pterin-4-alpha-carbinolamine dehydratase 2 (PHS 2) (4-alpha-hydroxy- 
tetrahydropterin dehydratase 2) (DcoH-like protein DCoHm) (Dimerization 
cofactor of hepatocyte nuclear factor 1 from muscle) (HNF1 -alpha dimerization 
cofactor)...
muscle and microspikes RAS 
similar to F-box only protein 25
similar to chromosome 10 open reading frame 4; similar to putative acid 
phosphatase F26C11.1
similar to SMP3 mannosyltransferase /// similar to nuclear cap binding protein 
subunit 2
similar to Phosphatidylserine decarboxylase proenzyme 
galactokinase 2
epoxide hydrolase 1, microsomal 
3-hydroxy-3-methylglutaryl-Coenzyme A lyase
similar to Vacuolar protein sorting protein 25 (ELL-associated protein of 20 kDa) LOC681059 /// LOC688199 1.45
similar to UPF0308 protein C9orf21 LOC498685 1.45
similar to RIKEN cDNA G630055P03 gene RGD1309383 1.45
ashl (absent, small, or homeotic)-like (Drosophila) (predicted) Ash1l_predicted 1.45
E74-like factor 5 (predicted) Elf5_predicted 1.44
CD59 antigen Cd59 1.44
interleukin 11 receptor, alpha chain 1 Il11ra1 1.44
placenta-specific 8 (predicted) Plac8_predicted 1.44
peroxisomal membrane protein 2 Pxmp2 1.44
tetraspanin 1 Tspan1 1.44
histidine triad nucleotide binding protein 2 (predicted) Hint2_predicted 1.44
elongation factor Tu GTP binding domain containing 1 (predicted) Eftud1_predicted 1.44
immunoglobulin superfamily, member 4A Igsf4a 1.44
Zinc finger, ZZ-type with EF hand domain 1 (predicted) Zzef1_predicted 1.44
Fibroblast growth factor receptor 3 Fgfr3 1.43
O-linked N-acetylglucosamine (GlcNAc) transferase (UDP-N- Ogt 1.43acetylglucosamine:polypeptide-N-acetylglucosaminyl transferase)
LOC683319 1.46
Mras 1.46
LOC364637 1.46
RGD1309482 1.46
LOC684506 /// LOC689116 1.46
LOC681361 1.46
Galk2 1.45
Ephx1 1.45
Hmgcl 1.45
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zinc finger protein 291
yippee-like 5 (Drosophila)
similar to hypothetical protein FLJ21827
tumor-associated calcium signal transducer 2
Sell (suppressor of lin-12) 1 homolog (C. elegans)
similar to Der1 -like domain family, member 2
ARP10 actin-related protein 10 homolog (S. cerevisiae)
Ras association (RalGDS/AF-6) domain family 1
golgi reassembly stacking protein 1
RAB33A, member of RAS oncogene family (predicted)
SH3/ankyrin domain gene 3 
transcription factor 12 
mitochondrial ribosomal protein L9 
similar to RIKEN cDNA 2310042N02 
2-4-dienoyl-Coenzyme A reductase 2, peroxisomal
similar to chromosome 16 open reading frame 33; minus -99 protein (predicted) 
Sortilin 1
mitochondrial carrier domain containing protein RGD1359361 
vesicle-associated membrane protein 1 
similar to hypothetical protein D2Ertd391e (predicted) 
similar to KIAA0368 (predicted)
Cobl-like 1 (predicted)
similar to hypothetical protein FLJ34389 (predicted)
similar to Acyl-CoA dehydrogenase family member 8, mitochondrial precursor 
(ACAD-8) (predicted)
RNA binding motif, single stranded interacting protein 2 
Bardet-Biedl syndrome 2 homolog (human) 
aldehyde dehydrogenase family 1, member A1 
Y box protein 2 (predicted) 
membrane-associated DHHC1 zinc finger protein 
transmembrane 4 superfamily member 13 
transcobalamin 2 
fucosidase, alpha-L- 1, tissue 
vacuolar protein sorting 11 (yeast) (predicted)
similar to DNA-directed RNA polymerase II 23 kDa polypeptide (RPB25) 
(RPB5) (RPABC1)
similar to MYST histone acetyltransferase monocytic leukemia 4 (predicted)
similar to Sec1 family domain containing protein 2 (Syntaxin binding protein 1-
like 1) (Neuronal Sec1)
cell growth regulator with EF hand domain 1
similar to CG9117-PA
similar to DKFZP547E1010 protein /// similar to Protein C 1orf77 homolog 
aprataxin
WD repeat domain 44
similar to CG12935-PA
L1 cell adhesion molecule
DENN/MADD domain containing 2D (predicted)
protoporphyrinogen oxidase (predicted)
autophagy-related 4B (yeast)
male-enhanced antigen
DEAH (Asp-Glu-Ala-His) box polypeptide 38 (predicted) 
transmembrane emp24 domain containing 3 
Sterol O-acyltransferase 1
nuclear receptor binding SET domain protein 1 (predicted) /// similar to Histone-
lysine N-methyltransferase, H3 lysine-36 and H4 lysine-20 specific (H3-K36-
HMTase) (H4-K20-HMTase) (Nuclear receptor binding SET domain containing
protein 1) (NR-binding SET domain containing protein)
all-trans-13,14-dihydroretinol saturase
RAB3 GTPase activating protein subunit 2
chromobox homolog 7
LIM domain only 2
similar to RIKEN cDNA 2810453I06
similar to RIKEN cDNA 2610528E23
glucan (1,4-alpha-), branching enzyme 1
similar to Protein CXorf17 homolog (predicted)
asparagine-linked glycosylation 9 homolog (yeast, alpha 1,2
mannosyltransferase) (predicted)
N-acetylneuraminic acid synthase (sialic acid synthase) (predicted)
Znf291 1.43
Ypel5 1.43
RGD1307682 1.43
Tacstd2 1.43
Sel1h 1.43
LOC687738 /// LOC691956 1.43
Actr10 1.43
Rassf1 1.43
Gorasp1 1.43
Rab33a_predicted 1.43
Shank3 1.43
Tcf12 1.42
mrpl9 1.42
RGD1309886 1.42
Decr2 1.42
RGD1310922_predicted 1.42
Sort1 1.42
RGD1359361 1.42
Vamp1 1.42
RGD1310685_predicted 1.42
RGD1306148_predicted 1.41
Cobll1_predicted 1.41
RGD1305243_predicted 1.41
RGD1564209_predicted 1.41
Rbms2 1.40
Bbs2 1.40
Aldh1a1 1.40
Ybx2_predicted 1.40
LOC291967 1.40
Tm4sf13 1.39
Tcn2 1.39
Fuca 1.39
Vps11_predicted 1.39
LOC687055 /// LOC690966 1.39
RGD1566399_predicted 1.39
LOC498353 1.39
Cgref1 1.38
RGD1306932 1.38
LOC361990 /// LOC500378 1.38
Aptx 1.38
Wdr44 1.38
LOC686289 /// LOC690285 1.38
L1cam 1.38
Dennd2d_predicted 1.37
Ppox_predicted 1.37
Atg4b 1.37
Mea1 1.37
Dhx38_predicted 1.36
Tmed3 1.36
Soat1 1.36
LOC686060 /// Nsd1_predicted 1.36
Retsat 1.36
Rab3gap2 1.36
Cbx7 1.36
Lmo2 1.36
LOC498145 1.36
RGD1309437 1.36
Gbe1 1.35
RGD1564253_predicted 1.35
Alg9_predicted 1.35
Nans_predicted 1.35
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similar to FLJ22405 protein (predicted) RGD1304842_predicted 1.35
cytochrome P450, family 27, subfamily a, polypeptide 1 Cyp27a1 1.35
FSHD region gene 1 (predicted) Frg1_predicted 1.35
similar to SWI/SNF-related matrix-associated actin-dependent regulator of 
chromatin c2 isoform b /// similar to SWI/SNF-related matrix-associated actin- LOC684513 /// LOC685179 1.35
dependent regulator of chromatin c2
cell division cycle 42 homolog (S. cerevisiae) Cdc42 1.35
similar to RIKEN cDNA 5730593F17 (predicted) RGD 1561062_predicted 1.35
SEL1 domain containing protein RGD735029 RGD735029 1.35
TMEM9 domain family, member B (predicted) Tmem9b_predicted 1.34
similar to RIKEN cDNA 5730453I16 RGD1305441 1.34
similar to engrailed protein (predicted) RGD 1561842_predicted 1.34
Similar to hypothetical protein A430031N04 (predicted) RGD1559643_predicted 1.34
cereblon Crbn 1.34
hypothetical protein LOC682888 LOC682888 1.34
similar to Vps41 protein (predicted) RGD 1560511_predicted 1.34
oligonucleotide/oligosaccharide-binding fold containing 1 Obfc1 1.33
ATPase, Ca++-sequestering Atp2c1 1.33
similar to HSPC049 protein (predicted) RGD1306697_predicted 1.33
similar to acetyl-coA dehydrogenase -related (111.6 kD) (5G231) (predicted) RGD 1310159_predicted 1.33
similar to HCV NS3-transactivated protein 1 (predicted) RGD1306332_predicted 1.33
similar to RIKEN cDNA E030034P13 (predicted) RGD1309385_predicted 1.33
FGF receptor activating protein 1 Frag1 1.33
similar to modulator of estrogen induced transcription RGD1307526 1.33
syntaxin 4A (placental) Stx4a 1.33
acyl-Coenzyme A binding domain containing 4 Acbd4 1.33
Ubiquitin-Like 5 Protein LOC500954 1.33
heterogeneous nuclear ribonucleoprotein R Hnrpr 1.33
similar to autophagy-related 10-like LOC688555 1.33
secretory granule neuroendocrine protein 1 Sgne1 1.33
LOC360807 LOC360807 1.33
similar to RIKEN cDNA 2010012F05 (predicted) RGD1309846_predicted 1.32
similar to ubiquinol-cytochrome c reductase complex 7.2kDa protein isoform b LOC685322 1.32
NAD kinase Nadk 1.31
cytidine monophospho-N-acetylneuraminic acid synthetase Cmas 1.31
G-protein signalling modulator 1 (AGS3-like, C. elegans) Gpsm1 1.31
ankyrin repeat and SAM domain containing 1 (predicted) Anks1_predicted 1.31
WAP four-disulfide core domain 2 Wfdc2 1.31
flavin adenine dinucleotide synthetase Flad1 1.31
similar to hypothetical protein FLJ14007 (predicted) RGD 1309519_predicted 1.31
adenylate kinase 3 Ak3 1.31
similar to hypothetical protein FLJ20014 LOC497934 1.31
similar to homeotic protein Hox B5 - mouse (predicted) RGD1562292_predicted 1.31
general transcription factor IIB Gtf2b 1.30
chemokine orphan receptor 1 Cmkor1 1.30
cAMP responsive element binding protein-like 2 Crebl2 1.30
farnesyl diphosphate synthase Fdps 1.30
prolactin regulatory element binding Preb 1.30
polycomb group ring finger 2 (predicted) Pcgf2_predicted 1.30
X-box binding protein 1 Xbp1 1.30
HESB like domain containing 2 Hbld2 1.30
ATPase, H transporting, lysosomal V1 subunit F Atp6v1f 1.30
neuroblastoma, suppression of tumorigenicity 1 Nbl1 1.30
alpha 1,4-galactosyltransferase A4galt 1.30
stromal cell derived factor 2 (predicted) Sdf2_predicted 1.30
vacuolar protein sorting 29 (S. pombe) (predicted) Vps29_predicted 1.29
NADH dehydrogenase (ubiquinone) Fe-S protein 8 (predicted) Ndufs8_predicted 1.29
similar to ORM1-like 3 LOC360618 1.29
myelin protein zero-like 1 Mpzl1 1.29
similar to hypothetical protein FLJ20487 RGD1309216 1.29
similar to RIKEN cDNA 2010008E23 gene RGD1304758 1.29
Bat4 gene Bat4 1.28
T-cell leukemia translocation altered gene Tcta 1.28
Similar to RIKEN cDNA 5033406L14 RGD1305755 1.28
phosphoenolpyruvate carboxykinase 2 (mitochondrial) (predicted) Pck2_predicted 1.28
torsin A interacting protein 2 Tor1aip2 1.28
similar to cDNA sequence BC031181 (predicted) RGD1562987_predicted 1.28
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similar to scaffold attachment factor B2
similar to hypothetical protein DKFZp564D0478 (predicted)
similar to Late endosomal/lysosomal Mp1 interacting protein (p14) (predicted)
similar to hypothetical protein D630010C10
trafficking protein particle complex 4
engulfment and cell motility 3, ced-12 homolog (C. elegans)
mitochondrial ribosomal protein S23 (predicted)
ATP-binding cassette, sub-family C (CFTR/MRP), member 4 
low density lipoprotein receptor-related protein associated protein 1 
phosphatidylinositol glycan, class Q
intraflagellar transport 88 homolog (Chlamydomonas) (predicted)
centaurin, delta 2
zinc and ring finger 1 (predicted)
paraoxonase 2
oxysterol binding protein-like 2
similar to 2810437L13Rik protein (predicted)
PQ loop repeat containing 1
GIPC PDZ domain containing family, member 1
protein kinase, interferon inducible double stranded RNA dependent activator 
Coenzyme Q6 homolog (yeast) 
insulin-like growth factor 1 
Scinderin
exonuclease 3''-5" domain-like 2 (predicted)
MOCO sulphurase C-terminal domain containing 2
nuclear mitotic apparatus protein 1
similar to RIKEN cDNA 2810421I24
similar to RIKEN cDNA 1110059P08
similar to hypothetical protein FLJ13188 (predicted)
similar to chromosome 6 open reading frame 80; chemokine C-C motif receptor­
like 1 adjacent
acetyl-Coenzyme A dehydrogenase, medium chain 
similar to hypothetical p38 protein (predicted)
RNA binding motif protein 8 (predicted) 
similar to zinc finger protein 11b (KOX 2) 
similar to RIKEN cDNA 2310028N02 
two pore channel 1 
MAP-kinase activating death domain 
PERP, TP53 apoptosis effector (predicted)
Rab geranylgeranyl transferase, a subunit
similar to chondroitin sulfate GalNAcT-2 (predicted)
similar to zinc finger protein 277 isoform 1
similar to hypothetical protein MGC52110 (predicted)
abhydrolase domain containing 1
cytochrome c oxidase, subunit XVII assembly protein homolog (yeast) 
tripartite motif protein 35
myb-like, SWIRM and MPN domains 1 (predicted)
THAP domain containing, apoptosis associated protein 3 (predicted)
torsin family 1, member B
similar to hypothetical protein (predicted)
peroxisome biogenesis factor 19 /// similar to Peroxisomal biogenesis factor 19 
(Peroxin-19) (Peroxisomal farnesylated protein) 
similar to Negative elongation factor D (NELF-D) (TH1-like protein) 
similar to KIAA0974 protein
similar to Exocyst complex component Sec15B (predicted) 
phosphatidylserine synthase 2 (predicted)
excision repair cross-complementing rodent repair deficiency, complementation 
group 3
small nuclear RNA activating complex, polypeptide 2
similar to peroxisomal long chain acyl-CoA thioesterase Ia (predicted)
similar to D11Bwg0434e protein (predicted)
vacuolar protein sorting 4a (yeast)
Tp53rk binding protein
similar to CG14286-PA
Mitochondrial ribosomal protein L49
inositol hexaphosphate kinase 2
thioredoxin domain containing 1
similar to RIKEN cDNA 4631427C17 (predicted)
LOC301126
RGD1304793_predicted
RGD1562501_predicted
RGD1309752
Trappc4
Elmo3
Mrps23_predicted
Abcc4
Lrpap1
Pigq
Ift88_predicted
Centd2
Znrf1_predicted
Pon2
Osbpl2
RGD1305631_predicted
Pqlc1
Gipc1
Prkra
Coq6
Igf1
Scin
Exdl2_predicted
Mosc2
Numa1
RGD1307883
RGD1305031
RGD1305500_predicted
RGD1310326
Acadm
RGD 1311910_predicted
Rbm8_predicted
RGD1359435
RGD1359339
Tpcn1
Madd
Perp_predicted
Rabggta
RGD1563660_predicted
LOC298977
RGD1565095_predicted
Abhd1
Cox17
Trim35
Mysm1_predicted
Thap3_predicted
Tor1b
RGD1305045_predicted
LOC679129 /// Pex19
LOC679203
RGD1359592
RGD1560638_predicted
Ptdss2_predicted
Ercc3
Snapc2
RGD1564089_predicted
RGD1305687_predicted
Vps4a
Tprkb
LOC686765
Mrpl49
Ihpk2
Txndc1
RGD1564895_predicted
24
21
20
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similar to RIKEN cDNA 0610037P05 RGD1305823 1.16
RB1-inducible coiled-coil 1 (predicted) Rb1cc1_predicted 1.16
nuclear factor of kappa light chain gene enhancer in B-cells inhibitor, beta Nfkbib 1.16
hypothetical LOC308869 MGC72560 1.16
similar to chromosome 20 open reading frame 155 RGD1311037 1.16
topoisomerase (DNA) I /// similar to topoisomerase (DNA) I LOC499179 /// Top1 1.16
xeroderma pigmentosum, complementation group C (predicted) Xpc_predicted 1.15
secretory carrier membrane protein 1 Scamp1 1.15
NADH dehydrogenase (ubiquinone) 1 beta subcomplex 8 (predicted) Ndufb8_predicted 1.15
hypothetical LOC303211 RGD1311260 1.14
endosulfine alpha Ensa 1.14
Kelch-like ECH-associated protein 1 Keap1 1.14
ADP-ribosylation factor 2 Arf2 1.13
GTPase activating protein and VPS9 domains 1 (predicted) Gapvd1_predicted 1.12
hypothetical protein LOC500991 LOC500991 1.11
choline kinase beta Chkb 1.10
DEAD (Asp-Glu-Ala-Asp) box polypeptide 51 (predicted) Ddx51_predicted 1.10
hypothetical protein LOC498606 LOC498606 1.06
similar to zinc finger protein (predicted) RGD 1562173_predicted 0.94
calpain 10 Capn10 0.94
similar to RIKEN cDNA 0610016J10 gene RGD1309929 0.93
similar to RIKEN cDNA 2500001K11 (predicted) RGD1309602_predicted 0.93
similar to Est1p-like protein B LOC681012 0.93
ATP synthase, H+ transporting, mitochondrial F0 complex, subunit F6 Atp5j 0.92
Phosphatidylinositol binding clathrin assembly protein Picalm 0.92
chromatin modifying protein 1A Chmp1a 0.91
asparagine-linked glycosylation 12 homolog (yeast, alpha-1,6- 
mannosyltransferase) (predicted) Alg12_predicted 0.91
rho/rac guanine nucleotide exchange factor (GEF) 18 (predicted) Arhgef18_predicted 0.91
Similar to Bcl2-associated athanogene 2 LOC690038 0.90
similar to CG9882-PA (predicted) RGD 1306157_predicted 0.90
B-cell translocation gene 2, anti-proliferative Btg2 0.90
ADP-dependent glucokinase Adpgk 0.90
transmembrane protein 32 (predicted) Tmem32_predicted 0.90
PHD finger protein 5A Phf5a 0.90
Similar to splicing factor, arginine/serine-rich 2, interacting protein LOC312030 0.90
similar to RIKEN cDNA 2510040D07 (predicted) RGD1565004_predicted 0.89
nucleolar protein 10 Nol10 0.89
zinc finger and BTB domain containing 7a Zbtb7a 0.89
similar to 2700078E 11Rik protein RGD1308127 0.89
protein kinase, AMP-activated, beta 1 non-catalytic subunit Prkab1 0.89
similar to RIKEN cDNA 2210009G21 (predicted) RGD 1563120_predicted 0.88
similar to Hypothetical protein MGC28888 LOC304361 0.88
similar to X83328 protein RGD1304846 0.88
formin binding protein 4 Fnbp4 0.88
similar to Trithorax homolog 2 (Mixed lineage leukemia gene homolog 2 protein) 
(predicted) RGD1308331_predicted 0.88
similar to H2B histone family, member T LOC682665 0.88
basic helix-loop-helix domain containing, class B, 9 Bhlhb9 0.88
Similar to small nuclear RNA activating complex, polypeptide 5 LOC691501 0.88
NAD(P)H dehydrogenase, quinone 1 Nqo1 0.88
tripartite motif protein 41 (predicted) Trim41_predicted 0.87
similar to PAK/PLC-interacting protein 1 MGC125015 0.87
mannoside acetylglucosaminyltransferase 1 Mgat1 0.87
similar to CG14977-PA (predicted) RGD1309735_predicted 0.87
hypothetical protein LOC691543 LOC691543 0.87
similar to RIKEN cDNA D030060M11 RGD1308076 0.86
similar to UDP-N-acteylglucosamine pyrophosphorylase 1 homolog (predicted) RGD 1561967_predicted 0.86
SRY-box containing gene 4 (predicted) Sox4_predicted 0.86
immunoglobulin mu binding protein 2 Ighmbp2 0.86
chromobox homolog 1 (Drosophila HP1 beta) (predicted) Cbx1_predicted 0.86
farnesyltransferase, CAAX box, beta Fntb 0.85
Karyopherin (importin) alpha 3 Kpna3 0.85
O-sialoglycoprotein endopeptidase Osgep 0.85
similar to Caspase recruitment domain protein 4 (predicted) RGD1562269_predicted 0.85
similar to SH3-domain binding protein 3 LOC688018 0.85
transcription elongation factor A (SII) 1 Tcea1 0.85
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similar to HLA-B associated transcript-2 isoform a LOC296637 0.85
tripartite motif protein 3 Trim3 0.85
coiled-coil domain containing 43 Ccdc43 0.84
golgi reassembly stacking protein 2 Gorasp2 0.84
DPH5 homolog (S. cerevisiae) Dph5 0.84
mannose-6-phosphate receptor, cation dependent M6pr 0.84
RIO kinase 3 (yeast) (predicted) Riok3_predicted 0.84
similar to RIKEN cDNA 2700091N06 (predicted) RGD1310710_predicted 0.84
zinc ribbon domain containing, 1 Znrd1 0.84
similar to WD-repeat protein 43 LOC362703 0.84
retinoblastoma binding protein 7 Rbbp7 0.84
similar to RIKEN cDNA 2700085E05 RGD1307010 0.84
similar to capping protein (actin filament) muscle Z-line, alpha 1 LOC691149 0.84
hypothetical protein LOC687491 /// hypothetical protein LOC689755 LOC687491 /// LOC689755 0.84
similar to RIKEN cDNA 1810055G02 RGD1311946 0.83
coagulation factor 5 (mapped) F5 0.83
zinc finger protein 313 Zfp313 0.83
COP9 (constitutive photomorphogenic) homolog, subunit 5 (Arabidopsis 
thaliana) Cops5 0.83
Citrate synthase Cs 0.83
similar to junction-mediating and regulatory protein (predicted) RGD1563506_predicted 0.83
tRNA nucleotidyl transferase, CCA-adding, 1 Trnt1 0.83
ATG16 autophagy related 16-like 1 (S. cerevisiae) (predicted) Atg16l1_predicted 0.83
zinc finger protein 598 (predicted) Zfp598_predicted 0.83
family with sequence similarity 38, member A (predicted) Fam38a_predicted 0.83
similar to LOC495800 protein LOC499770 0.82
glucocorticoid receptor DNA binding factor 1 (predicted) /// similar to 
Glucocorticoid receptor DNA-binding factor 1 (GAP-associated protein p190) Grlf1_predicted /// LOC686520 0.82
Similar to hypothetical protein F730001J03 (predicted) RGD 1311757_predicted 0.82
ubiquitin specific protease 19 Usp19 0.82
YTH domain family 1 Ythdf1 0.82
ADP-ribosylation factor 1 Arf1 0.82
Treacher Collins Franceschetti syndrome 1, homolog (predicted) Tcof1_predicted 0.82
Crn, crooked neck-like 1 (Drosophila) Crnkl1 0.82
serine/threonine kinase receptor associated protein Strap 0.82
centrosomal protein 78 Cep78 0.82
similar to AHA1, activator of heat shock 90kDa protein ATPase homolog 1 LOC681996 0.82
interferon-induced protein with tetratricopeptide repeats 2 Ifit2 0.82
Wolf-Hirschhorn syndrome candidate 2 (human) Whsc2 0.82
putative regulation protein GS3 Gs3 0.82
suppressor of var1, 3-like 1 (S. cerevisiae) Supv3l1 0.82
3-hydroxybutyrate dehydrogenase, type 1 Bdh1 0.82
similar to Ubiquitin-like protein SMT3A precursor (Ubiquitin-related protein LOC499417 0.81SUMO-2)
similar to zinc finger, DHHC domain containing 14 LOC499014 0.81
chromosome segregation 1-like (S. cerevisiae) (predicted) Cse1l_predicted 0.81
synovial sarcoma translocation, Chromosome 18 Ss18 0.81
dipeptidylpeptidase 8 (predicted) Dpp8_predicted 0.81
COP9 (constitutive photomorphogenic) homolog, subunit 7b (Arabidopsis 
thaliana) (predicted) Cops7b_predicted 0.81
Harvey rat sarcoma viral (v-Ha-ras) oncogene homolog Hras 0.81
similar to hypothetical protein PP1665 (predicted) RGD1559673_predicted 0.81
phosphoribosyl pyrophosphate synthetase 1 Prps1 0.81
calumenin Calu 0.81
sema domain, immunoglobulin domain (Ig), short basic domain, secreted, 
(semaphorin) 3 F (predicted) Sema3f_predicted 0.81
FtsJ homolog 3 (E. coli) Ftsj3 0.81
SEC63-like (S. cerevisiae) (predicted) Sec63_predicted 0.81
Thymoma viral proto-oncogene 1 Akt1 0.81
similar to cofactor of BRCA1; negative elongation factor protein B (predicted) RGD1307832_predicted 0.81
Sjogren syndrome antigen B Ssb 0.81
nucleosome assembly protein 1-like 1 Nap1l1 0.81
asparagine-linked glycosylation 5 homolog (yeast, dolichyl-phosphate beta- Alg5 0.81glucosyltransferase)
U1 small nuclear ribonucleoprotein 1C (predicted) /// similar to U1 small nuclear LOC682020 /// LOC685273 /// 0.81ribonucleoprotein C (U1 snRNP protein C) (U1C protein) (U1-C) Snrp1c_predicted
Ubiquitin specific protease 7 (herpes virus-associated) Usp7 0.81
phenylalanine-tRNA synthetase-like, beta subunit Farslb 0.80
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Ubiquilin 1 Ubqln1 0.80
pseudouridine synthase 1 Pus1 0.80
FERM, RhoGEF and pleckstrin domain protein 2 (predicted) Farp2_predicted 0.80
GPI-anchored membrane protein 1 Gpiap1 0.80
oxidoreductase NAD-binding domain containing 1 (predicted) Oxnad1_predicted 0.80
similar to C1orf25 RGD1307890 0.80
prominin 1 Prom1 0.80
aminoacylase 1 Acy1 0.80
similar to CDV-3B LOC315970 0.80
splicing factor 3b, subunit 4 Sf3b4 0.80
tripartite motif protein 8 (predicted) /// similar to Tripartite motif protein 8 (RING 
finger protein 27) (Glioblastoma-expressed RING finger protein) LOC688785 /// Trim8_predicted 0.80
cordon-bleu (predicted) Cobl_predicted 0.80
optineurin Optn 0.80
heterogeneous nuclear ribonucleoprotein L Hnrpl 0.80
similar to protein tyrosine phosphatase, receptor type, D (predicted) RGD 1561090_predicted 0.80
similar to SET domain-containing protein LOC498178 /// LOC687538 /// LOC689820 0.80
spermatogenesis associated 6 Spata6 0.80
tumor protein p53 inducible protein 13 (predicted) Trp53i13_predicted 0.80
RNA pseudouridylate synthase domain containing 1 (predicted) Rpusd1_predicted 0.80
related RAS viral (r-ras) oncogene homolog 2 Rras2 0.80
RIO kinase 2 (yeast) Riok2 0.80
similar to 3000004C01Rik protein RGD1310360 0.79
similar to RIKEN cDNA 1200011M11 (predicted) RGD1306862_predicted 0.79
thymine-DNA glycosylase Tdg 0.79
PDRP protein Pdrp 0.79
KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulum protein retention receptor 2 Kdelr2 0.79
similar to Cell division protein kinase 8 (Protein kinase K35) (predicted) RGD1560888_predicted 0.79
nucleotide binding protein 1 Nubp1 0.79
ribosomal protein L15 Rpl15 0.79
similar to 5930416I19Rik protein MGC94282 0.79
similar to D-glucuronyl C5-epimerase (predicted) RGD1565253_predicted 0.79
similar to hypothetical protein MGC36831 (predicted) RGD 1306215_predicted 0.79
similar to KIAA0339 protein RGD1311624 0.79
nuclear cap binding protein subunit 1, 80kDa Ncbp1 0.79
similar to Leucine-rich repeats and calponin homology domain-containing protein
1 (Calponin homology domain-containing protein 1) LOC502020 0.79
SREBP cleavage activating protein (predicted) Scap_predicted 0.79
COMM domain containing 3 Commd3 0.79
cullin associated and neddylation disassociated 1 Cand1 0.79
zinc finger protein 532 (predicted) Znf532_predicted 0.79
similar to G protein pathway suppressor 2 LOC497941 0.79
cysteine-rich with EGF-like domains 2 Creld2 0.79
cell division cycle 2-like 5 (cholinesterase-related cell division controller) Cdc2l5 0.79
Msx-interacting-zinc finger Miz1 0.78
similar to RIKEN cDNA 4933428G09 (predicted) RGD1311045_predicted 0.78
Janus kinase 1 Jak1 0.78
PRP4 pre-mRNA processing factor 4 homolog (yeast) Prpf4 0.78
AT hook containing transcription factor 1 (predicted) Ahctf1_predicted 0.78
similar to Myb proto-oncogene protein (C-myb) (predicted) RGD1560020_predicted 0.78
LTV1 homolog (S. cerevisiae) Ltv1 0.78
WD repeat domain 12 Wdr12 0.78
TAR DNA binding protein Tardbp 0.77
similar to chromosome 13 open reading frame 7 (predicted) RGD1564706_predicted 0.77
expressed in non-metastatic cells 2 Nme2 0.77
La ribonucleoprotein domain family, member 1 (predicted) Larp1_predicted 0.77
aminolevulinic acid synthase 1 Alas1 0.77
WD repeat domain 5 Wdr5 0.77
poly (ADP-ribose) polymerase family, member 1 Parp1 0.77
steroid sensitive gene 1 Ssg1 0.77
inhibitor of growth family, member 1 Ing1 0.77
F-box only protein 5 (predicted) Fbxo5_predicted 0.77
RuvB-like protein 1 Ruvbl1 0.77
membrane protein, palmitoylated 6 (MAGUK p55 subfamily member 6) 
(predicted) Mpp6_predicted 0.77
similar to RIKEN cDNA 1110007L15 (predicted) RGD1311660_predicted 0.77
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nucleoporin 155 Nup155 0.77
Adrenergic receptor kinase, beta 1 Adrbk1 0.77
protein kinase C, eta Prkch 0.77
ubiquitin-conjugating enzyme E2I Ube2i 0.77
5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP Atic 0.77cyclohydrolase
gamma-glutamyltransferase 1 Ggt1 0.77
MAD homolog 1 (Drosophila) Smad1 0.77
plastin 1 (I isoform) (predicted) Pls1_predicted 0.77
v-maf musculoaponeurotic fibrosarcoma oncogene family, protein G (avian) Mafg 0.77
CKLF-like MARVEL transmembrane domain containing 8 Cmtm8 0.77
RAVER1 homolog (human) Raver1h 0.77
ubiquitin specific protease 14 Usp14 0.76
similar to mKIAA0259 protein (predicted) RGD1562949_predicted 0.76
hypothetical protein LOC686179 MGC125239 0.76
NudC domain containing 2 Nudcd2 0.76
glucosamine (N-acetyl)-6-sulfatase Gns 0.76
stromal membrane-associated protein 1-like Smap1l 0.76
RGD1562339 (predicted) RGD1562339_predicted 0.76
ribonucleic acid binding protein S1 Rnps1 0.76
bystin-like Bysl 0.76
type 1 tumor necrosis factor receptor shedding aminopeptidase regulator Arts1 0.76
eukaryotic translation initiation factor 3, subunit 10 (theta) Eif3s10 0.76
similar to mKIAA0227 protein (predicted) RGD1565985_predicted 0.76
similar to early estrogen-induced gene 1 protein LOC687750 0.76
dynein cytoplasmic 1 heavy chain 1 Dync1h1 0.76
chaperonin subunit 8 (theta) (predicted) Cct8_predicted 0.76
MOB1, Mps One Binder kinase activator-like 1B (yeast) Mobk1b 0.75
thyroid hormone receptor associated protein 4 Thrap4 0.75
similar to DNA segment, Chr 18, Wayne State University 98, expressed 
(predicted) RGD1560212_predicted 0.75
mitochondrial tumor suppressor 1 Mtus1 0.75
chaperonin subunit 4 (delta) Cct4 0.75
discs, large (Drosophila) homolog-associated protein 1 Dlgap1 0.75
midasin homolog (yeast) Mdn1 0.75
Similar to CG3740-PA LOC690000 0.75
agrin Agrn 0.75
Serine/arginine-rich protein specific kinase 1 Srpk1 0.75
Similar to 5730420B22Rik protein (predicted) RGD1306755_predicted 0.75
similar to KTI12 homolog, chromatin associated MGC108874 0.75
similar to RIKEN cDNA 1500009M05 (predicted) RGD1566242_predicted 0.75
Hspb associated protein 1 Hspbap1 0.75
acid phosphatase 1, soluble Acp1 0.75
similar to RIKEN cDNA 4930431E10 (predicted) /// similar to Smad LOC690516 /// 0.74ubiquitination regulatory factor 1 isoform 2 RGD1309707_predicted
similar to CG11388-PA (predicted) RGD1308154_predicted 0.74
nucleoporin 54 Nup54 0.74
hypothetical LOC290577 LOC290577 0.74
splicing factor 3b, subunit 3 (predicted) Sf3b3_predicted 0.74
metastasis-associated gene family, member 2 Mta2 0.74
aquarius (predicted) Aqr_predicted 0.74
UDP-glucose dehydrogenase Ugdh 0.74
KDEL (Lys-Asp-Glu-Leu) containing 2 Kdelc2 0.74
growth factor, erv1 homolog (S. cerevisiae) Gfer 0.74
similar to RIKEN cDNA 4122402O22 RGD1310674 0.74
similar to U6 snRNA-associated Sm-like protein LSm6 (Sm protein F) 
(predicted) RGD1561937_predicted 0.74
LIM and SH3 protein 1 Lasp1 0.74
interleukin-1 receptor-associated kinase 1 (predicted) Irak1_predicted 0.73
similar to leucine rich repeat and fibronectin type III domain containing 4 LOC684051 /// LOC688721 0.73
similar to Peroxisomal biogenesis factor 19 (Peroxin-19) (Peroxisomal LOC289233 0.73farnesylated protein)
similar to splicing factor, arginine/serine-rich 2 Sfrs2 0.73
proteaseome (prosome, macropain) 28 subunit, 3 Psme3 0.73
PAP associated domain containing 1 (predicted) Papd1_predicted 0.73
protein kinase C, iota Prkci 0.73
similar to C530044N13Rik protein RGD1306568 0.73
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potassium channel regulator 1 LOC245960 0.73
ZUBR1 Rbaf600 0.73
nucleoporin 107 Nup107 0.73
similar to TBP-associated factor 172 (TAF-172) (TAF(II)170) (predicted) RGD1564130_predicted 0.73
FYVE, RhoGEF and PH domain containing 1 Fgdl 0.73
exosome component 8 (predicted) Exosc8_predicted 0.73
G protein-coupled receptor kinase interactor 1 Gitl 0.73
similar to Ubc6p homolog MGC94113 0.73
ELL associated factor 1 (predicted) Eaf1_predicted 0.73
similar to Metaxin 1, isoform 2 LOC295241 0.73
chemokine (C-X-C motif) ligand 11 Cxclll 0.73
similar to RIKEN cDNA 1810029B16 (predicted) RGD1305222_predicted 0.73
similar to Microtubule-associated serine/threonine-protein kinase 3 L0C684053 /// L0C688540 0.73
solute carrier family 39 (zinc transporter), member 14 (predicted) Slc39a14_predicted 0.73
similar to 2810022L02Rik protein RGD1309930 0.73
Ras association (RalGDS/AF-6) and pleckstrin homology domains 1 (predicted) Raph1_predicted 0.73
tripartite motif protein 27 (predicted) Trim27_predicted 0.73
serologically defined colon cancer antigen 33 (predicted) Sdccag33_predicted
Cct6a /// L0C303526 /// L0C316484
0.72
chaperonin subunit 6a (zeta) /// similar to chaperonin subunit 6a (zeta) /// L0C688183 0.72
protein-kinase, interferon-inducible double stranded RNA dependent inhibitor, 
repressor of (P58 repressor) (predicted) Prkrir_predicted 0.72
RNA terminal phosphate cyclase-like 1 Rcl1 0.72
eukaryotic translation initiation factor 4A1 Eif4a1 0.72
prolyl endopeptidase Prep 0.72
ras homolog gene family, member D (predicted) Rhod_predicted 0.72
staphylococcal nuclease domain containing 1 Sndl 0.72
CD276 antigen Cd276 0.72
myeloblastosis oncogene-like 2 (predicted) Mybl2_predicted 0.72
HLA-B-associated transcript 1A Batla 0.72
hormone-regulated proliferation associated protein 20 Hrpap20 0.72
small inducible cytokine subfamily E, member 1 Scyel 0.72
hypothetical LOC305452 (predicted) RGD1309634_predicted 0.72
CDC16 cell division cycle 16 homolog (S. cerevisiae) Cdc16 0.72
poly(rC) binding protein 2 Pcbp2 0.72
UDP-N-acetyl-alpha-D-galactosamine:polypeptide N- Galnt1 0.72acetylgalactosaminyltransferase 1
regulator of chromosome condensation 2 (predicted) Rcc2_predicted 0.72
similar to down-regulated in metastasis (predicted) RGD1560606_predicted 0.72
peptidylprolyl isomerase domain and WD repeat containing 1 (predicted) Ppwd1_predicted 0.72
similar to TR4 orphan receptor associated protein TRA16 L0C361128 0.72
villin 2 Vil2 0.72
similar to doublecortin-like kinase 2 (predicted) Dclk2_predicted 0.72
similar to hypothetical protein FLJ12994 (predicted) RGD1308795_predicted 0.72
exosome component 7 Exosc7 0.71
aldehyde dehydrogenase family 7, member A1 Aldh7a1 0.71
zinc finger and BTB domain containing 2 (predicted) Zbtb2_predicted 0.71
DEAD (Asp-Glu-Ala-Asp) box polypeptide 10 (predicted) Ddx10_predicted 0.71
eukaryotic translation initiation factor 4, gamma 2 (predicted) Eif4g2_predicted 0.71
mesoderm development candidate 1 Mesdc1 0.71
nuclear fragile X mental retardation protein interacting protein 1 Nufip1 0.71
forkhead box J3 (predicted) Foxj3_predicted 0.71
Hypothetical protein LOC691031 L0C691031 0.71
similar to Hypothetical protein KIAA0419 (predicted) RGD 1310509_predicted 0.71
t-complex protein 1 Tcp1 0.70
similar to HN1-like protein RGD1305117 0.70
bromodomain containing 2 Brd2 0.70
similar to Clast4 protein (predicted) RGD1560908_predicted 0.70
similar to GA binding protein transcription factor, beta subunit 2 (GABPB2) 
(predicted) RGD 1560391_predicted 0.70
glutamate-cysteine ligase, catalytic subunit Gclc 0.70
similar to hypothetical protein FLJ13149 (predicted) RGD1563839_predicted 0.70
CAMP responsive element modulator Crem 0.70
nuclear factor, erythroid derived 2, like 2 Nfe2l2 0.70
beta-2 microglobulin B2m 0.70
similar to ankyrin repeat domain 40 L0C688144 /// L0C690586 0.70
polymerase (DNA directed), alpha 2 Pola2 0.70
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Myosin, heavy polypeptide 9, non-muscle 
nucleoporin 37 (predicted) 
adenylate kinase 2
similar to Rap1-interacting factor 1 (predicted)
similar to hypothetical protein LOC92922 (predicted)
similar to chromosome 14 open reading frame 130
THAP domain containing 4
WD repeat domain 77
similar to 6030466N05Rik protein
solute carrier family 3 (activators of dibasic and neutral amino acid transport), 
member 2
F-box and leucine-rich repeat protein 10 
ferritin light chain 1 
Ring finger protein 44 
histone deacetylase 6
MORC family CW-type zinc finger 4 (predicted)
embryonic ectoderm development (predicted)
nucleoporin 98
similar to Protein C22orf5
BH3 interacting domain death agonist
insulin-like growth factor 2 receptor
zinc finger, MYND domain containing 19
tenascin XA
forkhead box K2 (predicted) /// similar to forkhead box K2 isoform 1
tumor-suppressing subchromosomal transferable fragment 4
ATP-binding cassette, sub-family E (OABP), member 1
karyopherin (importin) beta 1
similar to nitrogen fixation cluster-like (predicted)
ubiquitin carboxyl-terminal hydrolase L5
inner centromere protein (predicted)
cadherin 3, type 1, P-cadherin (placental)
asparaginyl-tRNA synthetase
stress-induced phosphoprotein 1
hypothetical protein LOC100125365
DNA cross-link repair 1A, PSO2 homolog (S. cerevisiae) (predicted) 
casein kinase II, alpha 2, polypeptide (predicted) 
deoxythymidylate kinase (predicted)
hypothetical gene supported by Y16641; Y16641 (predicted) /// hypothetical 
protein LOC679731 
Cnksr family member 3 
de-etiolated homolog 1 (Arabidopsis)
LOC363020 (predicted)
transient receptor potential cation channel, subfamily C, member 2 
Tnf receptor-associated factor 3 (predicted)
LRRGT00141
similar to mKIAA1924 protein (predicted) 
melanoma cell adhesion molecule 
heterogeneous nuclear ribonucleoprotein D 
isocitrate dehydrogenase 3 (NAD+) alpha 
insulin-like growth factor binding protein 2 
nuclear transport factor 2 
zinc finger protein 180 
desmuslin
leucine rich repeat containing 59 
TBC1 domain family, member 2B 
retinoic acid induced 14
similar to Zinc finger protein ZFPM1 (Zinc finger protein multitype 1) (Friend of
GATA protein 1) (Friend of GATA-1) (FOG-1)
general transcription factor II H, polypeptide 1 (predicted)
Tripartite motif protein 37 (predicted)
OTU domain containing 4
REV3-like, catalytic subunit of DNA polymerase zeta RAD54 like (S. cerevisiae) 
similar to Ribonuclease P protein subunit p30 (RNaseP protein p30) (RNase P 
subunit 2)
hypothetical protein LOC685203
CDW92 antigen
cold shock domain protein A
Myh9 0.70
Nup37_predicted 0.70
Ak2 0.70
RGD1562474_predicted 0.70
RGD1308684_predicted 0.70
RGD1359144 0.70
Thap4 0.70
Wdr77 0.70
LOC290741 0.70
Slc3a2 0.70
Fbxl10 0.70
Ftl1 0.70
Rnf44 0.70
Hdac6 0.69
Morc4_predicted 0.69
Eed_predicted 0.69
Nup98 0.69
RGD1306591 0.69
Bid 0.69
Igf2r 0.69
Zmynd19 0.69
Tnxa 0.69
Foxk2_predicted /// LOC688330 0.69
Tssc4 0.69
Abce1 0.69
Kpnb1 0.69
RGD1309562_predicted 0.69
Uchl5 0.69
Incenp_predicted 0.69
Cdh3 0.69
Nars 0.69
Stip1 0.69
LOC100125365 0.69
Dclre 1a_predicted 0.69
Csnk2a2_predicted 0.69
Dtymk_predicted 0.69
LOC679731 ///
RGD1561108_predicted
Cnksr3
0.68
0.68
Det1 0.68
RGD1309410_predicted 0.68
Trpc2 0.68
Traf3_predicted 0.68
LOC499235 0.68
RGD1561785_predicted 0.68
Mcam 0.68
Hnrpd 0.68
Idh3a 0.68
Igfbp2 0.68
NTF2 0.68
Zfp180 0.68
Dmn 0.68
Lrrc59 0.68
Tbc1d2b 0.68
Rai14 0.68
LOC691504 0.67
Gtf2h1_predicted 0.67
Trim37_predicted 0.67
Otud4 0.67
Rev3l 0.67
LOC685332 /// LOC687772 0.67
LOC685203 0.67
Cdw92 0.67
Csda 0.67
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heterogeneous nuclear ribonucleoprotein M Hnrpm 0.67
F-box and leucine-rich repeat protein 14 (predicted) Fbxl14_predicted 0.67
phosphoglycerate mutase family member 5 Pgam5 0.67
activating transcription factor 1 Atf1 0.67
tubulin, gamma 1 Tubg1 0.67
similar to CPSF4 protein MGC108785 0.67
ELAV (embryonic lethal, abnormal vision, Drosophila)-like 1 (Hu antigen R) 
(predicted) Elavl1_predicted 0.67
Nucleoside 2-deoxyribosyltransferase domain containing protein RGD620382 RGD620382 0.67
brix domain containing 1 (predicted) Bxdc1_predicted 0.67
RNA binding motif protein 22 Rbm22 0.66
a disintegrin and metalloprotease domain 8 (predicted) Adam8_predicted 0.66
exonuclease 1 (predicted) Exo1_predicted 0.66
cyclin-dependent kinase 4 Cdk4 0.66
HIRA interacting protein 3 Hirip3 0.66
integrin alpha V (predicted) Itgav_predicted 0.66
similar to CG3880-PA LOC680531 0.66
brain expressed X-linked 1 Bex1 0.66
nucleophosmin 1 Npm1 0.66
retinoblastoma 1 Rb1 0.66
mutS homolog 2 (E. coli) Msh2 0.66
EF hand domain containing 2 Efhd2 0.66
proteosome (prosome, macropain) subunit, beta type 9 Psmb9 0.65
prostaglandin F2 receptor negative regulator Ptgfrn 0.65
hypothetical protein LOC499339 LOC499339 0.65
rhomboid family 1 (Drosophila) Rhbdf1 0.65
similar to ribosomal protein P0-like protein; 60S acidic ribosomal protein PO; 
ribosomal protein, large, P0-like (predicted) RGD1311709_predicted 0.65
general transcription factor II I repeat domain-containing 1 Gtf2ird1 0.65
E2F transcription factor 8 E2f8 0.65
similar to AMSH-family protein LOC687696 0.65
nucleophosmin 1 /// similar to Nucleophosmin (NPM) (Nucleolar phosphoprotein LOC300303 /// Npm1 0.65B23) (Numatrin) (Nucleolar protein NO38)
ribosomal protein S2 Rps2 0.65
Sp1 transcription factor Sp1 0.65
B-cell CLL/lymphoma 9-like (predicted) Bcl9l_predicted 0.65
mitochondrial ribosomal protein S5 (predicted) Mrps5_predicted 0.64
Bloom syndrome homolog (human) (predicted) Blm_predicted 0.64
colony stimulating factor 1 (macrophage) Csf1 0.64
Rac GTPase-activating protein 1 (predicted) Racgap1_predicted 0.64
cirrhosis, autosomal recessive 1A (human) Cirh1a 0.64
dihydrofolate reductase Dhfr 0.64
actinin, alpha 1 Actn1 0.64
nucleolar protein 5A Nol5a 0.64
BCL2-antagonist/killer 1 Bak1 0.64
downstream neighbor of SON Donson 0.64
CTF18, chromosome transmission fidelity factor 18 homolog (S. cerevisiae) 
(predicted) Chtf18_predicted 0.64
ribosomal protein S6 kinase polypeptide 6 (predicted) Rps6ka6_predicted 0.63
ubiquitin-conjugating enzyme E2S (predicted) Ube2s_predicted 0.63
Tetratricopeptide repeat domain 9C Ttc9c 0.63
nuclear pore membrane glycoprotein 121 Pom121 0.63
mitogen-activated protein kinase kinase kinase kinase 4 (predicted) Map4k4_predicted 0.63
polymerase (DNA directed), epsilon 3 (p17 subunit) Pole3 0.63
protein kinase N3 Pkn3 0.63
Lamin B1 Lmnb1 0.63
origin recognition complex, subunit 6-like (S. cerevisiae) Orc6l 0.63
similar to polyamine-modulated factor 1 LOC681050 0.63
nipsnap homolog 3A (C. elegans) Nipsnap3a 0.63
plasminogen activator, tissue Plat 0.63
similar to tubulin, beta 2 LOC498736 0.63
pitrilysin metallepetidase 1 (predicted) Pitrm1_predicted 0.63
human immunodeficiency virus type I enhancer binding protein 2 Hivep2 0.62
RGD1566118 (predicted) RGD1566118_predicted 0.62
Retinol dehydrogenase 10 (all-trans) Rdh10 0.62
apurinic/apyrimidinic endonuclease 1 Apex1 0.62
achalasia, adrenocortical insufficiency, alacrimia (Allgrove, triple-A) (predicted) Aaas_predicted 0.62
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nucleoporin 62 Nup62 0.62
wild-type p53-induced gene 1 Wig1 0.62
nuclear ubiquitous casein kinase and cyclin-dependent kinase substrate Nucks 0.62
similar to CGI-09 protein (predicted) RGD1308877_predicted 0.62
nucleoporin 93 Nup93 0.62
MAD2 (mitotic arrest deficient, homolog)-like 1 (yeast) (predicted) Mad2l1_predicted 0.62
proteasome (prosome, macropain) 26S subunit, ATPase 3, interacting protein Psmc3ip 0.62
Cadherin 5 (predicted) Cdh5_predicted 0.62
UDP-Gal:betaGlcNAc beta 1,4-galactosyltransferase, polypeptide 5 (predicted) B4galt5_predicted 0.62
complement component 1, q subcomponent binding protein C1qbp 0.62
tumor protein p53 Tp53 0.62
similar to spindlin LOC682571 0.62
inhibitor of growth family, member 1-like (predicted) Ing1l_predicted 0.62
S-adenosylhomocysteine hydrolase Ahcy 0.62
tetratricopeptide repeat domain 7B (predicted) Ttc7b_predicted 0.62
carboxypeptidase M (predicted) Cpm_predicted 0.62
similar to Nucleoporin Nup43 LOC683983 0.61
similar to CDNA sequence BC022692 (predicted) RGD1561555_predicted 0.61
cell division cycle associated 2 Cdca2 0.61
bromodomain containing 7 (predicted) Brd7_predicted 0.61
carbonic anhydrase 3 Ca3 0.61
guanylate nucleotide binding protein 2 Gbp2 0.61
metastasis associated 1 Mta1 0.61
glycerol-3-phosphate dehydrogenase 2, mitochondrial Gpd2 0.61
similar to KIAA1205 protein (predicted) RGD1309896_predicted 0.61
Replication protein A1 Rpa1 0.61
retinoblastoma binding protein 6 Rbbp6 0.61
DEK oncogene (DNA binding) Dek 0.60
kinesin heavy chain family, member 2 Kif2 0.60
PAP associated domain containing 5 (predicted) Papd5_predicted 0.60
similar to RIKEN cDNA 1700022L09 LOC499933 0.60
similar to Pins (predicted) RGD1560967_predicted 0.60
similar to potassium channel tetramerisation domain containing 15 LOC499129 0.60
receptor accessory protein 6 Reep6 0.60
similar to SERTA domain containing 4 (predicted) RGD1565408_predicted 0.60
MTERF domain containing 1 Mterfd1 0.60
vascular endothelial growth factor B Vegfb 0.60
replication factor C (activator 1) 5 (predicted) Rfc5_predicted 0.60
zinc finger, CW-type with coiled-coil domain 1 (predicted) Zcwcc 1_predicted 0.60
similar to RIKEN cDNA 1810065E05 (predicted) RGD1565787_predicted 0.60
polymerase (DNA-directed), delta 3, accessory subunit Pold3 0.59
Tnf receptor associated factor 4 (predicted) Traf4_predicted 0.59
nucleolar and coiled-body phosphoprotein 1 Nolc1 0.59
phosphatase and tensin homolog Pten 0.59
vaccinia related kinase 1 Vrk1 0.59
histone aminotransferase 1 Hat1 0.59
geminin (predicted) Gmnn_predicted 0.59
dual specificity phosphatase 1 Dusp1 0.59
similar to RIKEN cDNA 2810037C03 RGD1307397 0.58
SMC4 structural maintenance of chromosomes 4-like 1 (yeast) Smc4l1 0.58
baculoviral IAP repeat-containing 5 Birc5 0.58
similar to ADP-ribosylation factor-like protein 4C (ADP-ribosylation factor-like
7-1 LOC367311 0.58
similar to Pabpc4_predicted protein (predicted) /// poly A binding protein, 
cytoplasmic 4
similar to nucleolar protein family A, member 1 
spermidine synthase
similar to differential display and activated by p53 
Synaptotagmin binding, cytoplasmic RNA interacting protein 
tumor necrosis factor receptor superfamily, member 5 
similar to 1110008L16Rik protein (predicted) 
angiopoietin-like 4
inosine 5-monophosphate dehydrogenase 2 
leucine zipper protein 5 (predicted)
RAN, member RAS oncogene family 
similar to 2700029M09Rik protein (predicted)
GATA zinc finger domain containing 2A
Pabpc4 III RGD1562451_predicted 0.58
LOC499709 0.58
Srm 0.58
MGC125042 0.58
Syncrip 0.58
Tnfrsf5 0.58
RGD1305089_predicted 0.58
Angptl4 0.57
Impdh2 0.57
Luzp5_predicted 0.57
Ran 0.57
RGD 1311747_predicted 0.57
Gatad2a 0.57
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high mobility group nucleosomal binding domain 2 Hmgn2 0.57
pericentrin 1 Pcnt1 0.57
similar to RIKEN cDNA 2310035C23 (predicted) RGD1307235_predicted 0.57
fibroblast growth factor 13 Fgf13 0.57
similar to Bifunctional methylenetetrahydrofolate dehydrogenaseIcyclohydrolase, LOC680308 0.57mitochondrial precursor
sideroflexin 1 Sfxn1 0.57
zinc finger, DHHC domain containing 2 Zdhhc2 0.56
neuropilin (NRP) and tolloid (TLL)-like 2 (predicted) Neto2_predicted 0.56
similar to CG14803-PA (predicted) RGD1304693_predicted 0.56
Importin 9 (predicted) Ipo9_predicted 0.56
similar to chromosome 14 open reading frame 145 LOC500700 0.56
similar to Enhancer of zeste homolog 2 (ENX-1) LOC312299 0.56
KH domain containing, RNA binding, signal transduction associated 3 Khdrbs3 0.56
similar to hypothetical protein 9630025C22 (predicted) RGD1559945_predicted 0.56
DEAD (Asp-Glu-Ala-Asp) box polypeptide 21a Ddx21a 0.56
Mak3 homolog (S. cerevisiae) (predicted) Mak3_predicted 0.56
similar to Sestrin 2 (Hi95) (predicted) RGD 1566319_predicted 0.55
RGD1560010 (predicted) RGD 1560010_predicted 0.55
tripartite motif-containing 59 (predicted) Trim59_predicted 0.55
thioredoxin reductase 1 Txnrd1 0.55
ubiquitin-conjugating enzyme E2T (putative) (predicted) Ube2t_predicted 0.55
cytidine 5'-triphosphate synthase (predicted) Ctps_predicted 0.55
transformed mouse 3T3 cell double minute 2 homolog (mouse) (predicted) Mdm2_predicted 0.55
cyclin dependent kinase 2 Cdk2 0.55
Ly1 antibody reactive clone Lyar 0.55
XK-related protein 5 LOC497083 0.55
kinesin family member 2C Kif2c 0.55
mitochondrial ribosomal protein S2 (predicted) Mrps2_predicted 0.55
kinesin family member 15 Kif15 0.55
similar to 2610203E10Rik protein (predicted) RGD 1309314_predicted 0.54
MARCKS-like 1 Marcksl1 0.54
mediator of DNA damage checkpoint 1 Mdc1 0.54
nucleoporin 205kDa (predicted) Nup205_predicted 0.54
similar to mKIAA0056 protein LOC315508 0.54
synaptotagmin-like 2 (predicted) Sytl2_predicted 0.54
nucleolar protein 5 Nol5 0.54
DNA primase, p58 subunit Prim2 0.53
similar to 2610528M18Rik protein LOC363198 0.53
replication factor C (activator 1) 3 Rfc3 0.53
nucleolar protein family A, member 2 (predicted) Nola2_predicted 0.53
similar to RAD51 associated protein 1 LOC689055 0.53
extra spindle poles like 1 (S. cerevisiae) (predicted) Espl1_predicted 0.53
sulfatase 2 Sulf2 0.53
discs, large homolog 7 (Drosophila) (predicted) Dlg7_predicted 0.53
clusterin Clu 0.53
zinc finger protein 275 (predicted) Zfp275_predicted 0.53
similar to brain expressed X-linked protein 2 III brain expressed X-linked 1 Bex1 III LOC363498 0.53
polymerase (DNA directed), epsilon Pole 0.52
Fc receptor, IgE, low affinity II, alpha polypeptide Fcer2a 0.52
FSH primary response 1 Fshprh1 0.52
Fas (TNF receptor superfamily, member 6) Fas 0.52
similar to protein 4.1G (predicted) RGD1563977_predicted 0.52
aurora kinase A Aurka 0.52
poly(A) binding protein, cytoplasmic 1 Pabpc1 0.51
similar to Protein diaphanous homolog 3 (Diaphanous-related formin-3) (DRF3) LOC290396 0.51(mDIA2) (p134mDIA2)
similar to cell division cycle 45 homolog (S. cerevisiae)-like LOC287961 0.51
RAN binding protein 5 (predicted) Ranbp5_predicted 0.51
minichromosome maintenance deficient 10 (S. cerevisiae) (predicted) Mcm10_predicted 0.51
splicing factor prolineIglutamine rich (polypyrimidine tract binding protein 
associated) Sfpq 0.51
PAX interacting (with transcription-activation domain) protein 1 (predicted) Paxip1_predicted 0.51
similar to Zwilch LOC691493 0.51
DEADIH (Asp-Glu-Ala-AspIHis) box polypeptide 11 (CHL1-like helicase 
homolog, S. cerevisiae) (predicted) Ddx11_predicted 0.50
flap structure-specific endonuclease 1 Fen1 0.50
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methylenetetrahydrofolate dehydrogenase (NADP+ dependent), Mthfd1 0.50methenyltetrahydrofolate cyclohydrolase, formyltetrahydrofolate synthase
karyopherin (importin) alpha 2 Kpna2 0.50
proliferating cell nuclear antigen Pcna 0.50
similar to RIKEN cDNA 9230117N10 RGD1311155 0.50
similar to chemokine (C-X-C motif) ligand 16 Cxcl16 0.49
nurim (nuclear envelope membrane protein) Nrm 0.49
myelin basic protein Mbp 0.49
DEAD (Asp-Glu-Ala-Asp) box polypeptide 39 Ddx39 0.49
Wolf-Hirschhorn syndrome candidate 1 (predicted) Whsc1_predicted 0.49
replication factor C (activator 1) 2 Rfc2 0.49
timeless homolog (Drosophila) Timeless 0.49
chromatin assembly factor 1, subunit B (p60) Chaf1b 0.49
protease, serine, 22 (predicted) Prss22_predicted 0.49
Feminization 1 homolog b (C. elegans) (predicted) Fem1b_predicted 0.49
nuclear autoantigenic sperm protein (histone-binding) Nasp 0.49
v-ets erythroblastosis virus E26 oncogene homolog 1 (avian) Ets1 0.48
filamin, alpha (predicted) Flna_predicted 0.48
similar to THO complex subunit 4 (Tho4) (RNA and export factor binding LOC688305 0.48protein 1) (REF1-I) (Ally of AML-1 and LEF-1) (Aly/REF)
cyclin-dependent kinase inhibitor 1A Cdkn1a 0.48
sulfiredoxin 1 homolog (S. cerevisiae) Srxn1 0.47
poly A binding protein, cytoplasmic 4 Pabpc4 0.47
hyaluronan mediated motility receptor (RHAMM) Hmmr 0.47
hypothetical protein LOC687595 /// hypothetical protein LOC691750 LOC687595 /// LOC691750 0.47
exportin 1, CRM1 homolog (yeast) Xpo1 0.47
similar to 4931433E08Rik protein (predicted) RGD1565838_predicted 0.46
cyclin B1 Ccnb1 0.46
ligase I, DNA, ATP-dependent Lig1 0.46
breast cancer 2 Brca2 0.46
polymerase (DNA directed), delta 2, regulatory subunit Pold2 0.46
TBC1D12: TBC1 domain family, member 12 (predicted) Tbc1d12_predicted 0.45
ASF1 anti-silencing function 1 homolog B (S. cerevisiae) (predicted) Asf1b_predicted 0.45
SMC2 structural maintenance of chromosomes 2-like 1 (yeast) (predicted) Smc2l1_predicted 0.45
similar to myeloid leukemia factor 1 interacting protein LOC306464 0.45
activating transcription factor 5 Atf5 0.45
DNA (cytosine-5-)-methyltransferase 1 Dnmt1 0.44
similar to snRNP core protein SMX5 LOC684148 0.44
solute carrier family 16 (monocarboxylic acid transporters), member 1 Slc16a1 0.44
cyclin-dependent kinase inhibitor 2C (p18, inhibits CDK4) Cdkn2c 0.44
cell division cycle 25 homolog B (S. pombe) Cdc25b 0.44
kinesin family member 4 Kif4 0.44
similar to transcription factor MGC112830 0.44
G protein-coupled receptor 19 Gpr19 0.44
minichromosome maintenance deficient 7 (S. cerevisiae) Mcm7 0.44
WD repeat and HMG-box DNA binding protein 1 (predicted) Wdhd1_predicted 0.44
thymidine kinase 1 Tk1 0.43
thymidylate synthase Tyms 0.43
similar to RIKEN cDNA 2810433K01 (predicted) RGD1310784_predicted 0.42
pleckstrin 2 (predicted) Plek2_predicted 0.42
RGD1561797 (predicted) RGD1561797_predicted 0.42
thymopoietin Tmpo 0.42
polymerase (DNA directed), delta 1, catalytic subunit Pold1 0.42
chemokine (C-C motif) ligand 28 Ccl28 0.42
transferrin receptor Tfrc 0.42
cell division cycle associated 4 Cdca4 0.41
polo-like kinase 1 (Drosophila) Plk1 0.41
nuclear pore membrane glycoprotein 210 Pom210 0.41
suppressor of variegation 3-9 homolog 1 (Drosophila) (predicted) Suv39h1_predicted 0.41
cell division cycle associated 8 Cdca8 0.41
cyclin E2 (predicted) Ccne2_predicted 0.40
chemokine (C-X-C motif) ligand 10 Cxcl10 0.40
similar to Chromatin assembly factor 1 subunit A (CAF-1 subunit A) (Chromatin LOC363333 0.39assembly factor I p150 subunit) (CAF-I 150 kDa subunit) (CAF-Ip150)
Fanconi anemia D2 protein Fancd2 0.39
Similar to Lmnb2 protein (predicted) RGD1563803_predicted 0.39
Cyclin D1 Ccnd1 0.39
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polymerase (DNA directed), epsilon 2 (p59 subunit) (predicted) Pole2_predicted 0.39
uracil-DNA glycosylase Ung 0.39
ribonucleotide reductase M1 Rrm1 0.38
aurora kinase B Aurkb 0.38
replication factor C (activator 1) 4 (predicted) Rfc4_predicted 0.38
similar to Shc SH2-domain binding protein 1 LOC687121 0.38
similar to RIKEN cDNA 6330512M04 gene (predicted) RGD 1563319_predicted 0.38
lipocalin 2 Lcn2 0.37
checkpoint kinase 1 homolog (S. pombe) Chek1 0.37
cyclin G1 Ccng1 0.37
deoxyuridine triphosphatase Dut 0.36
Best5 protein Best5 0.36
ubiquitin specific peptdiase 1 Usp1 0.36
tubulin, beta 2c Tubb2c 0.36
E2F transcription factor 1 E2f1 0.36
sperm associated antigen 5 Spag5 0.36
DEP domain containing 1a (predicted) Depdc1a_predicted 0.36
ubiquitin-like, containing PHD and RING finger domains, 1 Uhrf1 0.35
epithelial membrane protein 1 Emp1 0.35
ribonucleotide reductase M2 Rrm2 0.35
similar to mKIAA0159 protein (predicted) RGD1562596_predicted 0.35
asp (abnormal spindle)-like, microcephaly associated (Drosophila) (predicted) Aspm_predicted 0.35
cell division cycle associated 7 Cdca7 0.35
M-phase phosphoprotein 1 (predicted) Mphosph1_predicted 0.34
Cd27 binding protein (Hindu God of destruction) (predicted) Siva_predicted 0.34
Ttk protein kinase (predicted) Ttk_predicted 0.34
minichromosome maintenance deficient 2 mitotin (S. cerevisiae) (predicted) Mcm2_predicted 0.34
cell division cycle 20 homolog (S. cerevisiae) Cdc20 0.33
transforming, acidic coiled-coil containing protein 3 Tacc3 0.33
TRAF4 associated factor 1 Traf4af1 0.32
transcription factor 19 Tcf19 0.32
similar to Anillin (predicted) RGD1566097_predicted 0.31
RAD18 homolog (S. cerevisiae) (predicted) Rad18_predicted 0.31
pituitary tumor-transforming 1 Pttg1 0.30
kinesin family member 11 Kif11 0.30
chemokine (C-C motif) ligand 20 Ccl20 0.29
ATPase family, AAA domain containing 2 (predicted) Atad2_predicted 0.29
minichromosome maintenance deficient 4 homolog (S. cerevisiae) Mcm4 0.29
budding uninhibited by benzimidazoles 1 homolog (S. cerevisiae) (predicted) Bub1_predicted 0.29
polo-like kinase 4 (Drosophila) (predicted) Plk4_predicted 0.29
similar to RIKEN cDNA 2610510J17 RGD1310953 0.28
kinesin family member 22 Kif22 0.28
kinesin family member C1 Kifc1 0.28
cell division cycle associated 1 Cdca1 0.28
similar to Condensin complex subunit 2 (Barren homolog protein 1) LOC680089 0.28(Chromosome-associated protein H) (mCAP-H) (XCAP-H homolog)
RS21-C6 protein Rs21c6 0.28
peptidylprolyl isomerase C Ppic 0.27
similar to B99 protein (predicted) RGD 1563164_predicted 0.27
minichromosome maintenance deficient 5, cell division cycle 46 (S. cerevisiae) 
(predicted) Mcm5_predicted 0.27
kinetochore associated 1 (predicted) Kntc1_predicted 0.26
pleckstrin homology-like domain, family A, member 3 Phlda3 0.25
kinesin family member 23 (predicted) Kif23_predicted 0.25
cyclin A2 Ccna2 0.24
nucleolar and spindle associated protein 1 (predicted) Nusap1_predicted 0.24
similar to Coatomer gamma-2 subunit (Gamma-2 coat protein) (Gamma-2 COP) 
(predicted) RGD 1566215_predicted 0.24
hypothetical protein LOC689399 LOC689399 0.24
SoxLZ/Sox6 leucine zipper binding protein in testis (predicted) Solt_predicted 0.23
retroviral integration site 2 (predicted) Ris2_predicted 0.23
stathmin 1 Stmn1 0.23
minichromosome maintenance deficient 3 (S. cerevisiae) (predicted) /// similar to
DNA replication licensing factor MCM3 (DNA polymerase alpha holoenzyme- LOC367976 /// Mcm3_predicted 0.23
associated protein P1) (P1-MCM3)
kinesin family member 20A (predicted) Kif20a_predicted 0.23
zinc finger protein 367 Zfp367 0.23
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topoisomerase (DNA) 2 alpha Top2a 0.23
cytoskeleton associated protein 2 (predicted) Ckap2_predicted 0.23
tubulin, beta 6 Tubb6 0.22
spindle pole body component 25 homolog (S. cerevisiae) Spbc25 0.22
PDZ binding kinase (predicted) Pbk_predicted 0.22
similar to hypothetical protein MGC5528 (predicted) RGD 1561749_predicted 0.21
similar to HTGN29 protein; keratinocytes associated transmembrane protein 2 RGD1310352 0.21
maternal embryonic leucine zipper kinase (predicted) Melk_predicted 0.21
cyclin B2 Ccnb2 0.21
spindle pole body component 24 homolog (S. cerevisiae) (predicted) Spbc24_predicted 0.20
schlafen 8 Slfn8 0.20
similar to Cyclin-dependent kinases regulatory subunit 2 (CKS-2) (predicted) RGD1562047_predicted 0.20
ubiquitin-conjugating enzyme E2C (predicted) Ube2c_predicted 0.19
minichromosome maintenance deficient 6 (MIS5 homolog, S. pombe) (S. Mcm6 0.19cerevisiae)
tubulin, beta 5 Tubb5 0.17
cell division cycle associated 3 /// similar to cell division cycle associated 3 
(predicted) Cdca3 /// RGD1562067_predicted 0.16
ect2 oncogene (predicted) Ect2_predicted 0.14
similar to RIKEN cDNA 2610034E18 gene (predicted) RGD1309007_predicted 0.13
cell division cycle 2 homolog A (S. pombe) Cdc2a 0.13
antigen identified by monoclonal antibody Ki-67 (predicted) Mki67_predicted 0.12
similar to DNA repair protein RAD51 homolog 1 (predicted) RGD1563603_predicted 0.12
NS5A (hepatitis C virus) transactivated protein 9 Ns5atp9 0.10
Table 3. Protein kinases detected in the m icroarray of rat IMCD cells
Gene Title Gene ID Li/Con(fold Changes)
cell division cycle 2, G1 to S and G2 to M CDC2 0.126
CDC28 protein kinase regulatory subunit 2 CKS2 0.195
maternal embryonic leucine zipper kinase MELK 0.209
PDZ binding kinase PBK 0.217
budding uninhibited by benzimidazoles 1 homolog (yeast) BUB1 0.286
polo-like kinase 4 (Drosophila) PLK4 0.286
TTK protein kinase TTK 0.336
CHK1 checkpoint homolog (S. pombe) CHEK1 0.367
aurora kinase B AURKB 0.38
polo-like kinase 1 (Drosophila) PLK1 0.412
CDC28 protein kinase regulatory subunit 1B CKS1B 0.422
thymidine kinase 1, soluble TK1 0.432
aurora kinase A AURKA 0.518
cyclin-dependent kinase 2 CDK2 0.549
vaccinia related kinase 1 VRK1 0.589
nuclear casein kinase and cyclin-dependent kinase substrate 1 NUCKS1 0.622
protein kinase N3 PKN3 0.63
mitogen-activated protein kinase kinase kinase kinase 4 MAP4K4 0.632
ribosomal protein S6 kinase, 90kDa, polypeptide 6 RPS6KA6 0.634
cyclin-dependent kinase 4 CDK4 0.662
deoxythymidylate kinase (thymidylate kinase) DTYMK 0.686
casein kinase 2, alpha prime polypeptide CSNK2A2 0.687
adenylate kinase 2 AK2 0.702
bromodomain containing 2 BRD2 0.704
doublecortin-like kinase 2 DCLK2 0.715
microtubule associated serine/threonine kinase 3 MAST3 0.727
protein kinase C, iota PRKCI 0.731
interleukin-1 receptor-associated kinase 1 IRAK1 0.735
SFRS protein kinase 1 SRPK1 0.75
adrenergic, beta, receptor kinase 1 ADRBK1 0.769
protein kinase C, eta PRKCH 0.769
membrane protein, palmitoylated 6 (MAGUK p55 subfamily member 6) MPP6 0.77
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non-metastatic cells 2, protein (NM23B) expressed in NME2 0.775
Janus kinase 1 JAK1 0.781
cell division cycle 2-like 5 (cholinesterase-related cell division controller) CDC2L5 0.785
RIO kinase 2 (yeast) RIOK2 0.795
v-akt murine thymoma viral oncogene homolog 1 AKT1 0.807
phosphoribosyl pyrophosphate synthetase 1 PRPS1 0.809
RIO kinase 3 (yeast) RIOK3 0.839
protein kinase, AMP-activated, beta 1 non-catalytic subunit PRKAB1 0.885
ADP-dependent glucokinase ADPGK 0.902
choline kinase beta CHKB 1.104
inositol hexakisphosphate kinase 2 IP6K2 1.172
phosphoenolpyruvate carboxykinase 2 (mitochondrial) PCK2 1.282
adenylate kinase 3 AK3 1.308
fibroblast growth factor receptor 3 FGFR3 1.434
galactokinase 2 GALK2 1.454
CDC42 binding protein kinase beta (DMPK-like) CDC42BPB 1.468
N-myc downstream regulated 1 NDRG1 1.504
cyclin-dependent kinase 10 CDK10 1.545
inositol polyphosphate multikinase IPMK 1.566
SFRS protein kinase 2 SRPK2 1.620
src kinase associated phosphoprotein 1 SKAP1 1.702
testis-specific serine kinase substrate TSKS 1.721
pyruvate dehydrogenase kinase, isozyme 2 PDK2 1.840
NIMA (never in mitosis gene a)-related kinase 3 NEK3 1.913
mitogen-activated protein kinase kinase kinase kinase 1 MAP4K1 2.110
calcium/calmodulin-dependent protein kinase kinase 2, beta CAMKK2 2.111
aarF domain containing kinase 5 ADCK5 2.202
platelet-derived growth factor receptor-like PDGFRL 2.264
chaperone, ABC1 activity of bc1 complex homolog (S. pombe) CABC1 2.275
v-raf murine sarcoma 3611 viral oncogene homolog ARAF 2.513
Table 4. Transcription factors detected in the microarray of rat IM CD
cells
Gene Title Gene ID Li/Con(fold Changes)
zinc finger protein 367 ZNF367 0.227
pituitary tumor-transforming 1 PTTG1 0.299
transcription factor 19 TCF19 0.318
ubiquitin-like with PHD and ring finger domains 1 UHRF1 0.352
E2F transcription factor 1 E2F1 0.361
cyclin-dependent kinase inhibitor 2C (p18, inhibits CDK4) CDKN2C 0.441
activating transcription factor 5 ATF5 0.45
breast cancer 2, early onset BRCA2 0.459
v-ets erythroblastosis virus E26 oncogene homolog 1 (avian) ETS1 0.482
THO complex 4 THOC4 0.482
poly(A) binding protein, cytoplasmic 1 PABPC1 0.512
Mdm2 p53 binding protein homolog (mouse) MDM2 0.55
enhancer of zeste homolog 2 (Drosophila) EZH2 0.558
GATA zinc finger domain containing 2A GATAD2A 0.57
polymerase (DNA-directed), delta 3, accessory subunit POLD3 0.594
DEK oncogene DEK 0.605
metastasis associated 1 MTA1 0.612
inhibitor of growth family, member 2 ING2 0.617
tumor protein p53 TP53 0.618
human immunodeficiency virus type I enhancer binding protein 2 HIVEP2 0.625
polyamine-modulated factor 1 PMF1 0.628
Sp1 transcription factor SP1 0.646
nucleophosmin 1 NPM1 (includes EG:18148) 0.647
GTF2I repeat domain containing 1 GTF2IRD1 0.649
nucleophosmin 1 NPM1 (includes EG:18148) 0.657
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retinoblastoma 1 RB1 0.657
activating transcription factor 1 ATF1 0.667
cold shock domain protein A CSDA 0.67
general transcription factor IIH, polypeptide 1, 62kDa GTF2H1 0.675
retinoic acid induced 14 RAI14 0.675
zinc finger protein 180 ZNF180 0.676
heterogeneous nuclear ribonucleoprotein D (AU-rich element RNA binding 
protein 1, 37kDa) HNRNPD 0.678
LRRGT00141 LOC499235 0.681
forkhead box K2 FOXK2 0.691
embryonic ectoderm development EED 0.694
histone deacetylase 6 HDAC6 0.695
nuclear factor (erythroid-derived 2)-like 2 NFE2L2 0.703
cAMP responsive element modulator CREM 0.704
eukaryotic translation initiation factor 4E nuclear import factor 1 EIF4ENIF1 0.704
forkhead box J3 FOXJ3 0.708
eukaryotic translation initiation factor 4 gamma, 2 EIF4G2 0.712
v-myb myeloblastosis viral oncogene homolog (avian)-like 2 MYBL2 0.721
eukaryotic translation initiation factor 4A, isoform 1 EIF4A1 0.722
teashirt zinc finger homeobox 1 TSHZ1 0.724
tripartite motif-containing 27 TRIM27 0.725
ELL associated factor 1 EAF1 0.728
BTAF1 RNA polymerase II, B-TFIID transcription factor-associated, 170kDa 
(Mot1 homolog, S. cerevisiae) BTAF1 0.729
splicing factor, arginine/serine-rich 2 SFRS2 0.733
metastasis associated 1 family, member 2 MTA2 0.741
mediator complex subunit 24 MED24 0.754
eukaryotic translation initiation factor 3, subunit A EIF3A 0.758
v-maf musculoaponeurotic fibrosarcoma oncogene homolog G (avian) MAFG 0.765
SMAD family member 1 SMAD1 0.766
RuvB-like 1 (E. coli) RUVBL1 0.77
inhibitor of growth family, member 1 ING1 0.771
TAR DNA binding protein TARDBP 0.775
v-myb myeloblastosis viral oncogene homolog (avian) MYB (includes EG:4602) 0.779
AT hook containing transcription factor 1 AHCTF1 0.781
protein inhibitor of activated STAT, 2 PIAS2 0.785
cullin-associated and neddylation-dissociated 1 CAND1 0.787
COP9 constitutive photomorphogenic homolog subunit 5 (Arabidopsis) COPS5 0.831
retinoblastoma binding protein 7 RBBP7 0.836
zinc ribbon domain containing 1 ZNRD1 0.838
transcription elongation factor A (SII), 1 TCEA1 0.848
SRY (sex determining region Y)-box 4 SOX4 0.857
small nuclear RNA activating complex, polypeptide 5, 19kDa SNAPC5 0.876
myeloid/lymphoid or mixed-lineage leukemia 4 MLL4 0.878
zinc finger and BTB domain containing 7A ZBTB7A 0.889
PHD finger protein 5A PHF5A 0.897
BTG family, member 2 BTG2 0.903
kelch-like ECH-associated protein 1 KEAP1 1.138
nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, beta NFKBIB 1.161
small nuclear RNA activating complex, polypeptide 2, 45kDa SNAPC2 1.193
zinc finger protein 277 ZNF277 1.227
zinc finger protein 157 ZNF157 1.234
HLA-B associated transcript 4 BAT4 1.284
polycomb group ring finger 2 PCGF2 1.302
prolactin regulatory element binding PREB 1.302
X-box binding protein 1 XBP1 1.302
cAMP responsive element binding protein-like 2 CREBL2 1.304
general transcription factor IIB GTF2B 1.304
homeobox B5 HOXB5 1.305
engrailed homeobox 2 EN2 1.343
SWI/SNF related, matrix associated, actin dependent regulator of chromatin, 
subfamily c, member 2 SMARCC2 (includes EG:6601) 1.35
nuclear receptor binding SET domain protein 1 NSD1 1.361
Y box binding protein 2 YBX2 1.398
mitochondrial ribosomal protein L9 MRPL9 1.424
transcription factor 12 TCF12 1.424
SH3 and multiple ankyrin repeat domains 3 SHANK3 1.425
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elongation factor Tu GTP binding domain containing 1 
E74-like factor 5 (ets domain transcription factor) 
ashl (absent, small, or homeotic)-like (Drosophila)
SCAN domain containing 1 
RNA binding motif protein 39 
zinc finger protein 446 
MAX interactor 1
AT rich interactive domain 2 (ARID, RFX-like)
excision repair cross-complementing rodent repair deficiency, complementation 
group 8
suppressor of Ty 3 homolog (S. cerevisiae)
zinc finger with KRAB and SCAN domains 1
SATB homeobox 1
thyrotrophic embryonic factor
calcium binding and coiled-coil domain 1
ankyrin repeat and BTB (POZ) domain containing 1
interleukin enhancer binding factor 2
nuclear protein, transcriptional regulator, 1
alpha thalassemia/mental retardation syndrome X-linked (RAD54 homolog, S. 
cerevisiae)
vestigial like 1 (Drosophila)
regulatory factor X-associated ankyrin-containing protein
EFTUD1
ELF5
ASH1L
SCAND1
RBM39
ZNF446
MXI1
ARID2
ERCC8
SUPT3H (includes EG:685697)
ZKSCAN1
SATB1
TEF
CALCOCO1
ABTB1
ILF2 (includes EG:310612) 
NUPR1
ATRX
VGLL1
RFXANK
1.437
1.442
1.447
1.47
1.476
1.478
1.545
1.556
1.643
1.661
1.711
1.794
1.813
1.821
2.034
2.107
2.143
2.2
3.227
4.098
Table 5. Cytokines detected in the m icroarray of rat IMCD cells
Gene Title Gene ID
Li/Con
(fold Changes)
chemokine (C-C motif) ligand 20 CCL20 0.292
chemokine (C-X-C motif) ligand 10 CXCL10 0.396
chemokine (C-C motif) ligand 28 CCL28 0.418
chemokine (C-X-C motif) ligand 16 CXCL16 0.494
interleukin 33 IL33 0.498
colony stimulating factor 1 (macrophage) CSF1 0.642
aminoacyl tRNA synthetase complex-interacting multifunctional protein 1 AIMP1 0.72
chemokine (C-X-C motif) ligand 11 CXCL11 0.727
CKLF-like MARVEL transmembrane domain containing 8 CMTM8 0.765
nicotinamide phosphoribosyltransferase NAMPT 1.966
Table 6 . G-protein coupled receptors, growth factors and ion channels 
detected in the m icroarray of rat IMCD cells
Gene Title Gene ID Li/Con(fold Changes) Types
G protein-coupled receptor 19 GPR19 0.436 G-protein coupled receptor
chemokine (C-X-C motif) receptor 7 CXCR7 1.304 G-protein coupled receptor
arginine vasopressin receptor 2 AVPR2 1.85 G-protein coupled receptor
apelin receptor APLNR 3.782 G-protein coupled receptor
G protein-coupled receptor 37 (endothelin receptor type B-like) GPR37 5.677 G-protein coupled receptor
fibroblast growth factor 13 FGF13 0.567 growth factor
insulin-like growth factor 1 (somatomedin C) IGF1 1.253 growth factor
placental growth factor PGF 1.89 growth factor
fibroblast growth factor 18 FGF18 2.56 growth factor
GAR1 ribonucleoprotein homolog (yeast) GAR1 0.58 ion channel
potassium channel tetramerisation domain containing 15 KCTD15 0.602 ion channel
transient receptor potential cation channel, subfamily C, member 2 TRPC2 0.682 ion channel
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(pseudogene)
two pore segment channel 1 TPCN1 1.233 ion channel
sodium channel, nonvoltage-gated 1 alpha SCNN1A 1.519 ion channel
FXYD domain containing ion transport regulator 2 FXYD2 2.065 ion channel
chloride intracellular channel 3 CLIC3 3.648 ion channel
Table 7. Genes detected in rat IM CD cells with at least 2 fold changes in 
response to 3 days lithium treatment.
Gene Title Gene ID Li/Con(fold Changes)
Upregulated genes
septin 2 NGEF 9.181
G protein-coupled receptor 37 (endothelin receptor type B-like) GPR37 5.677
ATPase, H+ transporting, lysosomal 56/58kDa, V1 subunit B1 ATP6V1B1 5.528
Src-like-adaptor SLA 4.898
osteomodulin OMD 4.702
gamma-glutamyltransferase 5 GGT5 4.513
deoxyribonuclease I DNASE1 4.156
regulatory factor X-associated ankyrin-containing protein RFXANK 4.098
cytochrome P450, family 4, subfamily B, polypeptide 1 CYP4B1 4.059
apelin receptor APLNR 3.782
fibrinogen-like 2 FGL2 3.774
chloride intracellular channel 3 CLIC3 3.648
PNMA-like 2 PNMAL2 3.628
Rh family, C glycoprotein RHCG 3.415
vestigial like 1 (Drosophila) VGLL1 3.227
hypothetical protein LOC686432 LOC686432 3.065
transmembrane protein 213 TMEM213 2.979
defensin, beta 1 DEFB1 2.947
crystallin, mu CRYM 2.939
branched chain keto acid dehydrogenase E1, alpha polypeptide BCKDHA 2.913
EPS8-like 1 EPS8L1 2.896
MACRO domain containing 1 MACROD1 2.826
slit homolog 2 (Drosophila) SLIT2 2.78
aldo-keto reductase family 1, member C19 AKR1C19 2.681
period homolog 3 (Drosophila) PER3 2.677
golgi-specific brefeldin A resistant guanine nucleotide exchange factor 1 GBF1 2.595
transmembrane protein 86A TMEM86A 2.589
fibroblast growth factor 18 FGF18 2.56
microfibrillar-associated protein 3-like MFAP3L 2.526
v-raf murine sarcoma 3611 viral oncogene homolog ARAF 2.513
transmembrane protein 61 TMEM61 2.483
solute carrier family 6 (neurotransmitter transporter), member 17 SLC6A17 (includes EG:613226) 2.475
dicarbonyl/L-xylulose reductase DCXR 2.474
adenylate cyclase 3 ADCY3 2.455
RAB40B, member RAS oncogene family RAB40B 2.407
glutathione S-transferase alpha 1 GSTA1 2.382
pyruvate dehydrogenase phosphatase isoenzyme 2 PDP2 2.355
coiled-coil domain containing 53 CCDC53 2.343
aldo-keto reductase family 7, member A3 (aflatoxin aldehyde reductase) AKR7A3 2.342
dynactin 6 DCTN6 2.332
sialidase 1 (lysosomal sialidase) NEU1 2.332
polymerase (DNA-directed), delta 4 POLD4 2.307
steroid sulfatase (microsomal), isozyme S STS 2.307
aldo-keto reductase family 1, member C12 AKR1C12 (includes EG:361266) 2.305
chaperone, ABC1 activity of bc1 complex homolog (S. pombe) CABC1 2.275
similar to Histone H1.2 (H1 VAR. 1) (H1c) LOC684681 2.266
platelet-derived growth factor receptor-like PDGFRL 2.264
cathepsin F CTSF 2.255
S100 calcium binding protein A5 S100A5 2.254
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adipose differentiation-related protein ADFP 2.244
histone cluster 1, H4h HIST1H4H (includes EG:8365) 2.227
prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and PTGS1 2.21cyclooxygenase)
catenin (cadherin-associated protein), alpha-like 1 CTNNAL1 2.208
premature ovarian failure, 1B POF1B 2.204
aarF domain containing kinase 5 ADCK5 2.202
alpha thalassemia/mental retardation syndrome X-linked (RAD54 homolog, S. 
cerevisiae) ATRX 2.2
trafficking protein particle complex 6A TRAPPC6A 2.165
complement factor H CFH 2.163
family with sequence similarity 101, member B FAM101B 2.156
FK506 binding protein 14, 22 kDa FKBP14 2.153
similar to hypothetical protein FLJ32825 RGD1564257 2.146
nuclear protein, transcriptional regulator, 1 NUPR1 2.143
R3H domain containing 2 R3HDM2 2.116
ubiquitin specific peptidase 33 USP33 2.113
calcium/calmodulin-dependent protein kinase kinase 2, beta CAMKK2 2.111
mitogen-activated protein kinase kinase kinase kinase 1 MAP4K1 2.11
interleukin enhancer binding factor 2 ILF2 (includes EG:310612) 2.107
retinoblastoma binding protein 9 RBBP9 2.105
chromodomain helicase DNA binding protein 2 CHD2 2.092
MPN domain containing MPND (includes EG:681944) 2.085
histone cluster 2, H2aa3 HIST2H2AA3 2.076
monoglyceride lipase MGLL 2.074
FXYD domain containing ion transport regulator 2 FXYD2 2.065
ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-N- ST6GALNAC3 2.063acetylgalactosaminide alpha-2,6-sialyltransferase 3
pleckstrin homology domain containing, family B (evectins) member 1 PLEKHB1 2.06
similar to germinal histone H4 gene LOC684887 2.055
breast carcinoma amplified sequence 3 BCAS3 2.049
guanine nucleotide binding protein (G protein), alpha 15 (Gq class) GNA15 2.045
yippee-like 3 (Drosophila) YPEL3 2.037
ankyrin repeat and BTB (POZ) domain containing 1 ABTB1 2.034
tripartite motif-containing 6 TRIM6 2.032
EGF-like-domain, multiple 6 EGFL6 2.028
RAB31, member RAS oncogene family RAB31 2.027
transmembrane 6 superfamily member 1 TM6SF1 2.024
heat shock protein, alpha-crystallin-related, B6 HSPB6 2.015
chordin CHRD 2.009
RGD1563912 RGD1563912 2.002
chromosome 21 open reading frame 33 C21ORF33 2.001
Downregulated genes
karyopherin alpha 2 (RAG cohort 1, importin alpha 1) KPNA2 0.5
proliferating cell nuclear antigen PCNA 0.498
interleukin 33 IL33 0.498
chemokine (C-X-C motif) ligand 16 CXCL16 0.494
nurim (nuclear envelope membrane protein) NRM 0.493
myelin basic protein MBP 0.493
DEAD (Asp-Glu-Ala-Asp) box polypeptide 39 DDX39 0.491
Wolf-Hirschhorn syndrome candidate 1 WHSC1 0.49
replication factor C (activator 1) 2, 40kDa RFC2 0.49
timeless homolog (Drosophila) TIMELESS 0.488
chromatin assembly factor 1, subunit B (p60) CHAF1B 0.488
protease, serine, 22 PRSS22 0.488
nuclear autoantigenic sperm protein (histone-binding) NASP 0.485
v-ets erythroblastosis virus E26 oncogene homolog 1 (avian) ETS1 0.482
filamin A, alpha (actin binding protein 280) FLNA 0.482
THO complex 4 THOC4 0.482
cyclin-dependent kinase inhibitor 1A (p21, Cip1) CDKN1A 0.48
sulfiredoxin 1 homolog (S. cerevisiae) SRXN1 0.474
poly(A) binding protein, cytoplasmic 4 (inducible form) PABPC4 0.473
hyaluronan-mediated motility receptor (RHAMM) HMMR 0.469
transmembrane protein 107 TMEM107 0.468
exportin 1 (CRM1 homolog, yeast) XPO1 0.467
N-acetyltransferase 11 (GCN5-related, putative) NAT11 0.463
cyclin B1 CCNB1 0.461
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ligase I, DNA, ATP-dependent LIG1 0.461
breast cancer 2, early onset BRCA2 0.459
polymerase (DNA directed), delta 2, regulatory subunit 50kDa POLD2 0.455
helicase, lymphoid-specific HELLS 0.453
ASF1 anti-silencing function 1 homolog B (S. cerevisiae) ASF1B 0.451
structural maintenance of chromosomes 2 SMC2 0.451
MLF1 interacting protein MLF1IP 0.45
activating transcription factor 5 ATF5 0.45
DNA (cytosine-5-)-methyltransferase 1 DNMT1 0.444
similar to snRNP core protein SMX5 LOC684148 0.444
solute carrier family 16, member 1 (monocarboxylic acid transporter 1) SLC16A1 0.443
cyclin-dependent kinase inhibitor 2C (p18, inhibits CDK4) CDKN2C 0.441
cell division cycle 25 homolog B (S. pombe) CDC25B 0.44
kinesin family member 4A KIF4A 0.439
similar to transcription factor MGC112830 0.437
G protein-coupled receptor 19 GPR19 0.436
minichromosome maintenance complex component 7 MCM7 0.436
WD repeat and HMG-box DNA binding protein 1 WDHD1 0.435
thymidine kinase 1, soluble TK1 0.432
thymidylate synthetase TYMS 0.426
chromosome 18 open reading frame 24 C18ORF24 0.424
pleckstrin 2 PLEK2 0.422
CDC28 protein kinase regulatory subunit 1B CKS1B 0.422
thymopoietin TMPO 0.421
polymerase (DNA directed), delta 1, catalytic subunit 125kDa POLD1 0.419
chemokine (C-C motif) ligand 28 CCL28 0.418
transferrin receptor (p90, CD71) TFRC 0.415
cell division cycle associated 4 CDCA4 0.413
polo-like kinase 1 (Drosophila) PLK1 0.412
nucleoporin 210kDa NUP210 0.412
suppressor of variegation 3-9 homolog 1 (Drosophila) SUV39H1 0.406
cell division cycle associated 8 CDCA8 0.405
cyclin E2 CCNE2 0.399
chemokine (C-X-C motif) ligand 10 CXCL10 0.396
chromatin assembly factor 1, subunit A (p150) CHAF1A 0.395
Fanconi anemia, complementation group D2 FANCD2 0.394
lamin B2 LMNB2 0.393
cyclin D1 CCND1 0.393
polymerase (DNA directed), epsilon 2 (p59 subunit) POLE2 0.392
uracil-DNA glycosylase UNG 0.388
ribonucleotide reductase M1 RRM1 (includes EG:6240) 0.382
aurora kinase B AURKB 0.38
replication factor C (activator 1) 4, 37kDa RFC4 0.378
similar to Shc SH2-domain binding protein 1 LOC687121 0.378
similar to RIKEN cDNA 6330512M04 gene RGD1563319 0.377
lipocalin 2 LCN2 0.37
CHK1 checkpoint homolog (S. pombe) CHEK1 0.367
cyclin G1 CCNG1 0.365
deoxyuridine triphosphatase DUT (includes EG:497778) 0.363
radical S-adenosyl methionine domain containing 2 RSAD2 0.363
ubiquitin specific peptidase 1 USP1 0.363
tubulin, beta 2C TUBB2C 0.362
E2F transcription factor 1 E2F1 0.361
sperm associated antigen 5 SPAG5 0.358
DEP domain containing 1 DEPDC1 0.357
ubiquitin-like with PHD and ring finger domains 1 UHRF1 0.352
epithelial membrane protein 1 EMP1 0.349
ribonucleotide reductase M2 polypeptide RRM2 0.349
non-SMC condensin I complex, subunit D2 NCAPD2 0.348
asp (abnormal spindle) homolog, microcephaly associated (Drosophila) ASPM 0.347
cell division cycle associated 7 CDCA7 0.346
kinesin family member 20B KIF20B 0.344
SIVA1, apoptosis-inducing factor SIVA1 0.336
TTK protein kinase TTK 0.336
minichromosome maintenance complex component 2 MCM2 0.336
cell division cycle 20 homolog (S. cerevisiae) CDC20 0.33
transforming, acidic coiled-coil containing protein 3 TACC3 0.327
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chromosome 15 open reading frame 23 C15ORF23 0.319
transcription factor 19 TCF19 0.318
anillin, actin binding protein ANLN 0.315
RAD18 homolog (S. cerevisiae) RAD18 0.314
pituitary tumor-transforming 1 PTTG1 0.299
kinesin family member 11 KIF11 0.298
chemokine (C-C motif) ligand 20 CCL20 0.292
ATPase family, AAA domain containing 2 ATAD2 0.291
minichromosome maintenance complex component 4 MCM4 0.291
budding uninhibited by benzimidazoles 1 homolog (yeast) BUB1 0.286
polo-like kinase 4 (Drosophila) PLK4 0.286
centromere protein N CENPN 0.283
kinesin family member 22 KIF22 0.283
kinesin family member C1 KIFC1 0.282
NUF2, NDC80 kinetochore complex component, homolog (S. cerevisiae) NUF2 0.281
non-SMC condensin I complex, subunit H NCAPH 0.277
dCTP pyrophosphatase 1 DCTPP1 0.275
peptidylprolyl isomerase C (cyclophilin C) PPIC 0.274
G-2 and S-phase expressed 1 GTSE1 0.271
minichromosome maintenance complex component 5 MCM5 0.267
kinetochore associated 1 KNTC1 0.26
pleckstrin homology-like domain, family A, member 3 PHLDA3 0.25
kinesin family member 23 KIF23 0.246
cyclin A2 CCNA2 0.242
nucleolar and spindle associated protein 1 NUSAP1 0.241
similar to Coatomer gamma-2 subunit (Gamma-2 coat protein) (Gamma-2 COP) RGD1566215 0.24
chromosome 6 open reading frame 173 C6ORF173 0.238
centromere protein K CENPK 0.234
chromatin licensing and DNA replication factor 1 CDT1 0.231
stathmin 1 STMN1 0.23
minichromosome maintenance complex component 3 MCM3 0.229
kinesin family member 20A KIF20A 0.228
zinc finger protein 367 ZNF367 0.227
topoisomerase (DNA) II alpha 170kDa TOP2A 0.227
cytoskeleton associated protein 2 CKAP2 0.225
tubulin, beta 6 TUBB6 0.224
SPC25, NDC80 kinetochore complex component, homolog (S. cerevisiae) SPC25 0.218
PDZ binding kinase PBK 0.217
defective in sister chromatid cohesion 1 homolog (S. cerevisiae) DSCC1 0.212
chromosome 5 open reading frame 15 C5ORF15 0.209
maternal embryonic leucine zipper kinase MELK 0.209
cyclin B2 CCNB2 0.207
SPC24, NDC80 kinetochore complex component, homolog (S. cerevisiae) SPC24 0.203
schlafen family member 13 SLFN13 0.198
CDC28 protein kinase regulatory subunit 2 CKS2 0.195
ubiquitin-conjugating enzyme E2C UBE2C 0.193
minichromosome maintenance complex component 6 MCM6 0.188
tubulin, beta TUBB 0.17
cell division cycle associated 3 CDCA3 0.165
epithelial cell transforming sequence 2 oncogene ECT2 0.139
meiotic nuclear divisions 1 homolog (S. cerevisiae) MND1 0.128
cell division cycle 2, G1 to S and G2 to M CDC2 0.126
antigen identified by monoclonal antibody Ki-67 MKI67 0.123
RAD51 homolog (RecA homolog, E. coli) (S. cerevisiae) RAD51 0.119
KIAA0101 KIAA0101 0.098
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Chapter 7
The maintenance of water homeostasis is of vital importance for proper 
physiological functioning of many processes in our body. Consequently, it is 
not surprising that excessive water loss or water loading can result in cranial or 
nephrogenic diabetes insipidus, or SIADH, liver cirrhosis, heart failure, and 
kidney failure. AVP plays a central role in maintaining water homeostasis, and 
the highly regulated AVP-responsive AQP2 is the crucial gate keeper to 
achieve the final fine-tuning of water reabsorption in the kidney.
AVP regulates AQP2 in two ways: the short-term regulation (translocation) and 
the long-term regulation (expression). In the short-term, binding of AVP to its 
V2 receptors on the basolateral membrane of collecting duct principal cells 
leads to the activation of adenylyl cyclase and cAMP signaling cascade, which 
in turn increases PKA activity. This activation leads to phosphorylation of 
AQP2, which is stored in intracellular vesicles. Phosphorylated AQP2 is 
targeted towards and inserted into the apical membrane of collecting duct 
principal cells, making this membrane water permeable. Conversely, upon 
water intake, vasopressin levels in the blood decrease and AQP2 is recycled to 
the intracellular vesicles or further sorted for lysosomal degradation. Besides 
phosphorylation by PKA, the translocation event of AQP2 also involves Ca2+ 
signaling, actin depolymerisation, and several AQP2 interacting proteins. In the 
long-term regulation, AVP increases AQP2 expression in collecting duct 
principal cells, mediated through a cAMP-responsive element in the AQP2 
promoter CRE[1;2]. In addition, regulation of AQP2 expression by 
AVP-independent mechanisms has also been reported. Disturbances of either 
the short-term or the long-term regulatory processes lead to diseases, e.g. NDI.
PHOSPHORYLATION OF AQP2
In short-term regulation, phosphorylation of AQP2 at Ser256 by PKA is 
essential for AVP-induced apical translocation[3-5]. Although each AQP2 
monomer forms a functional water channel, AQP2 is expressed as a 
homotetramer, and phosphorylation of at least three out of four monomers is 
required for apical membrane localization[4]. In chapter 3, our study in the 
patient case of dominant NDI caused by a novel mutation of AQP2, R254Q, 
showed that AQP2-R254Q mutants are functional water channels but are 
impaired in their transport to the apical cell surface of principal cells. Because 
they are able to form heteroligomers with wt-AQP2, they exert the dominant
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feature by impairing trafficking of wt-AQP2 to the apical membrane. The 
cellular localization of AQP2-R254Q was similar to unstimulated wt-AQP2 or 
to the constitutively non-phosphorylated AQP2 mutant S256A, and the 
inability of forskolin to increase phosphorylation of AQP2-R254Q indicated 
that AQP2-R254Q causes dominant NDI due to its impaired phosphorylation of 
Ser256. Interestingly, an S256L mutation in AQP2 was reported to cause 
recessive congenital NDI in mice and NDI was also ascribed to the lack of 
Ser256 phosphorylation by PKA[6 ]. In contrast to our in vitro experiments of 
AQP2-R254Q, a considerable portion of wt-AQP2 (and likely AQP2-S256L) 
was found in the apical membrane of the AQP2-S256L heterozygote. This 
indicates that with AQP2 mutants interacting with wt-AQP2, the relative 
strength of the apical sorting signal in wt-AQP2 vs. the missorting signal in the 
AQP2 mutant determines recessive or dominant NDI, and that the mutation and 
its location within the AQP2 carboxyl-terminal tail (C-tail) determines the 
strength of the apical sorting signal. To be noted, this could also be due to the 
difference between humans and mice. Mice die of NDI due to V2R or AQP2 
mutations[7;8]; humans do not. We are (1) taken care of and (2) maybe less 
sensitive because we concentrate urine less than mice.
Recent data indicate that Ser256 is not the only site of which phosphorylation is 
important in AQP2 regulation. Besides Ser256, three novel phosphorylation 
sites (Ser261, Ser264 and Ser269) were newly identified in C-terminus of rat 
AQP2[9]. Studies of native rat IMCD cells further demonstrated that pSer256, 
pSer264 and pSer269 are increased with AVP stimulation, while pS261-AQP2 
is decreased[9;10]. PS261-AQP2 localizes sub-apically and gives a punctuate 
staining, suggesting a role for Ser261 phosphorylation in the trafficking of 
AQP2. PS264-AQP2 and pS269-AQP2 are increased by AVP 
stimulation[11;12]. Removal of AVP stimulation resulted in the appearance of 
pS264-AQP2 in early endosomes, but not in lysosomes, suggesting that this 
phosphorylation may influence intracellular compartmentalization of AQP2 
after endocytosis or that the enzymes that phosphorylate or dephosphorylate 
AQP2 at Ser264 are compartment-specific[13]. PS269-AQP2 was detected 
solely in the apical plasma membrane of renal collecting duct cells. 
Phosphorylation at Ser269 depends on prior PKA-mediated phosphorylation of 
Ser256 and enhances apical plasma membrane retention of AQP2[14]. The 
distinct subcellular localization of these four phosphorylated proteins suggests 
the presence of distinct subcellular pools of AQP2 and that phosphorylation 
may be involved in regulating the subcellular localization of AQP2.
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ROLE OF EPAC IN AQP2 REGULATION
In chapter 2, we demonstrated a complete mapping of Epac 1 and 2 in the renal 
tubular segments. In particular, we showed that Epac 2 co-localized with AQP2 
in the principal cells of cortical, outer medullary and inner medullary collecting 
ducts (CCD, OMCD and IMCD), but Epac1 only co-localized with AQP2 in 
OMCD. In CCD and IMCD, Epac1 seemed to be only expressed in 
AQP2-negative cells.
In the regulation of AQP trafficking, Ca2+ signaling, actin depolymerisation, 
and several AQP2 interacting proteins were demonstrated to be important. 
Recent studies showed that actin depolymerisation is a prerequisite for 
cAMP-dependent translocation of AQP2[15;16]. Before fusion with the apical 
membrane, the AQP2-bearing vesicles have to travel to the apical regions and 
the cytoskeleton has to be rearranged. In renal principal cells, small GTPase 
RhoA was found to play an important role in actin depolymerisation [15-18]. 
Inhibition of RhoA activity through Rho phosphorylation by PKA and 
interaction with Rho GDP dissociation inhibitor induces partial 
depolymerisation of the actin cytoskeleton, thereby facilitating the 
translocation of AQP2-bearing vesicles to the apical membrane[17]. 
Furthermore, the Ezrin-Radixin-Moesin (ERM) family protein moesin was 
demonstrated to be involved in AQP2 trafficking[19]. ERM proteins play an 
important role in the regulation of F-actin cytoskeleton by cross-linking actin 
filaments with proteins in the plasma membrane. Reduced active ERM 
(possibly by reduced phosphorylation of moesin) was shown to coincide with 
actin depolymerization and apical AQP2 trafficking, likely mediated by Rho 
signaling. ERM proteins function both upstream and downstream of the Rho 
GTPases and could therefore be affected by RhoA signaling or affects RhoA 
activity itself. Of interest, activation of Epac proteins in endothelial cells led to 
a downregulation of Rho and affected actin cytoskeleton due to a crosstalk 
between Epac-Rap1 and Rho signaling[20;21]. Furthermore, the Epac effectors 
Rap1 and PLC-s were shown to modulate actin-driven processes such as the 
formation of membrane protrusions, possibly through the inhibition of 
RhoA[22;23]. These suggests a crosslink of Epac signaling with RhoA in the 
regulation of actin rearrangements in AQP2 trafficking.
Yip demonstrated that Epac activation by the cAMP analog 8CPT-2Me-cAMP,
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which specifically activates Epac (and thus not PKA), triggered Ca2+ 
mobilization in IMCD cells[24]. Local increases in intracellular Ca2+ 
concentration are known to play an important role in triggering the fusion of 
vesicles with the plasma membrane (see review[25]). Using isolated IMCD 
cells, various studies have shown that AVP induces a transient increase in the 
intracellular Ca2+ concentration followed by sustained oscillations[26-28] and 
that intracellular Ca2+ is required for AQP2 membrane insertion[29;30]. Likely, 
AVP-induced Ca2+ mobilization is mediated by cAMP, which in turn activates 
the extracellular Ca2+ influx and intracellular Ca2+ release from 
ryanodine-sensitive Ca2+ stores[29-31]. Therefore, Yip suggested a role of Epac 
in Ca2+ signaling associated with AVP-induced AQP2 trafficking. Furthermore, 
Yip showed in the same study that activation of Epac indeed induced AQP2 
translocation in rat IMCD. The distinct localization of Epac1 and 2 proteins 
shown in our data implies that, if a cAMP-mediated PKA-independent Ca2+ 
mobilization is required for AQP2 trafficking, it is mediated by Epac2 rather 
than Epac 1.
The PDZ-domain containing protein signal-induced proliferation-associated 
protein 1 (SPA-1) is a specific GTPase-activating protein for Rap1 and 
inactivates Rap1[32]. Interestingly, SPA-1 is one of the known proteins that 
directly interact with AQP2 and are important to AQP2 trafficking[33]. Noda et 
al. demonstrated that AQP2 trafficking is impaired in SPA-1 deficient mice and 
in MDCK-AQP2 cells expressing constitutively-activated Rap1, indicating that 
activation of Rapl inhibits AQP2 trafficking., This contradicts Yip’s data in 
which Epac activation was shown to induce AQP2 translocation in rat 
IMCD[24], as Epac is a known activator for Rap1[34] and has been shown to 
activate Rap1 in renal cells (MDCK)[35]. Although the contradictory 
implications could be due to the use of different cell and animal models in these 
studies, it’s more likely due to the complexity of the Epac signaling networks 
and cross talks which may take place at different moments upon different 
stimuli. In any case, these data clearly point to an important role of Epac in 
AQP2 translocation.
AQP2 recycles constitutively and rapidly between intracellular stores and the 
cell surface. AVP removal or PKC activation causes endocytosis of 
AQP2[3;36;37], likely involving the clathrin-mediated endocytosis 
pathway[38;39], because inhibition of clathrin-mediated endocytosis resulted 
in AQP2 accumulation at the plasma membrane [40]. While phosphorylation of
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Ser256 is essential for AVP-induced AQP2 translocation to the plasma 
membrane, dephosphorylation of AQP2 does not seem to be required for its 
internalization[3]. The molecular mechanisms underlying AQP2 endocytosis is 
not yet clear, but Kamsteeg et al. recently demonstrated that AVP removal or 
PKC activation by TPA induced short-chain ubiquitination of AQP2 at position 
Lys-270, followed by endocytosis and degradation[41]. Consistently, 
AQP2-K270R was delayed in its internalization, demonstrating the importance 
of ubiquitination in AQP2 endocytosis. However, although delayed, 
AQP2-K270R was still internalized, which indicated that there are other 
mechanisms involved in AQP2 endocytosis. Interestingly, in several non-renal 
studies, Epac was shown to be involved in PKC activation[42-44] and, indeed, 
our preliminary data also showed that activation of Epac with Epac agonist 
8CPT-2Me-cAMP resulted in a reduced AQP2 expression in AVP-treated 
mpkCCD cells (Fig. 1). However, whether Epac is involved in PKC-mediated 
AQP2 degradation needs to be further investigated.
D D+A A
control; D: dDAVP; A: Epac agonist
Figure 1. Effect of Epac activation on endogenous AQP2 expression in 
mpkCCD cells. mpkCCD cells were grown to confluence, treated with or 
without dDAVP (D) for 96h with or without the Epac agonist 8CPT-2Me-cAMP 
(A) for the last 24h. Cells were then lysed and subjected to immunoblotting for 
AQP2 or actin (indicated). Molecular masses (in kDa) are indicated on the left.
LITHIUM -INDUCED NDI
Lithium-induced NDI is associated with decreased AQP2 protein and mRNA 
levels, attenuated apical targeting of AQP2 in rats[45-47], and decreased 
urinary AQP2 excretion in humans[48]. At later stage , lithium also induces the 
loss of principal cells in rats[49]. However, the underlying mechanism of which 
lithium causes NDI is yet poorly understood.
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In chapter 4 and 5, we first demonstrated that the mouse cortical collecting 
duct cell line mpkCCDc14 and mCCDcl1[50-52], are proper cell models to study 
lithium-induced NDI. Using the mpkCCD cells, we showed that, in contrast to 
the current dogma, the lithium-induced reduction in AQP2 expression was 
dissociated from adenylyl cyclase activity, which was confirmed in 
lithium-induced NDI rats. Detailed analysis further revealed that lithium 
reduced AQP2 gene transcription. These data indicate that lithium might have 
other cellular targets, including those downstream of cAMP, that are involved 
in reducing AQP2 expression.
1 . Gsk3p
Glycogen synthase kinase 3p (GSK3p), a serine/threonine protein kinase, 
is a key target of drug discovery in several diseases, including diabetes and 
Alzheimer disease. Lithium is known to be a potent Gsk3p inhibitor, and it 
was shown to inhibit Gsk3p in mice of lithium-induced NDI and to 
promote co-oxygenase (COX) 2-dependent polyuria[53]. In chapter 5, we 
demonstrated that therapeutic concentrations of lithium increased Gsk3p 
phosphorylation (inactivation) without changing the total expression level 
of Gsk3p, which coincided with AQP2 downregulation in mpkCCD cells. 
Similarly-reduced AQP2 levels and increased phosphorylation of Gsk3p 
were observed when using other Gsk3p inhibitors to treat mpkCCD cells. 
These data strongly suggest that in mpkCCD cells, lithium affects AQP2 
expression by inactivating Gsk3p through phosphorylation and 
inactivation of this enzyme.
In mice studies on lithium-induced NDI[53], it was proposed that the 
inhibition of Gsk3p by lithium might lead to NDI through increased COX2 
expression, as increased COX2 expression results in prostaglandin E2 
(PGE2) generation in the collecting duct interstitium, which antagonizes 
AVP activity at the principal cells basolateral membrane. However, Kotnik 
et al reported a markedly reduced COX1, COX2 and microsomal PGE2 
synthesis in rat IMCD with lithium-induced NDI[54]. Furthermore, a 
recent study revealed that treating rats with NSAIDS, including the 
COX-2-selective meloxicam, resulted in decreased AQP2 expression in 
renal inner medulla without significantly altering PGE2 production[55]. 
These data indicate that COX2 is unlikely involved in mediating 
lithium-induced NDI.
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In a proteomic study on rat IMCD of lithium-induced NDI, an increased 
phosphorylation and inactivation of Gsk3p and increased accumulation of 
p-catenin were also observed[56]. As p-catenin phosphorylation by Gsk3p 
results in proteosomal degradation of p-catenin, the accumulation of 
p-catenin with lithium could be attributed to the phosphorylation and 
inactivation of Gsk3p. This study further proposed that the accumulated 
p-catenin might subsequently translocate to the IMCD nucleus and 
regulate target genes transcription, such as AQP2.
Taken together, these data clearly showed that Gsk3p is involved in 
lithium-induced NDI, and that the direct targets of Gsk3p in this event 
need to be identified.
2. AQP2 transcription
Vasopressin regulates AQP2 expression via changes of AQP2 mRNA 
levels, and the cis-elements at the 5’flanking region of the AQP2 gene are 
crucial in this transcriptional regulation[57-59]. Transcription factor 
binding motifs for CRE, SP-1, GATA, AP1 and TonE were found in this 
region and appear to be involved in the regulation of AQP2 expression 
under different physiological conditions[60;61]. A system-level analysis 
of cell-specific AQP2 gene expression in renal collecting duct revealed 
that ETS family, HOX, RXR, CREB, and GATA family transcriptional 
regulators are likely involved in cell-specific expression of the AQP2 
gene[60]. In chapter 4, we demonstrated that lithium causes NDI possibly 
due to the reduced AQP2 transcription. In this study, we also showed that 
lithium didn’t influence the expression and phosphorylation of CREB, 
suggesting that CREB or the CRE element is not involved in 
lithium-induced reduction of AQP2 transcription. Instead, as reported in 
chapter 6 , we found that 3 days lithium treatment clearly reduced the 
expression of the NFkB inhibitory unit IkB in rat IMCD. As the activity of 
the transcription factor NFkB is primarily regulated by interaction with 
inhibitory IkB proteins, downregulation of IkB suggests an activation of 
NFkB. Previously, injection of bacterial endotoxin lipopolysaccharide 
(LPS) in rats was shown to cause a marked decrease of urine osmolality, 
which was associated with decreased V2 receptor and AQP2 expression in 
rat kidney inner medulla[62]. A recent study demonstrated that activation 
of transcription factor NFkB by LPS decreased AQP2 mRNA and protein
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levels in a time- and dose-dependent manner, via altered binding to two 
putative kB elements in AQP2 promoter[63]. Mutations of the kB 
elements in AQP2 promoter, or silencing of the NFkB proteins, abolished 
LPS-induced decrease of AQP2 promoter activity in mpkCCD cells. 
Furthermore, LPS decreased the AVP- and hypertonicity- induced AQP2 
mRNA expression to a similar extent. These data indicate that the 
LPS-induced downregulation of AQP2 expression is, at least in part, due 
to a direct effect on AQP2 transcription by the induced NFkB activity, and 
that NFkB negatively regulates AQP2 transcription likely through 
antagonizing the stimulatory effects of transcription factors CREB and 
TonEBP, which are responsible for the AVP- and hypertonicity- induced 
AQP2 mRNA expression, respectively. Therefore, NFkB could be a 
transcription factor that is directly involved in lithium-induced 
downregulation of AQP2 gene expression.
3. Proliferation vs. apoptosis
As we concluded that lithium enters the principal cells and possibly exerts 
its effect on directly reducing AQP2 mRNA levels, we carried out a gene 
profiling study on the transcriptome changes at the earliest moment 
lithium reduces AQP2 mRNA levels in rat IMCD, to screen for the 
molecular targets of lithium, as reported in chapter 6 . The detected genes 
with altered expression levels appeared to be related to a broad range of 
networks and functions, including DNA replication, recombination, and 
repair, cancer, cell cycle, cellular movement, nucleic acid metabolism, 
renal and urological disease, inflammatory response, cellular growth and 
proliferation. Chronic lithium treatment results in loss of renal principal 
cells in collecting ducts, and the fractional changes were shown as early as 
after 10 days lithium treatment, whereas the inner medullary collecting 
duct principal cells also showed an increased cell proliferation[64]. Our 
data reveal a tendency of proliferation rather than apoptosis in the rat 
IMCD cells after 3 days lithium treatment, based on the following:
1) the reduced gene expression of phosphatase and tensin homologue 
deleted on chromosome 10 tumor suppressor gene (PTEN, 
Li/Con=0.59). The serine/threonine kinase Akt plays a critical role in 
controlling the balance between cell survival and apoptosis. Renal 
carcinogenesis is promoted by overexpression of the activated Akt
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(phosphorylated Akt) and supposedly a concomitant reduction of 
PTEN, which is known to inhibit the activation of Akt[65]. Therefore 
the clear downregulation of PTEN would likely lead to or coincide with 
an increased activation of Akt after lithium treatment, which in turn 
triggers cell proliferation.
2) the increased gene expression of Araf (Li/Con=2.51), a member of the 
Raf family. Previous studies demonstrated that inhibition of c-Raf by 
phosphorylation, possibly mediated by PKA[66;67] or Akt[68], 
inhibited ERK1/2 activation and MEK1/2 phosphorylation. 1 or 2 
weeks lithium treatment, however, was shown to increase the 
abundance or phosphorylation of JNK, P38, and MAPK/ERK after, 
together with an increased phosphorylation (inhibition) of Akt[56]. Raf 
family kinases are known to activate MEK1/2 and promotes cell 
growth[69]. Thus, an increase of Araf expression may enhance cell 
proliferation.
3) the upregulated gene expression of fibroblast growth factor 18 (FGF18, 
Li/Con=2.56). FGF18 is one of the fibroblast growth factors that are 
known to stimulate proliferation in various tissues, and is known to be 
regulated by the activation of NFAT transcription factor family[70]. 
The upregulation of FGF18 could be due to lithium-induced inhibition 
of GSK3P activity, which leads to activation of signalling pathways 
including the NFAT transcription factor family[71].
4) the reduced gene expression of E2f1 (Li/Con=0.36) and tumor protein 
p53 genes (Li/Con=0.62). E2F1 overexpression has been shown to 
induce apoptosis in cooperation with p53 in various tissues[72]. E2F1 
also inhibits anti-apoptotic signals. Reduced E2F1 expression suggests 
the unlikelihood of apoptosis. Consistently, one of the pro-apoptotic 
members of the Bcl-2 family, Bak1, showed a reduced gene expression 
too (Li/Con=0.64).
5) the increased heat shock 27kDa protein 2 (Hspb2, Li/Con=1.80) and 
heat shock alpha-crystallin-related protein B6 (Hspb6, Li/Con=2.02). 
These proteins belong to the heat shock protein 27 family, and share 
anti-apoptotic properties[73].
Taken together, these data suggest that proliferation rather than apoptosis
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is induced in the early stage of lithium treatment in the rat IMCD. Indeed, 
the loss of collecting duct principal cells was only observed at a later time 
point of lithium treatment, for example after 2 weeks[49;74]. A 
comparison of collecting duct cell profiling between short and long term 
lithium treatments might provide more insight on this morphology change.
4. Heat shock proteins in AQP2 trafficking
In Chapter 6, our data showed an increased gene expression of heat shock 
70kDa protein 5 (Hspa5, also named as 78-kDa glucose-regulated protein 
or GRP78, Li/Con=1.54) and heat shock 70kDa protein 2 (Hspa2, 
Li/Con=1.83). This is consistent with the previous 2-D gel proteomic 
study of rats with 1 and 2 weeks lithium treatment, in which Hspa5 was 
also upregulated (Li/Con=1.6)[56]. Besides Hspa5, heat shock 70kDa 
protein 1B and heat shock 70kDa protein 1-like were found altered 
(Li/Con=0.64/1.7, Li/Con=0.64, respectively) in the 2-D gel proteomic 
study. Heat shock 70kDa proteins (Hsp70) were shown to interact with 
AQP2 and the Ser256 residue phosphorylated or non-phosphorylated in 
the AQP2 C-terminus is important for this direct interaction[75]. AQP2 is 
internalized possibly through the Clathrin-mediated endocytosis pathway, 
and Hsp70 is a part of the endocytotic machinery that regulates 
clathrin-mediated endocytosis[38;40;76]. Lu etal. demonstrated that AVP 
enhanced co-localization of Hsp70 and AQP2 on the apical membrane of 
principal cells in rat kidney collecting ducts, and disturbance of this 
interaction resulted in membrane accumulation of AQP2[75]. The 
upregulation of the Hsp70 proteins found in our 3 days lithium-treated rats 
suggest that lithium treatment may affect AQP2 trafficking at the early 
stage.
CONCLUSIONS
The aim of this thesis was to study the regulation of AQP2 in health and disease. 
During my study, we looked for novel proteins and mechanisms involved in the 
regulation of AQP2. We mapped the Epac1 and Epac2 expression profiles in 
the renal tubular segments, which we hope will lay a ground for understanding 
the roles of these key cAMP mediators in various renal settings. We unraveled 
the molecular mechanism of the case of dominant NDI caused by the
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loss-of-function mutation of AQP2-p.R254Q. This mutation, together with 
other mutations found at the C-terminus region of AQP2 that cause missorting 
of AQP2, underscores the importance of the AQP2 C-terminus in AQP2 
trafficking. The dominant negative feature of this mutant specifically indicates 
that with AQP2 mutants interacting with wt-AQP2, the relative strength of the 
apical sorting signal in wt-AQP2 vs. the missorting signal in the AQP2 mutant 
determines recessive or dominant NDI, and that the mutation and its location 
within the AQP2 C-terminus determines the strength of the apical sorting 
signal.
We explored the molecular mechanism of lithium-induced NDI. Our finding of 
the dissociation of cAMP with the lithium-induced downregulation of AQP2 
tuned the scope of the molecular targets of lithium to elements downstream of 
cAMP, in particular, transcription factors of AQP2. The transcription factor 
CREB is unlikely involved in lithium-induced reduction of AQP2, as neither 
the expression nor the phosphorylation of this protein was altered after lithium 
treatment. NFkB, on the contrary, was found possibly activated in response to 
lithium. GSK3p, the potent inhibitory target of lithium, was inactivated in the 
cells where lithium reduced AQP2 expression, suggesting the involvement of 
GSK3p in lithium-induced downregulation of AQP2. Lithium entry to the 
principal cells of renal collecting duct via ENaC was thoroughly investigated 
and established. Amiloride, which protects the principal cells from lithium by 
blocking ENaC, is therefore a promising option in treating lithium-induced 
NDI. We demonstrated that the earliest moment of downregulation of AQP2 in 
the collecting duct cells is after 3 days lithium diet and performed gene 
profiling of the transcriptome changes at this time point. Although our gene 
profiling data awaits further confirmation, the preliminary analysis on the data 
revealed a complex of networks of cellular effect of lithium, among which a 
tendency of induced proliferation rather than apoptosis in the IMCD cells. 
Further investigations, especially joint efforts utilizing state-of-art techniques 
such as transcriptomics and proteomics analysis, computerized system-level 
analysis as well as clinically-relevant cell models will give rise to a better 
comprehension of the molecular details of AQP2 regulation in health and 
disease, which will ultimately benefit the patients with disturbance of 
osmoregulation.
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SUM M ARY
Since the first water channel protein AQP1 was identified by the Nobel 
Laureate Peter Agre in 1990, two decades of scientific investigations on the 
aquaporins added tremendous growth of knowledge on water homeostasis in 
health and disease. Among the 13 aquaporins found so far, AQP2, a water 
channel found in the renal collecting ducts which is under control of the 
antidiuretic hormone arginine-vasopressin (AVP), appears to be a key 
component in osmoregulation. In conditions of a reduced blood volume 
[hypovolemia] or high blood sodium concentrations [hypernatremia], as 
occurs with sleeping and sport, this is detected by cardiovascular and brain 
receptors, which tell our brain to increase our body water content by 
stimulating us to drink water and to release AVP from the pituitary into our 
blood. AVP then travels to renal collecting ducts and binds the vasopressin 
type-2 receptor (V2R), upon which a cAMP signaling cascade is initiated, 
resulting in the movement of AQP2 proteins from intracellular vesicles into 
the apical (urinary side) membrane of the cells. Then, pro-urinary water will 
enter the cells through AQP2 and will leave the cells to the interstitium and 
blood via AQP3 and AQP4, which are located in the basolateral (blood side) 
membrane of these cells. With this uptake of water, urine becomes 
concentrated. Upon restoration of a normal blood volume or sodium 
concentration, AVP release is reduced and AQP2 water channels are retrieved 
from the apical membrane and restored in vesicles. Then, water reabsorption 
from the pro-urine is reduced and urine will become dilute again. Disturbance 
of this process of AQP2 regulation is associated with several common 
disorders of water balance, e.g. congestive heart failure, hepatic cirrhosis, the 
syndrome of inappropriate antidiuresis (SIADH) seen in many cancer patients, 
and nephrogenic diabetes insipidus (NDI). Although the mainline mechanism 
of AVP-regulated water reabsorption through AQP2 is established, the 
cellular actions involved in the regulation process are complex and not fully 
understood.
The main aim of this thesis was to further progress the molecular dissection of 
AQP2 regulation in health and disease. Special attention was given to 
exploring novel targets in the regulatory pathways leading to modification of 
AQP2.
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In Chapter 2, we reviewed the renal localization of the exchange protein 
directly activated by cAMP (EPAC) 1 and 2, which are alternative mediators 
for cAMP-dependent signaling pathways other than PKA. Co-staining of 
EPAC proteins with specific tubular markers revealed that EPAC1 and 
EPAC2 were expressed at the brush border of PT cells, but were absent from 
tDLH cells. In the TAL, EPAC1 and EPAC2 were expressed throughout the 
cells with some confinement towards the apical membrane. In the DCT/CNT, 
EPAC 1 was confined to the apical region of the cells, whereas EPAC2 was 
mainly expressed in the apical and basolateral regions. In the CD, a dispersed 
EPAC1 expression was found in intercalated cells only (CCD), principal and 
intercalated cells (OMCD), and mainly AQP2-negative cells in the IMCD. In 
contrast, EPAC2 expression was at the apical and basolateral membrane of 
cortical principal cells, dispersed and apical in both intercalated and principal 
cells of the OMCD and the IMCD. A similar distribution for EPAC1 and 2 
was found in the human kidney. The observed expression in different tubular 
segments suggests a potential role for EPAC1 and 2 in tubular transport 
physiology and cellular proliferation. Additionally, the different confinements 
of EPAC1 and 2 in the collecting duct principal cells suggest that these 
proteins may play different roles in the physiological processes that occur in 
these cells, for example, the regulation of AQP2 expression and/or trafficking.
In Chapter 3, we investigated a reported case of dominant NDI caused by a 
novel mutation of AQP2, p.R254Q. In oocytes, the mutant AQP2-p.R254Q 
appeared to be a functional water channel, but was impaired in its transport to 
the cells surface to the same degree as AQP2-pS256A, which mimics non- 
phosphorylated AQP2. In polarized MDCK cells, AQP2-p.R254Q was 
retained in the intracellular vesicles, similarly to that of unstimulated wt- 
AQP2 or non-phosphorylated AQP2. Upon co-expression, AQP2-p.R254Q 
interacted with, and retained wt-AQP2 in intracellular vesicles. In contrast to 
wt-AQP2, forskolin did not increase AQP2-p.R254Q phosphorylation at 
Ser256 or its translocation to the apical membrane. Mimicking constitutive 
phosphorylation in AQP2-p.R254Q with the p.S256D mutation, however, 
rescued its apical membrane expression. Our data reveal that the mutation 
located within the carboxyl terminal tail of AQP2 destroys the PKA 
consensus site. As the phosphorylation of Ser256 is essential for AQP2 
trafficking, this mutation causes dominant NDI due to the loss of function, 
namely phosphorylation.
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Lithium-induced NDI, the most common form of NDI, is associated with a 
decreased AQP2 expression and which is generally ascribed to reduced 
adenylyl cyclase activity and thereby a reduced cAMP cascade. Chronic 
lithium treatment also leads to severe loss of the renal principal cells. In 
Chapter 4, we first introduced a good cell model, the mouse cortical collecting 
duct cell line mpkCCDci4 cells, to study the molecular mechanisms of lithium- 
induced downregulation of AQP2. We demonstrated that these cells are 
sensitive to dDAVP stimulation and the dDAVP-induced AQP2 expression 
and plasma membrane localization are reduced in response to therapeutic 
levels of lithium treatment in a dose- and time-dependent manner. Our in vitro 
and in vivo studies further revealed that lithium-induced downregulation of 
AQP2 and development of NDI occur independent of adenylyl cyclase 
activity, and that lithium-induced downregulation is due to diminished AQP 
mRNA levels, likely through reduced AQP2 gene transcription. As such, our 
findings indicate a different cellular signaling pathway(s) by which lithium 
causes AQP2 downregulation and NDI development.
In Chapter 5, we evaluated the rationale of amiloride as a therapeutic in 
lithium-induced NDI and the underlying mechanisms. Using the mouse 
cortical collecting duct cell line mCCDcl and rats, we demonstrated that the 
amiloride-sensitive epithelial sodium channel (ENaC) forms the major entry 
site for lithium in principal cells. Blocking lithium entry with amiloride 
reduces the lithium-induced downregulation of AQP2 and protects the cellular 
composition of the collecting duct, thereby attenuating lithium-induced NDI.
In Chapter 6 , we set out to identify novel genes that are potentially involved 
in the pathogenesis of lithium-induced NDI, as well as in the regulation of 
AQP2. We first determined that the earliest moment at which rats show a 
reduction in AQP2 expression and polyuria induced by lithium is after 3 days. 
cDNA Microarray using the inner medulla collecting duct cells freshly 
isolated from rats of this time point revealed 1271 distinct genes, of which 
146 and 88  genes were more than 2-fold down- or up-regulated compared to 
samples of control rats, respectively. The Ingenuity pathway analysis of these 
234 altered genes identified 13 significant gene networks (p<0.001), with the 
top-scoring networks mostly associated with DNA replication, recombination, 
and repair, cancer, cell cycle, cellular movement, nucleic acid metabolism, 
renal and urological disease, inflammatory response, cellular growth and
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proliferation. Altered expression of genes that are involved in cell 
proliferation and apoptosis, including the genes in Akt signaling pathways and 
NFAT regulating pathways, indicated an induced proliferation by lithium. 
Furthermore, downregulated iKBa, the inhibitory unit of transcription factor 
NFkB, suggested an activation of NFkB. Combined with previous findings, 
we hypothesize that NFkB could be the direct target of lithium in the IMCD 
and that lithium-induced downregulation of AQP2 transcription could be 
mediated by NFkB.
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Sinds de ontdekking van het aquaporine 1 waterkanaal door nobelprijswinnaar 
Peter Agre in 1990, is de kennis over de regulatie van de waterbalans in het 
lichaam gedurende ziekte en gezondheid enorm toegenomen. 
Wetenschappelijk onderzoek naar de waterkanalen dat hierna is uitgevoerd 
heeft vervolgens de identificatie van 13 verschillende aquaporines opgeleverd. 
Eén daarvan is aquaporine 2, afgekort AQP2, een waterkanaal dat zich in de 
verzamelbuizen van de nieren bevindt. AQP2 is essentieel gebleken voor het 
constant houden van de osmotische waarde van de lichaamsvloeistoffen, ook 
wel osmoregulatie, in het lichaam. De expressie van AQP2 wordt aangestuurd 
door het antidiuretisch hormoon arginine-vasopressine (AVP). Gedurende 
momenten van een verlaagd bloedvolume (hypovolemie) of een hoge 
concentratie natrium in het lichaam (hypernatraemie), bijvoorbeeld tijdens het 
slapen of sporten, krijgen de hersenen een signaal dat een dorstgevoel 
veroorzaakt. Hierbij komt AVP vrij uit dehypofyse. AVP gaat via het bloed 
naar de nieren waar AVP kan binden aan specifieke receptoren die zich in de 
niercellen bevinden. Het binden van AVP aan de vasopressine type-2 receptor 
veroorzaakt een cascade van reacties, resulterend in de verplaatsing van 
AQP2 van binnenuit naar de celmembraan van de niercellen. Urine dat langs 
de cellen stroomt komt zo in contact met de AQP2 waterkanalen op de 
celmembraan. Water kan vanuit de urine de cellen instromen door de AQP2 
heen. Het water wordt vervolgens via de AQP3 en AQP4 vanuit de cel het 
bloed in getransporteerd. Zo verdwijnt het water niet via de urine maar blijft 
het water in het lichaam. Dit noemen we het concentrerend vermogen van de 
nieren. Wanneer de waterbalans in het lichaam normaal is, komt er minder 
AVP vrij vanuit de hypofyse en trekt AQP2 zich terug van de celmembraan 
naar intracellulaire compartimenten. Hierdoor wordt de urine minder 
geconcentreerd en verlaat meer water het lichaam via de urine. Een defect in 
bovengenoemde processen kan leiden tot een verstoring van de 
waterhuishouding in het lichaam zoals dit het geval is bij levercirrose, het 
syndroom van inadequate secretie van het antidiuretisch hormoon (SIADH) 
en nefrogene diabetes insipidus (NDI).
Omdat de complexe mechanismen die ten grondslag liggen aan AVP- en 
AQP2-gemedieerd watertransport niet volledig bekend zijn, is het doel van
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het onderzoek beschreven in dit proefschrift het verder in kaart brengen van 
de moleculaire werking van AVP/AQP2-regulatie in gezondheid en ziekte, 
met een bijzondere focus op de identificatie van nieuwe regulerende factoren.
In hoofdstuk 2 van dit proefschrift wordt beschreven waar de EPAC1 en 
EPAC2 eiwitten tot expressie komen in de nier. Beide eiwitten zijn essentieel 
voor de signalering tijdens de cyclisch AMP-afhankelijke regulatie van water­
en iontransport in de nier. Kleuring van de EPAC eiwitten in rattennieren liet 
zien dat EPAC1 en EPAC2 specifiek tot expressie komen in de borstelzone 
van proximale epitheelcellen en niet aanwezig zijn in cellen van het dunne 
opstijgende deel van de lus van Henle. In de cellen van het distaal convoluut 
en de verbindingsbuizen werd EPAC1 aan de apicale (urine-) zijde 
waargenomen, terwijl EPAC2 zowel aan de apicale als de basolaterale (bloed-) 
zijde van deze cellen voorkwam. In de verzamelbuizen van de schors werd 
EPAC expressie waargenomen in de tussenliggende (AQP2 negatieve) cellen, 
terwijl in de verzamelbuizen van het merg ook primaire (AQP2 positieve) 
cellen werden aangekleurd. In de humane nier werd een vergelijkbaar 
expressiepatroon gevonden. De geobserveerde expressie van de EPAC 
eiwitten in de verschillende segmenten van de nierbuizen suggereert dat 
EPAC1 en EPAC2 belangrijke fysiologische functies kunnen hebben in de 
nieren. Bovendien doet de gevarieerde expressie van EPAC1 en EPAC2 in de 
primaire en tussenliggende cellen van de verzamelbuizen vermoeden dat deze 
eiwitten verscheidene functies kunnen hebben in deze cellen, bijvoorbeeld 
met betrekking tot AQP2 expressie en/of regulatie.
In hoofdstuk 3 staat het onderzoek naar de p.R254Q mutatie in het AQP2 
eiwit centraal. Deze mutatie werd ontdekt in een patiënt met dominante NDI. 
Experimenten in het oocytenmodel (eicellen van de Afrikaanse klauwpad, 
Xenopus laevis) lieten zien dat deze mutatie weliswaar resulteert in een 
normaal functionerend waterkanaal, maar niet normaal tot expressie komt op 
de celmembraan. Dit resultaat was vergelijkbaar met de AQP2 p.S256A 
mutant welke alleen intracellulair tot expressie komt en niet op de membraan. 
Ook in expressiestudies in gepolariseerde MDCK cellen lokaliseerde de 
p.R254Q mutant niet op de membraan. Gezamenlijke expressie van wild-type 
AQP2 en de AQP2-p.R254Q mutant gaf een dominant beeld van de mutatie 
en dus een intracellulaire retentie van de eiwitten. Stimulatie van AQP2 met 
forskoline gaf geen translocatie naar de membraan van de AQP2-p.R254Q
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mutant, wat erop duidt dat deze mutant de fosforylering van AQP2 op het 
Ser256 aminozuur nadelig beïnvloedt. Het additioneel aanbrengen van een 
constante fosforylering in de p.R254Q AQP2 mutant leidde uiteindelijk tot 
een normale expressie van AQP2 op de celmembraan. Bovenstaande 
resultaten geven duidelijk aan dat de p.R254Q mutatie in de carboxyl 
terminus van AQP2 de PKA consensus site die essentieel is voor fosforylering 
van het eiwit vernietigd. Omdat fosforylering van AQP2 essentieel is voor de 
beweging vanuit het intracellulaire compartiment naar de celmembraan, geeft 
deze dominante mutatie een functieverlies voor AQP2, welke causaal is voor 
NDI in de mens.
Het therapeutisch gebruik van lithium kan ook NDI veroorzaken. 
Kenmerkend voor lithiumgeïnduceerde NDI is de afname van AQP2 
expressie, mogelijk door een verlaagde adenylyl cyclase activiteit en 
afwezigheid van de cAMP cascade. Chronische behandeling met lithium leidt 
bovendien tot een verlies van primaire (AQP2-positieve) cellen in de 
verzamelbuizen van de nieren. In hoofdstuk 4 staat de studie in het nieuwe 
mpkCCDc14 celmodel beschreven waarin het principe van 
lithiumgeinduceerde NDI is nagebootst. Deze studie laat zien dat deze cellen, 
afkomstig uit de verzamelbuizen van muizen, gevoelig zijn voor dDAVP, een 
analoog van AVP. Stimulatie van de cellen met dDAVP leidt tot activering 
van AQP2 en expressie van de waterkanalen op de celmembraan. 
Behandeling van de cellen met lithium liet echter een dosisafhankelijke 
verlaagde respons van AQP2 expressie op dDAVP zien. In aanwezigheid van 
lithium is de activering van AQP2 dus verminderd, wat een verminderd 
concentrerend vermogen van de nier tot gevolg heeft. Lithiumgeïnduceerde 
NDI bleek onafhankelijk te zijn van de adenylyl cyclase-activiteit in de cel en 
gepaard te gaan met een verlaagde AQP2 mRNA expressie, waarschijnlijk 
door verlaagde AQP2 gentranscriptie. Deze studie impliceert dat er andere 
signaleringsprocessen betrokken zijn bij lithiumgeinduceerde NDI dan bij de 
genetische vormen van NDI.
Hoofdstuk 5 beschrijft het onderzoek naar amiloride, een medicijn dat wordt 
toegepast tegen het ontstaan van lithiumgeinduceerde NDI. In ratten en het 
mCCDcl14 celmodel laten we zien dat de amiloride-gevoelige epitheliale 
natriumkanalen (ENaC) de belangrijkste route zijn voor lithium om de cellen 
van de verzamelbuizen binnen te gaan in de nier. Door toediening van
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amiloride wordt deze route geblokkeerd, verminderde expressie van AQP2 
voorkomen en het lichaam beschermt tegen lithiumgeïnduceerde NDI.
De identificatie van nieuwe genetische factoren die betrokken zijn bij de 
regulatie van AQP2 en het ontstaan van lithiumgeïnduceerde NDI staat 
beschreven in hoofdstuk 6 . In ratten is de afname van AQP2 expressie vanaf 3 
dagen na toediening van lithium zichtbaar. Dit heeft directe verhoging van de 
urine-excretie tot gevolg. Bij de ratten is op dag 3 na toediening van lithium 
cDNA uit de verzamelbuizen geïsoleerd en geanalyseerd op genexpressie in 
een micro-array experiment. Het cDNA-profiel van deze ratten vertoonde een 
significant veranderd expressiepatroon voor 1271 genen in vergelijking met 
ratten die geen lithium toegediend hadden gekregen. 146 genen lieten een 
verlaagde expressie zien, terwijl 88  genen verhoogd tot expressie kwamen na 
toediening van lithium. Verder onderzoek naar deze 234 genen bracht aan het 
licht dat ze belangrijke schakels vormden in 13 genetische netwerken voor o.a. 
DNA replicatie, DNA recombinatie en reparatie, celcyclus, celbeweging, 
nucleïnezuurmetabolisme, nierziekten, ontsteking, celgroei en celproliferatie. 
De significante verandering in de expressie van genen/eiwitten die betrokken 
zijn bij celproliferatie en celdood, zoals Akt signaleringseiwitten en NFAT 
regulerende eiwitten, duidt op veranderde celgroei na lithiumgebruik. De 
significant verlaagde expressie van het iKBa gen, welke de inhibitie van 
transcriptiefactor NFkB reguleert, leidt mogelijk tot een verhoogde activering 
van NFkB door lithium. Concluderend zijn er sterke aanwijzingen dat lithium 
NFKB activeert in de verzamelbuizen van de nieren, met als gevolg de 
verlaagde expressie van AQP2 en het ontstaan van lithiumgeïnduceerde NDI.
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CD collecting duct
CLCNKB chloride channel Kb
CLSM confocal laser scanning microscopy
CNT connecting tubule
COX2 cooxygenase 2
CRE cAMP responsive element
CREB cAMP responsive element binding protein
DCT distal convoluted tubule
DCT distal convoluted tubule
dDAVP 1-desamino-8-D-arginine vasopressin
DI diabetes insipidus
ECF extracellular fluid
EEA1 early endosome antigen 1
ENaC epithelial sodium channel
EPAC exchange protein directly activated by cAMP
FGF18 fibroblast growth factor 18
G Glomerulus
g gram(s)
GAPDH glyceralsehyde -3 -phosphate dehydrogenase
GFP green flourecent protein
GFR glomerular filtration rate
GSK glycogen synthase kinase
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List o f  abbreviations
HEK293 human embryonic kidney 293 cells
Hsp heat shock protein
ICF intracellular fluid
IMCD inner medullary collecting duct
IPA Ingenuity Pathways Analysis®
ISF interstitial fluid
IVT in vitro transcription
IkB inhibitory proteins of nuclear factor kappa B
JGA juxtaglomerular apparatus
kb Kilo-basepair(s)
kDa Kilo-dalton(s)
LLC-PK1 porcine kidney proximal tubule cell line
MAPK mitogen-activated protein kinase
mCCDcl1 mouse cortical colleting duct cell line clone 1
MDCK Madin-Darby Canine kidney
MEK MAPK kinase
mpkCCDcl4 mouse cortical colleting duct cell line clone 14
MR mineralocorticoid receptor
n number in group
NCC sodium chloride co-transporter
NDI nephrogenic diabetes insipidus
N FkB nuclear factor kappa B
NHE3 sodium hydron exchanger 3
NKCC2 sodium potassium co-transporter type 2
NSAID non-steroid anti-inflammatory drugs
NSIAD neprogenic syndrome of inappropriate antidiuresis
OMCD outer medullary collecting duct
OVLT organum vasculosum lamina terminalis
p27/KIP inhibitory protein of cyclin-dependent kinases p27
PAGE polyacrilamide gel electrophorysis
PGE2 prostaglandin E2
PKA protein kinase A
PKC protein kinase C
PLC-e phospholipase C-epsilon
PT proximal tubule
PTEN phosphatase and tensin homologue deleted on chromosome 10 
tumor suppressor gene
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List o f  abbreviations
PTH parathyroid hormone
PVN paraventricular nucleus
RAAS renin angiotensin aldosterone system
ROMK renal outer medullary potassium channel
SFO subfornical organ
SIADH syndrome of inappropriate antidiuretic hormone secretion
SON supraoptic nucleus
TAL thick ascending limbs of Henle’s loop
tDLH thin descending limbs of Henle’s loop
THP Tamm-Horsfall protein
TRPV transient receptor potential vanilloid ion channel
UTA-1 urea transporter A-1
V2R vasopressin type 2 receptor
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